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ABSTRACT 
 
HMGA proteins are a family of chromatin remodelers involved in many 
cellular processes including regulation of gene expression, apoptosis and cell 
proliferation. They have a crucial role in cell transformation and their 
overexpression is a constant feature of human malignant neoplasias, representing a 
poor prognostic index. Sequence analysis of HMGA proteins revealed the 
presence of a consensus site for ATM phosphorylation, which is highly conserved 
among different species and the different HMGA family members. Since ATM is 
the main cellular sensor to DNA damage, we decided to investigate the role of 
HMGA proteins in the ATM pathway and in the cellular response to DNA-
damaging agents. In this study we demonstrate that both members of HMGA 
family, HMGA1 and HMGA2, interact and are phosphorylated by ATM in 
response to DNA damage. Interestingly, RT-PCR and Western Blot analysis on 
Mouse Emrbyonic Fibroblasts (MEFs) lacking Hmga1, Hmga2 or both genes, 
revealed that, in the absence of HMGA proteins, mRNA and protein levels of 
ATM are strongly reduced. Moreover, p53 phosphorylation and the consequent 
activation of p21 transcription, induced by ATM kinase activity, were significantly 
affected by the absence of HMGA proteins. Consistent with these data, ChIP and 
luciferase assays demonstrated that HMGA proteins bind and positively regulate 
the promoter of the ATM gene. Moreover, induction of ATM kinase activity 
increased HMGA-mediated activation of ATM promoter, suggesting that, 
following DNA damage, ATM is able to trigger an HMGA-dependent positive 
feedback loop on its own promoter. Accordingly with the reduced expression of 
ATM, MEFs lacking both Hmga genes showed a significant impairment of the 
DNAdamage response. In fact, Hmga1/Hmga2 double knock-out MEFs displayed 
a reduction in the DNA repair activity and in the stress-induced senescence 
following the induction of DNA double strand breaks (DSBs), compared to wild-
type MEFs. It has been also demonstrated that inhibition of ATM determines cell 
sensitization to DNA damaging therapies. Thus, we investigated the role of 
HMGA proteins in cellular sensitivity to genotoxic drugs. On this purpose, we 
treated transformed thyroid cell lines with antisense oligonucleotides to abrogate 
the expression of HMGA proteins, and evaluated their response to DNA-damaging 
agents such as ionizing radiation and UV-light. As expected, down regulation of 
HMGA proteins reduced cellular levels of ATM. Moreover, following the 
exposure to DNA-damaging agents, absence of HMGA proteins determined 
alteration of cell-cycle checkpoints, reduced cell proliferation and promoted 
apoptosis. Taken together our data indicate that HMGA proteins play a crucial role 
in the cellular response to DNA damage, and may represent a new target to 
improve tumour sensitivity to conventional anti-cancer therapies.  
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1. INTRODUCTION 
 
 
1.1 The HMG proteins 
 
The High Mobility Group (HMG) proteins are a family of small nuclear non-
histone proteins which play a critical role in several cellular processes such as 
gene expression, DNA replication, meiotic recombination, apoptosis, cellular 
senescence and DNA repair (Bustin et al. 1990, Patterson et al. 1996). In the 
mammalian species the high-mobility-group HMG proteins have been grouped in 
three distinct families (HMGB, HMGN, and HMGA), based on their distinct DNA 
binding domains. 
The HMGB proteins (formerly HMG1/2) are characterized by the HMG-Box, a 
DNA-binding domain that both introduces a tight bend into DNA and binds 
preferentially to a variety of distorted DNA structures. The HMGB proteins seem 
to act primarily as architectural facilitators in the formation of nucleoprotein 
complexes; for example, in the assembly of complexes involved in recombination 
and transcription. Recent genetic and biochemical evidences suggest that these 
proteins can facilitate nucleosome remodeling. One mechanism by which HMGB 
proteins could prime the nucleosome for migration is to loosen the wrapped DNA 
and so enhance accessibility to chromatin-remodeling complexes and possibly also 
to transcription factors. By constraining a tight loop of untwisted DNA at the edge 
of a nucleosome, an HMGB protein could induce movements in the contacts 
between certain core histones that would result in an overall change in nucleosome 
structure (Bianchi et al. 2000, Thomas et al. 2001). 
The HMGN proteins (formerly HMG14/17) decompact the nucleosomal array 
altering the chromatin architecture. Two HMGN bind to each nucleosome through 
their nucleosome-binding domain, inducing chromatin unfolding, which results in 
increased gene expression and replication (Bustin 2001, Crippa et al. 1993, 
Vestner et al. 1998). 
The HMGA family (previously HMGI) comprises four members: HMGA1a, 
HMGA1b, HMGA1c and HMGA2. The characteristic DNA binding domains of 
this protein family, the so called “AT-Hooks”, are responsible for the binding of 
HMGA proteins to DNA sequences rich in adenine and thymine (AT-rich regions) 
(Geierstanger et al. 1994). Like the other HMGs, HMGA proteins do not present a 
transcriptional activity per se, but are involved in regulation of transcription by 
altering the architecture of chromatin and facilitating the assembly of multiprotein 
complexes of transcriptional factors (Thanos and Maniatis 1992). 
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1.2 The HMGA family 
 
HMGA proteins are encoded by two distinct genes, HMGA1, which 
produces by alternative splicing HMGA1a, HMGA1b and HMGA1c, and 
HMGA2, coding for the homonymous protein (Fusco and Fedele 2007). As above 
mentioned, all HMGA proteins are characterized by three N-terminal highly 
positively charged domains, called AT-Hooks, necessary for the binding to AT-
rich stretches of DNA. On the contrary, the C-terminus contains a high percentage 
of negatively charged amminoacids. The structure and sequence of HMGA 
proteins are very similar and highly conserved among species, but many 
differences can be found in the N-terminal region and between AT-Hooks (Fedele 
et al. 2001). Both HMGA genes are widely expressed during embryogenesis, 
whereas their expression is absent or low in adult tissues (Zhou et al. 1995, 
Chiappetta et al. 1996). In particular, expression of HMGA2 has not been detected 
in any of the several adult mouse and human tissues tested (Rogalla et al. 1996). 
Low expression has been observed in CD34-positive haematopoietic stem cells 
(Rommel et al. 1997), in mouse preadipocytic proliferating cells (Anand and 
Chada 2000) and in meiotic and post-meiotic cells secondary spermatocytes and 
spermatids) (Chieffi et al. 2002, Di Agostino et al. 2004). Conversely, HMGA1 is  
ubiquitary expressed, albeit at low levels, in adult murine and human tissues 
(Chiappetta et al. 1996).  
Studies of mice models have revealed a crucial role of HMGA proteins in 
adipogenesis (Zhou et al. 1995, Chiappetta et al. 1996, Battista et al. 1999), 
somatic growth (Battista et al. 1999), cardiac cell growth control (Fedele et al. 
2006) and glucose homeostasis (Foti et al. 2005, Chiefari et al. 2009). Consistent 
with this, HMGA mutations have been detected in human diseases such as lipomas 
(Sreekantaiah et al. 1991, Schoenmakers et al. 1995, Ashar et al. 1995), gigantism 
(Ligon et al. 2005), dwarfism (Buysse et al. 2009), and diabetes (Foti et al. 2005). 
Moreover, HMGA2 has also been suggested recently by three genome-wide SNP 
studies to influence human height variation (Weedon et al. 2007, Weedon et al. 
2008, Sanna et al. 2008). 
 
 
1.3 Regulation of gene expression by HMGA proteins 
 
HMGA proteins play a key role in assembling and modulating 
macromolecular complexes that are involved in various biological processes. In 
doing so, HMGA proteins directly bind to the DNA, modifying its conformation 
and consequently facilitating the binding of a group of transcriptional factors (TF). 
They interact with both DNA and TFs to generate a multiprotein stereospecific 
complex bound to DNA. HMGA proteins have been shown to participate in this 
way in the regulation of many gene, the best studied being the human interferon 
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(IFN)- β  gene. Indeed, the activation of IFN-β expression is due to a multifactor 
complex that assembles in the nucleosome-free enhancer region of the gene, which 
includes the factors nuclear factor κ B (NF-κB), the interferon regulatory factor 
(IRF), the activating transcriptional factor 2 (ATF2)/JUN and the HMGA1a 
protein (Thanos and Maniatis 1992, Thanos et al. 1993). 
The direct interaction of HMGA proteins with TFs can take place even in absence 
of DNA. In this case they modify the conformation of TFs, thus enhancing their 
affinity to DNA. The enhancement of transcriptional activity of the TF serum-
response factor by HMGA1a is an example of this mechanism (Chin et al. 1998). 
Finally, the HMGA proteins have the ability to alter chromatin structure. .  Indeed, 
they have been shown to be important elements, associated with matrix- and 
scaffold-associated regions (MARs/SARs), i. e. specific segments of genomic AT 
rich DNA that have a high affinity for the nuclear matrix. These sequences anchor 
chromatin to the nuclear scaffold and organize topologically independent DNA 
domains, which have functional roles both in DNA replication and transcription 
(Galande 2002). The binding of HMGA proteins to these regions de-represses 
transcription by displacement of histone H1 by DNA (Zhao et al. 1993).  
 
 
1.4 HMGA proteins and cancer 
 
In contrast to normal tissues, high levels of HMGA1 and HMGA2 are a 
common feature of human benign and malignant tumours. 
Benign tumors of mesenchymal origin (lipomas, leiomyomas, fibroadenomas, 
aggressive myxomas, pulmonary hamartomas and endometrial polyps) often 
contain chromosomal rearrangements involving the gene HMGA2. These 
rearrangements result in the formation of new hybrid genes that code for chimeric 
proteins in which the AT-hooks of HMGA2 are fused to ectopic peptidic 
sequences (Hess 1998), with loss of the C-terminus and of the 3’UTR of the gene. 
Given the great variability of the partners, but also by the fact that in some cases 
there is no effect attributable to the partner sequence, it is probably the truncation 
of HMGA2 and loss of its 3′ UTR rather than the formation of a new chimeric gene 
that is crucial (Kazmierczak et al. 1995, Kools and Van de Ven 1996). 
Rerrangements and overexpression of the HMGA2 gene have also been described 
in non-mesenchymal benign human tumours, such as pituitary adenomas (Finelli  
et al. 2002, Pierantoni et al. 2005). Consistently, transgenic mice overexpressing 
Hmga1 or Hmga2 develop pituitary adenomas, demostrating the causal role of 
HMGA proteins in the transformation of pituitary gland (Fedele et al. 2002, Fedele 
et al 2005). 
Overexpression of HMGA proteins is a constant feature of several human 
malignant neoplasias, including thyroid, prostate, uterus, breast, colorectum, ovary 
and pancreas carcinomas (Fedele et al. 2001). Moreover, it has been demonstrated 
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that high levels of HMGA represent a poor prognostic index as their 
overexpression often correlates with the presence of metastasis and with a reduced 
survival (Fusco and Fedele 2007). 
Regarding the mechanisms underlying the induction of the HMGA genes in 
malignant transformation, it is reasonable to assume that it probably occurs 
through oncofetal transcriptional mechanisms, which have not yet been well 
characterized (Fusco and Fedele 2007). 
Surprisingly, both heterozygous and homozygous Hmga1-null mice develop age-
dependent splenomegaly associated with lymphoid cell expansions, resembling 
various human B-cell lymphomas (Fedele et al. 2006), suggesting an unexpected 
role for HMGA proteins as tumor suppressors. The observation that HMGA 
proteins accumulate on chromatin in senescent fibroblasts and are essential 
structural components of senescence-associated heterochromatic foci (SAHFs) 
(Narita et al. 2006) could be a possible explanation for this unexpected role for 
HMGA proteins as tumor suppressor. In fact, HMGA proteins might cooperate 
with the p16INK4a tumour suppressor to promote SAHF formation and 
proliferative arrest, and stabilize senescence by contributing to the repression of 
proliferation-associated genes. 
 
 
1.5 Mechanisms of transformation by HMGA 
 
In last years, several studies have demonstrated the causal role of HMGA 
proteins in the process of cell trasformation. A direct evidence of the oncogenic 
role was the demonstration that transfection of HMGA1 or HMGA2 transforms 
rat1a fibroblasts and human lymphoblastoid cell lines (Wood et al. 2000). 
Moreover, infection of normal thyroid cells (FRTL-5) with transforming 
retroviruses such as KiMSV induces overexpression of HMGA proteins. 
Prevention of HMGA proteins expression using antisense oligonucleotides 
prevented the acquisition of the transformed phenotype (growth in soft agar and 
tumor induction in athymyc mice) following viral infection, confirming that 
expression of HMGA proteins has a causal role in cellular transformation 
(Berlingieri et al. 1995) 
Several mechanisms have been proposed to account for the transforming ability of 
the HMGA proteins. Because of their main function as regulators of gene 
transcription, most of these mechanisms are based on the ability of HMGA 
proteins to down- or up-regulate the expression of genes that have crucial roles in 
control of cell proliferation and invasion. Our group has recently demonstrated that 
HMGA2 induces E2F1 activity by displacing Histone Deacetylase 1 (HDAC1) 
from the pRB/E2F1 complex, thus resulting in enhanced acetylation of both E2F1 
and DNA-associated histones, promoting E2F1 dependent gene expression (Fedele 
et al. 2006b). Another mechanism by which the HMGA proteins might have a role 
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in cancer progression is through their interaction with p53. It has been found that 
HMGA1 binds p53 and interferes with the p53-mediated transcription of BCL2-
associated X (BAX)  and cyclin-dependent kinase inhibitor 1A (p21cip1) genes, as 
well as cooperates with p53 to activate transcription of the p53 inhibitor MDM2. 
HMGA1 can also interfere with the apoptotic function of p53 by another 
mechanism that increases the interaction with the proapoptotic p53 activator 
homeodomain-interacting protein kinase 2 (HIPK2) (Pierantoni et al. 2006). It has 
also been demonstrated that HMGA proteins induce cyclin A expression, AP1 
complex activity, and enhance the expression of inflammatory proteins (Fusco and 
Fedele 2007). Finally, recent studies demonstrated that HMGA proteins can 
regulate expression of genes having a crucial role in carcinogenesis, by modulating  
miRNAs  transcription (Fusco and Fedele 2007). 
 
 
1.6 HMGA proteins and DNA repair 
 
Several evidences propose an important role for the HMGA proteins in 
DNA repair. HMGA1 can compete with p53 and human MutS homologue proteins 
(MSH2–MSH6) for Holliday junction binding, exerting a negative influence on 
the DNA mismatch repair response (Subramanian and Griffith 2002). HMGA 
proteins also regulate the transcription of genes that are involved in DNA repair. 
Indeed, using transcriptional microarrays, Reeves and Adair (2005) described a 
number of genes involved in DNA repair that were negatively regulated in MCF7 
human breast-cancer cells by HMGA1 overexpression, suggesting that HMGA 
proteins can influence DNA repair by negatively regulating the transcriptional 
activity of genes involved in various aspects of DNA-damage-recognition and 
removal. Consistently, Borrmann et al. (2003) reported that HMGA2 binds the 
promoter of the nucleotide excision-repair gene ERCC1 and negatively modulates 
its activity. Moreover, it has been shown that HMGA1 can downregulate BRCA1 
expression, which is involved in homologous recombination, by binding directly to 
its promoter region, and that there is an inverse correlation between HMGA1 and 
BRCA1 expression in human breast carcinomas (Baldassarre et al. 2003). 
Consistent with the role of BRCA1 in double-strand break (DSB) repair, it has 
been shown that HMGA proteins enhance genotoxic stress induced by different 
DNA-damaging agents causing DSBs, such as cisplatin, bleomycin, doxorubicin 
and X-ray irradiation (Baldassarre et al. 2005, Boo et al. 2005). Finally, HMGA 
proteins can indirectly inhibit DNA repair through cyclin-A induction, and it has 
been recently reported that the cyclin A1–cyclin-dependent kinase 2 complex also 
regulates DSB repair (Muller-Tidow et al. 2004). 
Recently, a novel unexpected role in DNA repair for HMGA2 has been identified. 
Summer and colleagues demonstrated that HMGA2 is incorporated into the 
cellular Base Excision Repair machinery, operating as an enzyme in the cleavage 
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of abasic nucleotides. In addition, HMGA2 expression protects cancer cells from 
the DNA damage induced citotoxicity during chemotherapy (Summer et al. 2009). 
These observations suggest that the role of HMGA proteins in DNA repair still 
remains controversial, and that new studies will be needed to further analyze the 
effect of HMGA1 and HMGA2 in the DNA damage response and in the processes 
of resistance to anti-neoplastic drugs.  
 
 
1.7 The DNA damage response and the cancer connection 
 
Although its relatively inert chemical nature, DNA is constantly under 
attack by a large number of agents, and it has been estimated that many thousands 
of DNA lesions occur every day in each cell of the human body (Jackson 2009). 
Cellular DNA can be damaged in several different ways: nucleotide bases can be 
covalently altered, the DNA phosphodiester backbone can be broken on one strand 
(single strand breaks, SSBs) or on both strand (double strand break, DSBs) or 
chemical interstrand cross-links can be produced (Kastan and Bartek 2004). A 
large proportion of DNA lesions are a physiological consequence of hydrolytic 
reactions induced by reactive oxygen species produced by the normal cellular 
metabolism (Jackson 2009). Moreover, many environmental agents such as 
ionizing radiation (IR), ultraviolet (UV) light and chemical mutagens contribute to 
the DNA damage production (Jackson 2009). DNA lesions can cause inhibition of 
genome replication and transcription, and if they are not repaired or are repaired 
incorrectly, they can produce mutations or large-scale genome aberrations that 
may lead to cell malfunction or cell death (Mills et al. 2003, Caldecott 2008, 
Lobrich and Jeggo 2007). Because a broad range of DNA lesion can occur, 
evolution has provided a variety of different repair mechanisms to deal with both 
metabolic and external sources of DNA damaging agents (Jackson 2009). These 
mechanisms, fortunately, are able to accurately and efficiently repair the vast 
majority of the DNA damages (Jackson 2009). 
Free oxygen radicals, generated by normal metabolic processes or following the 
exposure to a source of IR, can alter the backbone of DNA helix breaking the 
phosphodiester bonds between two nucleotides, determining SSBs. 
When two or more of these breaks are present close to each other, but on opposite 
DNA strands, a DSB occurs. DNA DSBs are generally considered the most 
cytotoxic lesions produced by IR and radiomimetic drugs, and are also generated 
when the DNA replication machinery encounters DNA lesions such as SSBs or 
pyrimidine dimers, which can determine a stall of replication forks. Moreover, 
Topoisomerase II-inhibitors exert their cytotoxic activity inducing DSBs. 
Although many variations on the precise mechanisms of DSBs repair exist, two 
largely distinct and complementary repair pathways have been identified: Non-
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Homologous End Joining (NHEJ) and Homologous Recombination  (HR) 
(Jackson 2009, Haber 2000, Karran 2000). 
Repair of DNA DSBs is intrinsically more difficult than other types of DNA 
damage, and inefficiently repaired DSBs may cause mutations, loss or 
amplification of chromosomal material and, if it inactivates essential genes, can 
affect cell survival (Khanna and Jackson 2001, Rich 2000, Wyman and Kanaar 
2006). Moreover, defects in the DSBs repair machinery can lead to exchange of 
chromosomal arms, sometimes in a reciprocal fashion (Khanna and Jackson 2001). 
These chromosomal aberrations represent a common feature of human neoplasias. 
In fact, if a deleted region contains a tumour suppressor gene, or if an amplified 
region contains an oncogene, the chromosomal rearrangement may induce cellular 
transformation (Khanna and Jackson 2001). Sometimes the exchange of 
chromosomal arms leads to the formation of a fusion gene encoding for a 
chimerical protein which acquires an oncogenic potential, or places a proto-
oncogene under the transcriptional control of a strong promoter, determining its 
over-expression. Accordingly, epidemiologic studies, animal models and the 
observation that many human cancer susceptibility syndromes arise from 
mutations in genes involved in DNA damage responses have widely demonstrated 
that damage to cellular DNA has a causal role in cancer (Kastan and Bartek 2004). 
However, this notion is not the only interesting link between DNA repair and 
cancer. Induction of DNA damage is also the main therapeutic approach currently 
used by the majority of therapies used to treat malignancies, such as radiation 
therapy and chemotherapeutic agents (Kastan and Bartek 2004). Moreover the 
DNA damage-induced apoptosis is  the main determinant of side effects of 
common therapies, which are usually associated to bone marrow suppression, GI 
toxicities, and hair loss (Kastan and Bartek 2004). Thus, DNA damage is the cause 
of the disease, is used to treat the disease and is responsible for the toxicity of anti-
cancer therapies. 
 
 
1.8 Cellular response to DNA Double Strand Breaks 
 
The way that cells react to DSBs is to trigger a complex and co-ordinated 
set of events that is often termed the DNA damage response (DDR) (Zhou and 
Elledge 2000, Rouse and Jackson 2002). The DDR involves a number of proteins 
that sense the damage (DNA damage sensors) and activate downstream DNA 
damage transducers, which amplify the signal triggered by the sensors, and 
activate the effectors of DDR (Khanna and Jackson 2001). 
Initiation of the activities of the PI(3)K (phosphatidyl-inositol-3-OH kinase)-like 
kinases (PIKKs) ATM (ataxia teleangiectasia mutated) and ATR (ATM- and Rad-
3 related) and are the first step characterized to date in the activation of signal 
transduction pathways after DNA damage (Kastan and Bartek 2004). In particular, 
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the ATM kinase seems to be primarily activated following DNA damage whereas 
the ATR kinase is critical for cellular responses to the arrest of DNA-replication 
forks (Shiloh and Kastan 2001, Abraham 2001). However, although ATM and 
ATR have long been assumed to respond to non-overlapping damage signals 
(DNA DSBs in the case of ATM, and UV-induced base damage and stalled 
replication forks in the case of ATR) recent data suggest that ATM can activate 
ATR after DSBs in the S and G2 phases (Cuadrado et al. 2006), demonstrating the 
presence of a link between ATM and ATR pathways. 
Another member of the PIKKs family, DNA-PKcs (catalytic subunit of DNA 
dependent protein kinase) is also involved in the DNA damage response, but its 
role is more directly correlated to the process of DNA repair, rather than to the 
activation of cell cycle checkpoints or apoptosis (Cann and Hicks 2007). 
DSBs are recognized rapidly within cells, but the mechanism of DSB recognizing 
remains controversial (Cann and Hicks 2007). One model of DSB recognition 
hypothesizes that DSB-induced changes in chromatin structure are enough to 
activate ATM, the pinnacle kinase in the DSB signalling cascade (Bakkenist and 
Kastan, 2003). In this model, ATM would be the DNA damage sensor and the 
transducer of the DNA damage-triggered signalling, at the same time. Recent data 
indicate that ATM, in conjunction with the MRN (Mre11/Rad50/Nbs1) complex, 
can also activate ATR after DSBs in the S and G2 phases (Cuadrado et al. 2006, 
Jazayeri et al. 2006). Following the activation of MRN by ATM, the nuclease 
activity of Mre11 processes the DSB to produce ssDNA that is coated by RPA 
(replication protein A), which in turn leads to the recruitment of ATR, through the 
intermediary protein ATRIP. Hence, this first model indicates ATM and ATR as 
“proximal checkpoint kinases” (Shiloh 2003). In the other model of DSB 
recognition, the MRN complex first detects the DSB by binding to the broken 
ends. Once bound, the MRN complex recruits and promotes the activation of ATM 
(Lee and Paull 2005). Indeed, the C-terminus of Nbs1 contains an ATM 
interaction motif, which is required for the retention of ATM to sites of DNA 
damage, and activation of checkpoint pathways (Falck et al. 2005). Regardless of 
which protein physically recognizes the DSB, there appears to be a mutual 
promotion of activity between the MRN complex and ATM. In fact, ATM 
phosphorylates Nbs1 (Gatei et al. 2000) and the MRN complex enhances ATM 
kinase activity (Lee and Paull, 2005).  Following their activation, ATM and ATR 
directly phosphorylate a number of substrates that play a direct role in the cellular 
response to DNA damage. Moreover, this signalling is also amplified by the 
ATM/ATR dependent activation of other kinases such as CHK1 and CHK2 
(Zhang et al. 2004, Bartek and Lukas 2003) also known as transducer or effector 
kinases. The activation of CHK1 and CHK2 spread the alert signal and orchestrate 
the global cellular response to DNA damage. Indeed, DSB-induced activation of 
DNAdamage sensor initiates signal transduction pathways activating cell cycle 
checkpoints, DNA repair, apoptosis or senescence (Khanna and Jackson 2001). 
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Cell cycle checkpoints following DSBs 
One of the key aspects of these DNA-damage-signalling events is the induction of 
checkpoint mechanisms that slow down or stop cell-cycle progression while the 
damage persists, preventing the replication of DNA or segregation of damaged 
chromosomes during mitosis (Jackson 2009). 
Genotoxic stress can transiently delay cell-cycle progression in G1, S or G2 trough 
a checkpoint network response controlled by the ATM/ATR-CHK2/CHK1 
pathway (Kastan and Bartek 2004), or even impose a prolonged a durable cell 
cycle arrest in either G1 or G2 phases. Given the critical significance of error-free 
DNA replication and chromosome segregation for the maintenance of genomic 
integrity and the prevention of cancer, it is not surprising that these most 
vulnerable stages of the cell-division cycle are protected by a wider spectrum of 
checkpoint-effector mechanisms (Kastan and Bartek 2004). 
The dominant checkpoint response to DNA damage in mammalian cells traversing 
through G1 is the ATM(ATR)/CHK2(CHK1)-p53/MDM2-p21 pathway, which is 
capable of inducing sustained and sometimes even permanent G1 arrest (Kastan, 
and Lim 2000, Bartek and Lukas 2003, Wahl and Carr 2001). Although the 
expression of ATM and CHK2 is relatively constant during the cell cycle, the 
concentrations of ATR and CHK1 are low in the early-to-mid G1, and their 
activities become important only closer to the G1/S transition. ATM/ATR directly 
phosphorylate the p53 transcription factor within its amino-terminal 
transactivation domain, particularly on serine 15. In addition, the ubiquitin ligase 
MDM2, that normally binds p53 and ensures rapid p53 turnover, is targeted after 
DNA damage by ATM/ATR (Maya et al. 2001), as well as by CHK2/CHK1 
(Kastan and Bartek 2004). These modifications of p53 and MDM2 contribute to 
the stabilization and accumulation of the p53 protein, as well as to its increased 
activity as a transcription factor. The key transcriptional target of p53 is the 
p21CIP1/WAF1 inhibitor of cyclin-dependent kinases (Kastan and Lim 2000, 
Wahl and Carr 2001), which silences the G1/S-promoting cyclin E/Cdk2 kinase 
and thereby causes a G1 arrest. This leads not only to the inability to initiate DNA 
synthesis, but it also preserves the RB/E2F pathway in its active, growth-
suppressing mode, thereby causing a sustained G1 blockade (Kastan and Bartek 
2004). Thus, the G1 checkpoint response targets two critical tumour suppressor 
pathways, governed by p53 and pRB. These are arguably the two mechanisms that 
are most commonly deregulated in human cancer (Kastan and Lim 2000). 
Progression into the S phase and transition from G2 into M are regulated by the 
serine-threonine cdk2 and cdk1 (cdc2), respectively. Activation of cdk2 and cdk1 
(cdc2) requires the association of their positive subunits, cyclin A and cyclin B, 
respectively, and the phosphorylation of Thr161 by cdk-activating kinase. These 
cdk-cyclin complexes are also negatively regulated by phosphorylation at Thr14 
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and Tyr15, which are catalyzed by inhibitory protein kinases, including Wee1, 
Myt1 and Mik1 (Nigg 2001). 
During S phase progression and at G2/M phase transition, dephosphorylation of 
Thr14 and Tyr15 by the cdc25 protein phosphatase cdc25A, -B, and -C, triggers 
cdk2-cyclinA (intra-S phase) and cdk1 (cdc2)-cyclinB (at G2/M transition) 
activation. During the DNA damage response, activation of ATM/ATR and the 
downstream checkpoint kinases CHK1/CHK2 leads to the phosphorylation of 
cdc25 phosphatases, which creates binding sites for 14-3-3 proteins and 
sequestration of the phosphatases away from cdk2-cyclinA and cdk1 (cdc2)-
cyclinB (Borgne and Meijer 1996; Peng et al. 1997, Zeng et al. 1998, Sanchez et 
al. 1997, Matsuoka et al. 1998). 
The G2 checkpoint (also known as the G2/M checkpoint) prevents cells from 
initiating mitosis when they experience DNA damage during G2, or when they 
progress into G2 with some unrepaired damage inflicted during previous S or G1 
phases (Xu et al. 2002, Nyberg et al. 2002). The accumulation of cells in G2 may 
also reflect a contribution of the so-called DNA replication checkpoint (often 
referred to as the S/M checkpoint) that may sense some of the persistent DNA 
lesions from the previous S phase as being inappropriately or not fully replicated 
DNA. The critical target of the G2 checkpoint is the mitosis-promoting activity of 
the cyclin B/CDK1 kinase, whose activation after various stresses is inhibited by 
ATM/ATR, CHK1/CHK2 and/or p38-kinase- mediated subcellular sequestration, 
degradation and/or inhibition of the CDC25 family of phosphatases that normally 
activate CDK1 at the G2/M boundary (Donzelli and Draetta 2003, Nyberg et al. 
2002, Katsuhiro et al. in press, Mailand et al. 2002, Bulavin et al. 2001). In 
addition, other upstream regulators of CDC25C and/or cyclin B/CDK1, such as the 
Polo-like kinases PLK3 and PLK1 seem to be targeted by DNA-damage-induced 
mechanisms (Nyberg et al. 2002). 
 
Mechanisms of DNA repair following DSBs  
Following DNA damage, the main target of the cell is the repair of toxic genome 
lesions. Within minutes following exposure to ionizing radiation (IR), activated 
ATM phosphorylates H2AX in the C-terminal tail at Ser139 over a region of 
megabases surrounding a DSB (Burma et al. 2001). In a parallel manner, ATR 
phosphorylates H2AX after replicational stress (Ward and Chen 2001). Many 
DNA damage response proteins are then quickly recruited to the sites of DSBs, 
and this recruitment can be visualized almost immediately following laser beam-
induced DSBs (Celeste et al. 2003). These proteins, then, build up to form ionizing 
radiation-induced foci (IRIF), which are the conventional manifestation of DNA 
damage-induced relocalization. The time frame for IRIF formation is protein 
dependent: H2AX (Rogaku et al. 1998) 53BP1 (p53 Binding Protein 1)(Anderson 
et al. 2001) and MDC1 (mediator of mammalian DNA damage-checkpoint 1) 
(Stewart et al. 2003) IRIF formation occur within minutes following IR exposure, 
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and are thought to represent sites of DNA damage. Other factors, such as Rad51, 
MRN complex, ATM, BRCA1 and Rad52 do not form IRIF until over 3 hours 
after IR exposure (Celeste et al. 2002, Haaf et al. 1995). While the exact function 
of thee IRIF remains to be determined, H2AX has been shown to be required for 
the retention of BRCA1, 53BP1 and the MRN complex to these foci (Celeste et al. 
2002). H2AX is not required for the initial recruitment of these proteins, 
suggesting a role in the later development and maintenance of IRIF, but not in the 
recruitment of proteins to sites of DNA damage (Celeste et al. 2002). Probably, 
histone modifications such as phosphorylation of H2AX during the first phases of 
DNA damage repair have a crucial role in chromatin reorganization, necessary to 
improve the accessibility of DNA repair factors to the damaged DNA (Jackson 
2009). 
Following IR exposure, ATM also directly phosphorylates 53BP1 (Anderson et al. 
2001), MDC1 (Goldberg et al. 2003) BRCA1 (Xu et al. 2001) and c-Abl 
(Baskaran et al. 1997). C-Abl can regulate the function of Rad51 in both positive 
(Chen et al. 1999) and negative (Yuan et al. 1998) manners, indicating that ATM 
can also indirectly regulate Rad51 through its activation of c-Abl. ATM also 
indirectly activates BRCA1 via CHK2 (Zhang et al. 2004). The BRCA-Carboxy-
terminal domain (BRCT)-containing proteins Nbs1, MDC1, 53BP1 and BRCA1 
are all thought to function as mediators, helping to bring together various repair 
and checkpoint proteins (Li and Zou 2005) MDC1, for example, has been shown 
to be critical for recognizing phosphorylated H2AX and helps to amplify the DSB 
signal through interaction with ATM for a more effective response (Lou et al. 
2006). MDC1 also interacts with the recombinase Rad51 (Zhang et al. 2005) and 
functions in checkpoint control (Lou et al 2003).  BRCA2 can interact with both 
Rad51 and BRCA2 (Yoshida and Miki 2004), is required for some ATM-
dependent phosphorylation events (Foray et al. 2003), and has a role in checkpoint 
control (Xu et al. 2001). Nbs1 directly functions sensing damage and activating 
ATM through the MRN complex (Lee and Paull 2005). The MRN complex is also 
involved in repair because of the nuclease activity of Mre11 (Van den Bosch et al. 
2003). Moreover, Nbs1 also functions in the intra-S-phase checkpoint (Lim et al. 
2000) and helps ATM-dependent phosphorylation events required for the G1/S 
checkpoint (Girard et al. 2002). Finally, 53BP1 also appears to promote ATM 
activation following DSBs (Mochan et al. 2003) and functions in activating the 
G2/M checkpoint (Fernandez-Capetillo et al. 2002). 
Once the DSB response have been initiated, the breaks are repaired by two main 
pathways: non -omologous end-joining (NHEJ) or homologous recombination 
(HR) (Karagiannis and El-Osta 2004). 
NHEJ is the predominant pathway in mammalian cells and is used almost 
exclusively during G1 and early S phases (Karagiannis and El-Osta 2004). In this 
pathway, the regulatory subunits of DNA-PK, Ku70 and Ku80, first bind the 
broken ends of the DNA, thereby recruiting the catalytic subunit of DNA-PK 
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(DNA-PKcs). After DNA ends processing, potentially by the MRN complex or 
Artemis, the Ligase IV/XRCC4 complex ligates the strands together (Jackson 
2001). However, ligation of processed DNA ends usually incur in deletions or 
additions of nucleotides, and the repaired DNA shows a different sequence respect 
to the original DNA. Therefore, this process is considered an error-prone pathway 
(Jackson 2001, Karagiannis and El-Osta 2004). 
Homologous recombination preferentially uses sister chromatid as a template for 
this repair mechanism, and appears to be only used in late S and G2 phases (Hiom 
1999). The first step in HR is the production of 3’ single-stranded tails of DNA via 
a 5’-to-3’ strand resection on each side of the break site (Karagiannis and El-Osta, 
2004), by the MRN complex. Single stranded DNA is then coated with RPA 
(Iftode et al. 1999), and the recombinase enzyme Rad51 is loaded onto these tails. 
BRCA2 seems to play a critical role in this loading process, as well as in the sub-
cellular localization and regulation of Rad51 (Pellegrini and Venkitaraman 2004). 
The Rad51-loaded filament invades the homologous site of the intact sister 
chromatid to produce a D-Loop structure (Karagiannis and El-Osta 2004). Using 
the undamaged chromatid as a template, DNA polymerases synthesize new DNA 
to span the break site, beginning form the 3’ tails. Following this DNA synthesis, 
endonucleases cleave and resolve the Holliday Junctions, eventually generating 
two separate, intact chromatids (Karagiannis and El-Osta, 2004). Other proteins 
are involved in this repair mechanism, including the other Rad51-like proteins 
(Rad51B, Rad51C, Rad51D, XRCC2 and XRCC3) and Rad54 (Karagiannis and El 
Osta 2004). Rad54 is a member of the SWI2-SNF2 protein family, and its role is 
to unwind DNA, remodelling chromatin during repair to modulate the accessibility 
of DNA to DNA repair factors (Tan et al. 1999). 
 
Apoptosis following DSBs  
Depending on the severity of the DNA damage or the cell type involved, cells may 
undergo apoptosis instead of attempting to repair the damage (Sionov and Haupt 
1999). For example, lymphocytes are particularly sensitive to apoptosis, partly 
because IR exposure induces Bax expression, differently form fibroblast cell lines 
(Sionov and Haupt, 1999). Mouse embryonic stem cells also respond to IR 
exposure by undergoing apoptosis (Hong and Stambrook 2004). 
Following DSBs , apoptosis is initiated through an ATM directed pathway. ATM, 
as previously described, activates p53 directly and indirectly, via Chk2 (Bree et al. 
2004). Again, ATM also inactivates MDM2, the main negative regulator of p53 
(Khostravi et al. 1999). Transcription of pro-apoptotic genes is the main 
mechanism of p53-induced apoptosis. p53, in fact, is able to upregulate 
transcription of NOXA, PUMA and Bid (Schuler and Green 2005), which belongs 
to the BH3-only protein family, inhibitors of anti-apoptotic factors such as BCL-2 
and BCL-XL (Bree et al. 2004).  As mentioned above, p53 also upregulates the 
expression of Bax, a BH123 protein that forms channels in mitochondrial 
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membrane, which results in the release of Cytochrome C and Smac/Diablo, and 
determines the loss of mitochondrial membrane potential. Release of Cytochrome 
C activates the Apaf-1-Caspase 9 apoptotic pathway, and inhibition of IAPs 
(Inhibitor of Apoptosis Proteins) by Smac/DIABLO impairs caspase inhibition 
(Borner 2003). Recently it has been demonstrated that p53 modulates apoptosis 
also in a transcription independent manner. Following IR exposure, p53 is 
translocated to mitochondria, where it inhibits Bcl-2 and Bcl-XL, and activates 
Bak, another BH123 protein (Bree et al. 2004). 
The dual functions of ATM and p53 in promoting cell cylce arrest and apoptosis 
lead to some seemingly contradictory phenotypes. In fact, ATM defective cells are 
generally carachterized by radiation hypersensitivity (Barlow et al. 1996), while 
thymocytes from ATM-/- mice are actually resistant to radiation-induced apoptosis 
(Xu and Baltimore 1996). This duality of function also exists in other systems 
defective of DNA damage response proteins, including p53 (Bernstein et al. 2002) 
and DNA-PKcs (Bernstein et al. 2002). These observations suggest that there are 
as yet unidentified proteins involved in the regulation of the cross-talk between the 
mutually exclusive pathways of maintenance of life and initiation of death. In fact, 
while much is known about individual pathways within the cellular DSB response, 
there is still much we need to learn about how these pathways are integrated to 
provide a concerted response to DNA double strand breaks (Cann and Hicks 
2007). 
 
Cellular senescence following DSBs 
Recent investigations in the field of cellular senescence have revealed the 
importance of DNA damage responses and cell-cycle checkpoints to initiate cell-
cycle arrest associated with cellular senescence. Replicative (or the “Hayflick 
limit”) and premature senescence share a common signal, now recognized as DNA 
strand breaks. In replicative senescence, telomere erosion and shortening yield 
DNA double-strand breaks at chromosome ends that initiate DNA damage 
responses (Herbig et al. 2004, d'Adda di Fagagna et al. 2003). In premature 
senescence, oncogenic activation leads to elevated intracellular levels of reactive 
species, augmented numbers of active replicons, alterations in DNA replication 
fork progression, and the appearance of DNA single- and double-strand breaks that 
initiate DNA damage responses (Takahashi et al. 2006; Di Micco et al., 2006; 
Bartkova et al., 2006; Hemann and Narita, 2007). Similarly, DNA-damaging 
chemotherapeutic and radiotherapeutic agents provoke DNA-replication fork 
stalling and/or DNA single- and double-strand breaks with activation of the DNA 
damage response network (Holliday and Tarrant 1972, Kung et al. 1990, Di 
Leonardo et al. 1994, Waldman et al. 1996, Robles and Adami 1998). Indeed, in 
models of cellular senescence, ATM/ATR mediate the activation of cell-cycle 
checkpoints associated with cellular senescence, mainly via p53, CHK1 and 
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CHK2, with the participation of p21, p16 and Rb (Schmitt et al. 2007). It has been 
suggested previously that after genotoxic drug treatment, cell-cycle arrest and 
senescence development are dependent on the p53/p21 pathway in HCT116 colon 
cancer cells (Han et al. 2002). Similar observations concerning the importance of 
the p53/p21 pathway have been reported with other chemotherapeutic agents or 
irradiation (Di Leonardo et al. 1994, Waldman et al. 1996, Bunz et al. 1998, Linke 
et al. 1997). Likewise, studies with bleomycin, actinomycin D and 
cyclophosphamide have revealed that cells respond to these agents by engaging a 
p53/p16-dependent long-term senescence program (Robles and Adami 1998, 
Schmitt et al. 2002). However, others have reported senescence phenotypes 
(observed by flow cytometry after DNA staining as broader G1 or G2/M peaks, 
and with the appearance of a senescence-associated β -galactosidase activity) in 
p53-mutated cell lines derived from various types of human solid tumors, 
including cervical, larynx and colon carcinoma, glioma, osteosarcoma (Chang et 
al. 1999a) and lymphoma cell lines (Schmitt et al. 2007).  
The DNA damage responses induced in the early phase of cellular senescence 
initiation explain how cells will activate cell-cycle checkpoints and undergo cell-
cycle arrest at specific phases of the cell cycle. However, after DNA damage, cell-
cycle arrests do not always lead to cellular senescence. Indeed, cell-cycle arrests 
often afford cells the opportunity to repair DNA damage before progressing to the 
next phase of the cycle. In turn, inappropriate progression of damaged cells 
through the cell cycle is often associated with mitotic catastrophe, apoptosis and 
cell death. Thus, the stabilization of cell-cycle arrests to irreversible senescence 
involves other yet unknown critical events. Recently, epigenetic changes, 
including histone H3 lysine K9 trimethylation (H3K9) associated with gene 
silencing, have been suggested as critical mechanisms associated with the 
stabilization of cell-cycle arrest to cellular senescence, as senescent cells show 
focal histone H3K9 trimethylation. These foci are now referred to as senescence-
associated heterochromatin foci (SAHFs) (Schmitt et al. 2007, Strunnikova et al. 
2005, Guney and Sedivy 2006, Zhang et al. 2007). Early evidences indicated that 
H3K9 trimethylation controls DNA methylation in several model organisms 
(Tamaru and Selker 2001, Tamaru et al. 2003, Jackson et al. 2002). Methylation of 
CpG islands in promoters and locus control regions is strongly associated with 
H3K9 trimethylation and gene silencing. Indeed, others have indicated that some 
gene promoters are hypomethylated, whereas others undergo hypermethylation 
during cellular senescence, suggesting that differential DNA methylation patterns 
at specific gene promoters and locus control regions may stabilize the senescence 
phenotype (Tollefsbol and Andrews 1993). 
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1.9 ATM, guardian of the genome 
 
Ataxia-telangiectasia (A-T) is an autosomal recessive disorder that is 
characterized by early-onset progressive cerebellar ataxia, oculocutaneous 
telangiectasia, susceptibility to bronchopulmonary disease, and lymphoid tumours 
(Meulmeester et al. 2005). Various other abnormalities are also associated with 
this disorder, including the absence or the rudimentary appearance of a thymus, 
immunodeficiency, progressive apraxia of eye movements, insulin-resistant 
diabetes, clinical and cellular radiosensitivity, cell-cycle checkpoint defects and 
chromosomal instability (Taniguchi et al. 2002). The gene that is defective in A-T, 
A-T Mutated (ATM), was localized to chromosome 11q22–23 (Houldsworth et al. 
1980) and cloned by positional cloning (Falck et al. 2001). ATM is a Ser/Thr 
protein kinase and is a member of the phospho- inositide 3-kinase (PI3K)-related 
protein kinase (PIKK) family, which also includes ATM and Rad3-related protein 
(ATR), the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and 
SMG1, a protein kinase that is involved in the DNA damage response but is also 
required for nonsense-mediated decay of mRNA that contains premature 
terminator codons (Lavin and Kozlov 2007). The kinase domain is located close to 
the C-terminus in all of these proteins except SMG1, in which the kinase domain 
is more central. This domain has protein kinase activity, and p53 was the first 
substrate of ATM to be identified in vitro and in vivo (Peng et al. 1997, Xu et al. 
2001, Aprelikova et al. 2001). This was not surprising, because the stabilization 
and activation of p53 was defective in A-T cells, and these cells were also 
characterized by a defective G1–S checkpoint, in which p53 has a central role 
(Yarden et al. 2002, Gatei  et al. 2000). 
ATM has also a number of other domains, including a FAT domain (which is 
common to ATM, mammalian target of rapamycin (mTOR) and 
transformation/transcription domain- associated protein (TRRAP)) (Kozlov et al. 
2006) and an extreme C-terminal FATC domain that is found in combination with 
FAT domain in this subfamily of proteins. Other domains include an N-terminal 
substrate-binding domain, a leucine-zipper domain, a proline-rich region that 
enables it to bind to ABL kinase (Suzuki et al. 2004) and a peroxisomal targeting 
signal sequence (PTSI). 
ATM is present in the nucleus as an inactive dimer (or higher order oligomer) that, 
following DNA damages or structural changes of chromatin, undergoes activation 
through autophosphorylation and monomerization (Bakkenist and Kastan 2003). 
Once activated, ATM phosphorylates its substrates on residues of serine or 
threonine followed by a glutamine residue (the so called S/TQ domain) (Lavin and 
Kozlov 2003). As above described, ATM associates with the Nbs1-Mre11-Rad50 
(NMR) complex during activation process, and this complex subsequently acts as 
an adaptor for the phosphorylaton of many downstream pathways. The activation 
of ATM leads to the rapid phosphorylation of a multitude of proteins that are 
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involved in DNA repair, cell-cycle checkpoint activation and transcription (Kurose 
et al. 1981, Tanaka et al. 2007). A series of large-scale proteomic studies have 
identified extensive phosphoprotein networks that are responsive to DNA damage 
(Stark et al. 2006, Bakkenist and Kastan 2003, Di Tullio et al. 2002). In these 
studies, as many as 900 induced phosphorylations on ATM and ATR consensus 
sites of over 700 proteins have been identified. These proteins were found 
arranged in interconnecting modules that are involved in DNA repair, DNA 
replication and cell-cycle control (Stark et al. 2006). It is probably unlikely that all 
of these phosphorylations are direct substrates for ATM, and might be dependent 
on other PIKKs. 
Following its activation, ATM signals to cell-cycle checkpoints to slow the 
passage of cells through the cycle and facilitate DNA repair (Taniguchi et al. 
2002). ATM also responds to physiological breaks in DNA during the 
development and differentiation of B and T cells (Sapkota et al. 2002). It has been 
shown that ATM is also activated during the resolution of DNA DSBs that are 
generated by V(D)J recombination (Viniegra et al. 2005). 
Although ATM is predominantly a nuclear protein that responds to DNA DSBs, 
there is also evidence for a cytoplasmic form, which has been found to be 
associated with both peroxisomes and endosomes (Banin et al. 1998, Saito et al. 
2002). These findings suggest a more general signalling role for ATM that does 
not involve direct DNA damage. A series of abnormalities in ATM-deficient cells 
provide indirect evidence for an extranuclear role for ATM (Khosravi et al. 1999). 
These abnormalities include reduced internalization of phytohaemagglutinin 
(PHA), defective calcium mobilization, depolarization in response to extracellular 
potassium, greater growth factor demand and defective signalling through the 
epidermal growth factor (EGF) receptor. More direct evidence demonstrates the 
ability of insulin to activate ATM, as shown by the phosphorylation of 4EBP1 and 
the subsequent dissociation of eukaryotic translation-initiation factor (eIF)4E from 
4EBP1, thereby making it available for initiation of mRNA translation (Maya et al. 
2001). Pertinent to these results is the observation that some A-T patients develop 
insulin-resistant diabetes (Pereg et al. 2005, Chen et al. 2005). 
Rapid recruitment of DNA damage recognition and repair proteins to distinct foci 
is observed in response to agents that damage DNA or cause the arrest or collapse 
of DNA-replication forks (Cortezet al 2004, Yoo et al. 2004). Although this 
recruitment is rapid, the order in which these proteins localize to sites of DNA 
damage is gradually being resolved. DNA DSBs lead to the accumulation of the 
MRN complex, whose retention on chromatin is dependent on the mediator of 
DNA damage checkpoint protein-1 (MDC1) adaptor protein. ATM also arrives 
early at the damaged site, initially associating with DNA regions that flank the 
break, before associating with the MRN complex at the break site through the C-
terminus of NBS1 (Buscemi et al. 2006, Oakley et al. 2001). Interaction of MDC1 
with ATM through its PHA domain regulates the accumulation of ATM at 
 23 
damaged sites. MDC1 also mediates the interaction between ATM and the 
phosphorylated form of H2AX, which presumably contributes to the long-range 
phosphorylation of H2AX and the maintenance of the response (Yoo et al. 2004). 
The order of assembly of DNA-damage-response proteins at DNA DSBs, and the 
structural requirements for their interaction, has been facilitated by the use of 
microlasers and charged particle tracks to generate DSBs (Di Tullio et al. 2002, 
Huang et al. 2006). ATM-dependent phosphorylation of the histone variant H2AX 
to produce γH2AX seems to be the initial signal for subsequent accumulation of 
DNA-damage-response proteins (Ichijima et al. 2005, McManus et al. 2005). 
It seems likely that ATM is at least partially activated adjacent to DNA DSBs 
(Buscemi et al. 2006), probably owing to the initial relaxation of chromatin 
structure by the break. The activation of ATM by chloroquine, histone deacetylase 
inhibitors or hypotonic buffer supports this hypothesis (Rao et al. 2005). However, 
ATM that is activated by these factors does not localize to nuclear foci and fails to 
phosphorylate H2AX, but it is capable of phosphorylating p53, which suggests 
that ATM needs to be localized to the break for complete activation. During its 
activation, ATM undergoes autophosphorylation on at least three sites (Ser367, 
Ser1893, Ser1981), and one of them (Ser1981) seems to be instrumental in the 
monomerization and activation of ATM (Rao et al. 2005, Chen et al. 2005). 
Activation of ATM by okadaic acid suggests that also phosphatase activity is 
important in maintaining ATM in a basal state (Dornan et al. 2006). Moreover, 
agents that alter chromatin structure activate ATM and cause phosphorylation of 
p53, but fail to induce phosphorylation of SMC1, NBS1 and other substrates 
(Foray et al. 2002, Rao et al. 2005). 
It is indeed evident that ATM plays a central role in responding to DNA DSBs by 
directly phosphorylating or mediating the phosphorylation and activation of 
multiple substrates in signalling to the DNA repair machinery and the cell cycle 
checkpoints. 
 
 
 
1.10 Role of ATM and DDR in cellular resistance to genotoxic therapies 
 
As previously mentioned, it is clear that the field of DDR research is of huge 
relevance to cancer therapy. In fact, aside from surgery, DNA-damaging agents, in 
the form of radiotherapy and various chemotherapies, are numerically by far the 
most effective and broadly used treatments for cancer. Secondly, the effectiveness 
of such treatments and the side effects caused by them reflect the inability of 
cancer cells and normal cells respectively to repair therapy-induced DNA lesions. 
Conversely, when such treatments fail and cancer recurs, this is generally due to a 
fraction of the cancer cells having repaired the therapy-induced DNA lesions 
(Khanna and Jackson 2001, Kastan and Bartek 2004). To compensate for the loss 
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of specific DNA repair pathways, different or faulty DNA repair pathways may be 
induced to enable tumor cells to survive. The activation of other repair pathways 
has been suggested to be responsible for the limited response of tumors to radio- 
and chemotherapy. If the DNA repair pathways essential for the survival of cancer 
cells can be identified and disrupted, this will allow chemotherapy to be much 
more efficient. Thus, it can be argued that targeting both checkpoint and repair 
pathways in combination may selectively kill tumor cells over healthy cells 
(Bolderson et al. 2009). Moreover, it has been suggested that genetically unstable 
cells such as tumor cells are “addicted” from a single faulty DNA repair 
mechanism to improve their survival following DNA damages, while normal cells 
use several DNA repair mechanisms to correctly activate the DDR (Jackson 2009).  
Based on these observations, several groups have identified a number of chemical 
compounds that target the DSBs repair machinery, enhancing the effects of 
genotoxic chemo- and radiotherapy.   
The first suggestion that ATM may be an attractive target for chemotherapy was 
that cells from patients with the genomic instability disorder ataxia telangiectasia, 
resulting from a mutation in the ATM gene, were exquisitely sensitive to radiation 
(Savitsky et al. 1995). In addition, caffeine (a known inhibitor of ATM) could 
increase cellular sensitivity to radiation and chemotherapeutic drugs (Sarkaria et 
al. 1999, Sabisz et al. 2008), although its lack of specificity and potency makes it 
unsuitable as a clinical agent. LY294002 is another ATM inhibitor, which broadly 
inhibits the kinase activity of PIKKs. Like caffeine, the widespread use of 
LY294002 has been restricted by its lack of specificity. However, it has been used 
as a research tool for the design of more specific PIKK inhibitors. A highly 
specific small molecule ATP competitive inhibitor of ATM named KU-55933 was 
identified via screening of a drug library based on LY294002 (Hickson et al. 
2004). This compound can efficiently sensitize tumor cells to radiation and DSB-
inducing chemotherapeutic agents, such as camptothecin and etoposide, and there 
are suggestions that this compound may be used as a potential clinical treatment. 
There is also an indication that inhibitors of the ATM-mediated pathway may also 
sensitize cells deficient in other DNA repair pathways to cancer treatments. 
Validation of this idea was initially borne out when a high-throughput iRNA 
screen identified ATM as a target that disrupted the growth of cells deficient in the 
Fanconi anemia (FA) pathway (Kennedy et al. 2007).  
As for A-T cells, cells lacking DNA-PK are hypersensitive to IR and to DNA-
crosslinking agents, and are defective in DSB repair, whereas increased DNA-PK 
activity confers radioresistance and chemoresistance on tumor cells (Collis et al. 
2005, Shinohara et al. 2005); these reports lead to the conclusion that inhibition of 
DNA-PK could prevent efficient DNA repair, and thus could lead to accumulation 
of cytotoxic DNA lesions. Several selective DNA-PK inhibitors have also been 
developed recently: NU7026, NU7441, vanillin, IC87102, IC87361, and Su11752 
(Shinohara et al. 2005, Durant et al. 2003, Ismail et al. 2004, Willmore et al. 
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2004). These agents impede DSB repair and sensitize tumor cells to IR and/or 
DNA-damaging agents such as idarubicin, daunorubicin, etoposide, doxorubicin 
and cisplatin to different extents and with varying degrees of specificity. In 
addition, there are also reports that some DNA-damaging agents can inhibit DNA-
PK activity themselves, e.g. inhibiting topoisomerase II at the same time as 
disrupting the NHEJ pathway, providing an explanation for their greater 
effectiveness in cancer treatment (Lu et al. 2005). 
In addition to directly inhibiting ATM, ATR and DNA-PK pharmacologically, the 
levels of expression could also be regulated by using small interfering RNAs 
(siRNAs). For example, transfection of cells with specific siRNAs that target 
messenger RNAs, the expression level of ATM, ATR, or DNA-PKcs was reduced 
by 90%, and the resulting radiosensitivity was significantly higher than with use of 
wortmannin or LY294002 (Collis et al. 2003) 
Indeed, these data suggest that identification of new drugs or pharmacological 
approaches to inhibit the activity of ATM and/or to affect the DDR could reduce 
chemo-resistance and radio-resistance of cancer cells, main obstacles in the 
treatment and management of malignant cancers. 
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2. AIM OF THE STUDY 
 
 
Despite compelling evidences and results have suggested a critical role of 
HMGA proteins in DNA repair, the mechanisms by which they act in this 
fundamental cell process are still controversial and poorly understood. By 
sequence analysis we found a conserved SQ motif in both HMGA1 and HMGA2, 
the consensus recognized and phosphorylated by ATM. Therefore we investigated 
whether ATM interacts and phosphorylates HMGA proteins. Our results, reported 
here, prompted us to further investigate the role of HMGA proteins in the ATM 
pathway. Given the widely described ability of HMGA proteins to modulate gene 
expression, we analyzed the ability of both HMGA1 and HMGA2 to bind and 
regulate ATM promoter. Subsequently, we investigated the role of this novel 
identified ATM/HMGA pathway in the cellular response to different stresses 
affecting DNA stability. Finally, since it has been recently demonstrated that 
inhibition of ATM kinase activity reduces cancer cells resistance to DNA 
damaging agents, we explored the possibility that abrogation of HMGA protein 
expression could be used to enhance tumor sensitivity to genotoxic treatments. 
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3. MATERIALS AND METHODS 
 
3.1 Chemicals and treatments 
 
For γ-irradiation experiments, cells were irradiated by 6 MV X-ray of a 
linear accelerator with doses ranging from 0 to10 Gy. For UV-irradiation 
experiments, cells were treated using a Stratalinker 1800 (Stratagene) with doses 
ranging from 0 to 20 J/m2. For ATM inhibition experiments, cells were treated 
with KU-55933 (10 µM) for 1 h. 
 
 
3.2 Immunoprecipitations and Western Blots 
 
Cell extracts were prepared and co-immunoprecipitations were performed 
as previously described (Pentimalli et al. 2008) in the presence or absence of 100 
ng/µl ethidium bromide. Anti- FLAG M2 (Sigma) or anti-HA Clone 12CA5 
(Roche) monoclonal antibodies were used for co-immunoprecipitation 
experiments along with protein A/G-sepharose (Amersham Biosciences). Anti-P-
ATM-substrate (phospho-Ser/Thr antibody) (Cell Signalling Technology) was 
used to evaluate the phosphorylation of HMGA proteins by ATM in vivo. Proteins 
were resolved by 3–8% NuPAGE (Invitrogen) or by 15% SDS–PAGE and 
transferred to high or low molecular weight nitrocellulose, respectively. Western 
blots were performed using the above-mentioned anti-FLAG and anti-HA 
antibodies, or anti-ATM polyclonal antibody (Novus Biologicals) anti-HMGA1 
and anti-HMGA2 polyclonal antibodies (raised against the amino-terminal region 
of the proteins), anti-ATM S181p (Rockland), anti-p53 DO-1 and anti-p-p53 
(Ser15) (Santa Cruz). Anti-vinculin (7F9) (Santa Cruz) was used as loading 
control. All the antibodies were diluted (1:200/500) in 5% non-fat dry milk 
(Biorad). 
 
 
3.3 Cell cultures, Transfections and Plasmids 
 
HEK-293T, MCF-7, SAOS-2, HeLa and FRO cells were cultured in 
DMEM supplemented by 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 
U/ml penicillin and 0.1 mg/ml streptomycin (GIBCO-BRL). PC-Cl3 cells were 
grown in Ham's F-12 medium, Coon's modification (Sigma) supplemented with 
5% foetal calf serum (FCS) (ICN Flow), and six growth factors (10 nM TSH, 10 
nM hydrocortisone; 100 nM insulin; 5 µg/ml transferrin; 5 nM somatostatin; 20 
µg/ml glycyl-hystidyl-lysine) (6H). MEFs were established from 14.5 dpc 
embryos following the standard procedures, and cultured in DMEM supplemented 
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by 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin 
and 1% non-essential aminoacids (GIBCO-BRL). FRTL-5, FRTL-5-Ki and FRTL-
5-asHMGI-Ki cells (provided by Dr. M.T. Berlingieri) were cultured as described 
by Berlingieri et al. (1995). NIH-3T3 cells were grown in DMEM supplemented 
with 10% FCS, 100 U/ml penicillin and 0.1 mg/ml streptomycin (GIBCO-BRL). 
MEFs were transfected using Neon Electroporation System (Invitrogen) according 
to manufacturer’s instructions. All the other transfections were performed by 
Lipofectamine 2000, as suggested by the manufacturer. HMGA1 and HMGA2 
cDNA were cloned into pCEFL-HA in frame with the HA epitope, as described 
elsewhere (Pierantoni et al. 2001, Fedele et al. 2006). The pFLAG-ATM 
previously described (Canman et al. 1998) were kindly provided by Dr M.B. 
Kastan. The pLucATM reporter plasmid was a kind gift of Dr D. Ginsberg. 
 
 
3.4 Luciferase and Clonogenic assays 
 
For the Luciferase assay, cells were seeded into each well of six well plate 
and transiently transfected with 1 µg of pLucATM and with 500 ng of pCEFLHa-
HMGA1 and pCEFLHa-HMGA2 (except for PC-Cl3 cells, transfected with 50 ng 
of the same plasmids), together with 0.5 µg of Renilla and various amounts of the 
pCEFLHa plasmid to keep constant the total DNA concentration. Luciferase and 
Renilla activity were assessed with the dual light luciferase system (Promega). The 
Luciferase activity was normalized for the Renilla activity. All the experiments 
were performed three times in triplicate, and the mean ± S.D. was reported. 
For the clonogenic assay, FRTL-5, FRTL-5-Ki, FRTL-5-asHMGI-Ki, FRO and 
FRO-asHMGI cells were seeded at a density of 103 cells per 35-mm dish. Two 
days after, cells were treated with different doses of UV-light or IR, as described 
in the results. After 10 or 15 days, cells were stained with 500 mg/ml of crystal 
violet in 20% methanol, and the resulting colonies were counted. The mean of 
colony counts normalized for untreated control was reported. 
 
 
3.5 Senescence assays 
 
Early-passage MEFs, FRTL-5, FRTL-5-Ki and FRTL-5-asHMGI-Ki cells 
were treated as described in the results, and Senescence-Associated-β-
galactosidase activity was assessed. Cells were washed in PBS, fixed for 7 min 
(room temperature) in 2% formaldehyde/0,2% glutaraldehyde, washed and 
incubated at 37ºC (without CO2) over-night with fresh Senescence-Associated-β-
galactosidase staining. Cells were analyzed with light microscopy to determine the 
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percentage of senescent cells. At least 20 fields for each experimental point were 
analyzed. Reported values are the mean ± S.D. of three independent experiments. 
 
 
3.6 Cell-cycle analysis 
 
Cells were plated in 6-well plates at a density of 106 cells per well, 
incubated for 24 h and then exposed to 20 J/m2 of UV. Where indicated, cells were 
also treated with 0,2 µg/ml of Nocodazole, following the UV-treatment. Cells 
were harvested at different timepoints, as indicated in the results, then fixed with 
ice-cold 70% ethanol, treated with RNase-I (Invitrogen) and stained with 10 µg/ml 
of Propidium Iodide to label DNA. Cells were sorted on a FACS-Calibur flow 
cytometer (Becton Dickinson), and the results were analysed with ModFit 
software, 3.2 version (Verity Software House). Experiments were performed in 
triplicate and representative cell-cycle profiles were reported. 
 
 
3.7 Apoptosis Assays 
 
FRO and FRO-asHMGI were plated in 6-well plates at a density of 106 
cells per well, incubated for 24 h and untreated or exposed to 20 J/m2 of UV. Cells 
were then harvested after 24 h, fixed with  ice-cold 70% ethanol, stained with 10 
µg/ml of Propidium Iodide to label DNA and FITC-Annexin V antibody (BD 
Biosciences), following manufacturer’s instructions. Annexin V-PI positive cells 
were analyzed using FACS-Calibur flow cytometer (Becton Dickinson). 
Experiments were performed in triplicate and representative annexin V-PI profiles 
were reported. Apoptosis was also quantified by measuring caspase 3 and 7 
activation, using Caspase-Glo 3/7 assay (Promega) on a Bio-Tek Synergy HT 
multi detection microlpate reader. The assay was performed three times in 
triplicate, and the mean ± S.D. was reported. 
 
 
3.8 RNA extractions and semiquantiative (sq)RT-PCR 
 
Total RNAs were extracted from cell culture using TRI REAGENT 
(Molecular Research Center, Inc.) solution, according to the manufacturer’s 
instructions. The integrity of the RNA was assessed by denaturing agarose gel 
electrophoresis (virtual presence of sharp 28S and 18S bands) and 
spectrophotometry. RNAs were treated with Dnase-I (Invitrogen) and reverse-
transcribed using random exanucleotides as primers and MuLV reverse 
transcriptase (Perkin Elmer). For semiquantitative PCR, reactions were optimized 
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for the number of cycles to ensure product intensity within the linear phase of 
amplification. The PCR products were separated on a 2% agarose gel, stained with 
ethidium bromide and scanned using a Typhoon 9200 scanner. Primers used were: 
mmuATM-F: 5’-ATTGGGATGCTGTTTTCAGG-3’ 
mmuATM-R: 5’-TAGCCTGGGTGCTCTTTTGT-3’ 
mmup21-F: 5’-TCCACAGCGATATCCAGACA-3’ 
mmup21-R: 5’-GGCACACTTTGCTCCTGTG-3’ 
mmuActin-F: 5’-TCAGAAGGACTCCTATGTGG-3’ 
mmuActin-R: 5’-CGCAGCTCATTGTAGAAGGT-3’ 
 
 
3.9 Chromatin Immunoprecipitation (ChIP) assays 
 
ChIP assays were carried out with an acetyl-Histone H3 
immunoprecipitation assay kit (Upstate Biotechnology) according to 
manufacturer’s instructions, as described by De Martino et al. 2009. Chromatin 
was immunoprecipitated from NIH-3T3 and 293T cells transfected with 
pCEFLHa-HMGA1, pCEFLHa-HMGA2 or the empty vector using 2 µg of anti-
HA antibody (Santa Cruz) or normal rabbit IgG as negative control. Input and 
immunoprecipitated DNA were analyzed by PCR to detect the presence of human 
or murine ATM promoter. PCR reactions were performer with AmpliTaq gold 
DNA polymerase (Applied Biosystems). Primers used to amplify the sequence of 
promoters were: 
mmuATMprF: 5’-ATTGGGATGCTGTTTTCAGG-3’ 
mmuATMprR: 5’-TAGCCTGGGTGCTCTTTTGT-3’ 
hsaATMprF: 5’-AACACAGCGACAGCTCCTG-3’ 
hsaATMprR: 5’-AGTGACGACAGTTCCGAAGG-3’ 
 
 
3.10 Comet Assays 
 
MEFs irradiated or not with 4 Gy of IR were allowed to repair the DNA for 
0 and 3 h in complete medium and then processed for the COMET assay 
(Trevigen). The assay was performed following manufacturer’s instructions. 
Briefly, MEFs were plated at a density of 1 x 105 cells/ml the day before the assay. 
Cells were exposed or not to 4 Gy of IR, allowed to repair for 3 h and then 
harvested in 1 ml of PBS 1X. 50 µl of cells were suspended in 500 µl of low 
melting point agarose and pipetted onto a CometSlideTM. Slides were incubated at 
4°C for 20 min in the dark, immersed in prechilled lysis solution for 45 min and 
then in alkaline solution for 60 min in the dark. After two washes in TBE 1X, 
slides were transferred in a horizontal electrophoresis apparatus, covered with 
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TBE 1X buffer and run for 30 min at 1 V/cm. Slides were then incubated in 
ethanol for 5 min, air dried, and stained with SYBRTM Green and analysed with 
epifluorescence microscopy. Cell images were analysed using COMET ScoreTM 
(TriTek Corp.). Comet tail moment was used as the measure of DNA damage. In 
each experiment, 100 comets were measured per experimental point and the mean 
tail moment values + S.D. were evaluated. 
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4. RESULTS AND DISCUSSION 
 
 
4.1 HMGA proteins interact and are phosphorylated by ATM 
 
Similarly to other PIKKs, ATM phosphrylates its substrates on serine or 
threonine residues, generally followed by glutamine (the so-called SQ/TQ or S/TQ 
motif). Since HMGA proteins are extensively post-translationally modified and 
phosphorylation has been frequently reported (Edberg et al. 2005, Sgarra et al. 
2004, Zou and Wang 2005), we decided to investigate whether ATM can interact 
with and phosphorylate HMGA1 and HMGA2. Sequence analysis revealed that 
both HMGA proteins contain in their COOH terminal region a consensus site for 
ATM phosphorylation (serine 88/glutamine 89 for HMGA1, serine 102/glutamine 
103 for HMGA2), which is highly conserved among different species and the 
different HMGA family members (Figure 1a). To determine whether ATM 
interacts in vivo with HMGA1, we transiently transfected 293T cells with 
expression vectors containing the full-length cDNAs for ATM, fused to the FLAG 
tag, and HMGA1 fused to the HA epitope. Total cell lysates were 
immunoprecipitated using an anti-HA antibody and analyzed by western blot using 
either anti-ATM or anti-FLAG antibodies. As shown in Figure 1b, FLAG-ATM 
was specifically co-immunoprecipitated with HA-HMGA1. Moreover, HA-
HMGA1 was able to interact and co-immunoprecipitate also with the endogenous 
ATM protein. Similar experiments were obtained transfecting 293T cells with 
FLAG-ATM and HA-HMGA2 contructs. In fact, following immunoprecipitation 
using anti-FLAG antibody, HA-HMGA2 was revealed by western blotting using 
anti-HA antibody only in cells expressing FLAG-ATM (Figure 1c). Like HA-
HMGA1, also HA-HMGA2 interacted with endogenous ATM, as shown in Figure 
1d. Since ATM and HMGA proteins are chromatin-associated proteins, co-
immunoprecipitations in Figure 1b and 1c were performed also in the presence of 
ethidium bromide, to exclude that their co-immunoprecipitations may be 
dependent on contaminating DNA. 
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Figure 1. HMGA proteins interact with ATM. (a) Aminoacid sequence alignment of HMGA1 
and HMGA2 from the indicated species (AT-hooks are shown in bold, ATM consensus site is 
circled in red). (b-d) 293T cells were transfected as indicated, and total cell lysates were 
immunoprecipitated using anti-HA or anti-FLAG antibodies. Western blots were performed 
using the antibodies indicated on the side. Ethidium bromide (EtBr) was added during 
immunoprecipitations to exclude that co-immunoprecipitation could be dependent from 
contaminating DNA. Normal rabbit IgG (d) were used as a negative control for the co-
immunoprecitipation of HA-HMGA2 and endogenous ATM. 
 
 
To assess in vivo that HMGA1 and HMGA2 are phosphorylated by ATM, 293T 
cells were transfected with HA-HMGA1 or HA-HMGA2 expression vectors and 
treated with 10 Gy of IR. To assess the specificity of the phosphorylation, cells 
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were also treated with 10 µM KU-55933, a specific inhibitor of ATM kinase, for 1 
h before the exposure to IR. Cells were collected 30 min after the IR treatment and 
total cell lysates were immunoprecipitated using an antibody that recognizes serine 
and threonine residues phosphorylated by ATM (Anti-P-Sub-ATM). Analysis of 
the immunoprecipitates from HA-HMGA1-transfected cells by western blot using 
an anti-HA antibody revealed a band corresponding to the HA-HMGA1 only in 
cells exposed to IR. . This co-immunoprecipitation was prevented by using KU-
55933 to inhibite ATM kinase activity (Figure 2a). Conversely, HA-HMGA2 was 
immunoprecipitated by the Anti-P-Sub-ATM also in cells not treated with IR. 
However, IR treatment significantly increased the amount of immunoprecipitated 
HA-HMGA2, and ATM inhibition by KU-55933 prevented this increase (Figure 
2b). 
 
 
Figure 2. HMGA proteins are phosphorylated in vivo by ATM. 293T cells transfected with 
vectors expressing either HA-HMGA1 (a) or HA-HMGA2 (b) were treated or not with a 10 
Gy dose of IR to induce activation of endogenous ATM. Total cell extracts were 
immunoprecipitated with an antibody able to recognize serine and threonine residues 
phosphorylated by activated ATM (Anti-P-Sub-ATM). Immunoprecipitates were analysed by 
SDS–PAGE followed by Western blot with anti-HA antibody. 293T cells were also pre-
treated for 1 h with 10 µM KU-55933 as a control of the phosphorylation specificity. 
 
 
These data indicate that both HMGA1 and HMGA2 are novel interactors and 
substrates of ATM, following exposure to DNA damaging agents, such as IR. 
Moreover, they show that HMGA2 is also phosphorylated by other kinases in 
unperturbed cells, but its state of phosphorylation is significantly increased by the 
induction of ATM kinase activity. 
 
 
4.2 Lack of Hmga1 and Hmga2 affects ATM expression 
 
As mentioned above, HMGA proteins positively or negatively regulate the 
transcriptional activity of several genes (Fusco and Fedele 2007, Fedele et al. 
2001). In particular, our previous studies have demonstrated that HMGA proteins 
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enhance E2F1 transcriptional activity by displacing HDAC1 from the pRB/E2F1 
complex (Fedele et al. 2006 Since it has been shown that the ATM gene is a target 
for positive regulation by E2F1 (Berkovich and Ginsberg, 2003), we thought to 
evaluate a possible physiological role of HMGA proteins in the regulation of ATM 
expression. To this aim we analyzed the expression levels of ATM mRNA and 
protein in Mouse Embryonic Fibroblasts (MEFs) lacking one or both Hmga genes 
(De Martino et al., manuscript in preparation). As reported in Figure 3, western 
blot and semi-quantitative RT-PCR analysis showed that the expression levels of 
ATM are strongly influenced by the presence of HMGA proteins. In fact, ATM 
mRNA and protein levels were strongly reduced in MEFs carrying only one 
disrupted Hmga gene (Hmga1-/- or Hmga2-/- MEFs) were strongly reduced, 
compared to wild-type controls, and almost absent in double knock-out MEFs 
(Hmga1-/-/Hmga2-/- or Hmga1/2 DKO MEFs). These results, indicative of a 
positive regulation of ATM expression by HMGA proteins, are consistent with the 
above-mentioned role of HMGA in the positive regulation of E2F1 transcriptional 
activity. Moreover, reduced levels of active ATM, assessed using an antibody 
directed against its phopshorylated serine 1981 (ATMser1981), were also reduced 
in Hmga1/2 DKO MEFs compared to wild-type controls. These observations 
suggested that HMGA proteins have a positive role in the control of both ATM 
expression and activation, leading us to further investigate a possible impairment 
of ATM-downstream pathways in Hmga1/2 DKO MEFs. 
 
Figure 3. Reduced expression and activation of ATM  in Hmga1/2 DKO MEFs. (a) Total cell 
extracts from wild-type, Hmga1 SKO, Hmga2 SKO and Hmga1/2 DKO MEFs were analyzed 
by SDS-PAGE and western blot using the indicated antibodies. Vinculin was analyzed as a 
loading control. (b) Semi-quantitative (sq) RT-PCR, using mRNA from cells as in (a), was 
used to assess ATM and p21 gene expression levels. Actin gene expression was evaluated as 
well to normalize RNA levels. 
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Previous studies on Atm-/- MEFs have indicated a significant involvement of p53 
and p21 in cellular defects in the absence of ATM protein (Xu et al. 1996, Xu et al. 
1998). In fact it has been demonstrated that, following DNA damage, ATM 
phosphorylates p53 and enhances its transcriptional activity on several target 
promoter, such as p21 (Lavin and Kozlov 2007). Therefore, we first analyzed the 
levels of p53 phosphorylation on serine 15 (p53ser15), the p53 residue that is the 
target of ATM kinase activity (lavin1). According to the reduced expression of 
ATM in Hmga1/2 DKO MEFs, we found that the absence of HMGA proteins 
reduced the phosphorylation of p53 on this residue (Figure 3a). Then, p21 
expression was analyzed. As Figure 3b shows, the absence of both Hmga genes 
almost abolished the levels of p21 mRNA. However, MEFs lacking only the 
Hmga1 gene showed only a slight reduction of p21 mRNA, while Hmga2 knock-
out MEFs expressed p21 mRNA levels comparable to Hmga1/2 DKO MEFs. 
These data suggest that HMGA proteins, and in particular HMGA2, exert a 
positive effect on p21 expression, dependent, at least in part, by the ATM/p53 
pathway. 
 
 
4.3 HMGA proteins bind and activate ATM promoter 
 
To investigate whether HMGA proteins bind ATM promoter in vivo, we 
performed ChIP experiments using both murine NIH-3T3 (Figure 4a) and human 
293T (Figure 4b) cells transiently transfected with either HA-HMGA1 or HA-
HMGA2 expression vectors. Transfection with the empty vector pCEFL-HA was 
also carried out as a negative control. Chromatin was immunoprecipitated using 
anti-HA or normal rabbit IgG antibody. As shown in Figures 3a and 3b, the ATM 
promoter was amplified only from the DNA recovered with anti-HA antibody in 
both NIH-3T3 and 293T cells transfected with HA-HMGA1 or HA-HMGA2, but 
not in cells transfected with the empty vector. No amplification was obtained in 
the samples immunoprecipitated using normal rabbit IgG. 
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Figure 4 HMGA proteins bind the ATM promoter in vivo. Lysates from murine NIH-3T3 (a) 
and human cells, transfected with plasmids expressing HA-HMGA1, HA-HMGA2 and empty 
vector, as indicated in the above the panels, were subjected to ChIP using specific polyclonal 
antibody, as indicated on the right. Immunoprecipitates from each sample were analyzed by 
PCR using specfic primers for mouse and human ATM promoter. 
 
 
To confirm the positive effect of HMGA proteins on the ATM promoter, we 
performed luciferase assays transfecting a construct expressing the luciferase 
reporter gene under the transcriptional control of the human ATM promoter (pLuc-
ATM, region -512 to +9) (Berkovich and Ginsberg, 2003) along with either 
HMGA1 or HMGA2 expression vectors. As previously described, ATM promoter 
activity is dependent on the cellular context (Gueven et al. 2003), as well as 
HMGA proteins transcriptional activity (Martinez-Hoyos et al. 2004), therefore we 
performed luciferase assays in different cell types, including HeLa, SAOS-2, NIH-
3T3, MCF-7 and PC-Cl3 cells. As shown in Figures 5a-e, transfection of HMGA1 
had a positive effect on ATM promoter transcriptional activity in SAOS-2 and 
MCF-7 cells. Otherwise, HMGA2 activates ATM promoter in NIH-3T3 and HeLa 
cells. Finally, both HMGA1 and HMGA2 up-regulate ATM promoter in PC-Cl3 
cells. To further confirm our observations, we transfected the pLuc-ATM reporter 
plasmid in wild-type, Hmga1 KO, Hmga2 KO and Hmga1/2 DKO MEFs. Figure 
5f shows that transcriptional activity of ATM promoter is strongly dependent on 
the presence of HMGA proteins. In fact, absence of HMGA1, HMGA2 or both 
HMGA proteins significantly reduced ATM promoter activity, accordingly with 
the results obtained from semi-quantitative RT-PCR and western blot experiments 
(Figure 2). 
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Figure 5.	  Regulation of ATM promoter by HMGA proteins. (a-e) HeLa (a), MCF-7 (b), NIH-
3T3 (c), SAOS-2 (d) and PC-Cl3 (e) cells were transfected with expression vectors for either  
HMGA1 or HMGA2, along with luciferase reporter vector pLuc-ATM. Luciferase activity 
was assessed 48 h after the transfection. (f) Wild-type, Hmga1 KO, Hmga2 KO and Hmga1/2 
DKO MEFs were transfected with pLuc-ATM and luciferase activity was assessed after 48 h. 
The data reported are the mean ± S.D. of three independent experiments performed in 
triplicate. 
 
 
4.4 Phosphorylation of HMGA proteins by ATM enhances their 
transcriprional activity on ATM promoter 
 
ATM activation by DNA damaging agents determines the direct and 
indirect phosphorylation of a number of substrates, which results in the modulation 
of their function in order to trigger an effective cellular response to the DNA 
damage (Lavin and Kozlov 2007). Therefore, we hypothesized that ATM-
dependent phosphorylation of HMGA1 and HMGA2 could have a role in the 
modulation of their function following the exposure to DNA damaging agents. To 
evaluate this potential effect of ATM kinase activity on HMGA proteins, we 
performed luciferase assays co-transfecting the expression vectors encoding 
HMGA1 (Figure 6a) or HMGA2 (Figure 6b) along with the reporter construct 
pLuc-ATM, and assessed HMGA protein activity on ATM promoter following the 
exposure to IR. The transfections were performed in PC-Cl3 normal thyroid cells, 
which express very low levels of endogenous HMGA1 and HMGA2 with low 
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amounts of the HMGA expression vectors (50 ng), to prevent any toxic effect 
following the overexpression of these proteins. After 24 h from the transfection, 
PC-Cl3 cells were treated or not with 3 Gy of IR, in order to activate ATM kinase 
activity. As a specificity control of ATM kinase activation, cells were also pre-
incubated with KU-55933 for 1 h. As shown in Figures 6a and 6b, in the absence 
of HMGA proteins, both IR and KU-55933 did not affect the transcriptional 
activity of ATM promoter. Otherwise, in cells transfected with either HMGA1 or 
HMGA2, IR slightly but significantly (p<0,05) enhanced HMGA-dependent up-
regulation of this promoter. 
Conversely, the treatment with KU-55933 prevented the IR-dependent increase of 
HMGA activity on ATM promoter, indicating that this effect is dependent on 
ATM kinase activity. 
 
 
Figure 6 DNA damage activates HMGA-mediated ATM expression. PC-Cl3 cells were 
transfected with expression vectors encoding for HMGA1 (a) or HMGA2 (b), along with the 
luciferase reporter vector pLuc-ATM. 24 h after transfection, cells were treated or not 
treated with 10 µM KU-55933 for 1 h and then treated with 3 Gy of IR. 24 h after IR 
exposure, luciferase activity was assessed. Data reported are the mean ± SD of three 
independent experiments performed in triplicate. 
 
 
These data clearly indicate that HMGA proteins play a crucial role in the 
regulation of expression of ATM. Moreover our observations indicate the 
existence of a positive feedback loop on ATM promoter dependent by HMGA 
proteins. Following ATM activation in response to DNA damage, HMGA proteins 
increase their transcriptional activity and sustain the expression of ATM. 
 
 
4.5 MEFs lacking Hmga genes display an altered DNA damage response 
 
The data discussed above led us to investigate the biological effect of the 
HMGA-mediated regulation of ATM gene expression. To this aim, we analyzed 
the DNA damage response of MEFs lacking one or both Hmga genes, by 
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performing a single-cell gel electrophoresis (Comet) assay on these cells, 
following IR exposure. Wild-type, Hmga1 -/-, Hmga2 -/- and Hmga1/2 DKO 
MEFs were either treated or not with 4 Gy of IR to induce DNA DSBs and 
activate ATM-mediated DDR. Cells were harvested before or immediately after 
the treatment, or were allowed to repair DNA damage for 3 h. Then, we analyzed 
the ability of their DNA to migrate far from the cell under the influence of an 
electric field. Only undamaged DNA retains round shape, while damaged DNA 
migrates away from the nucleus depending on the molecular weight of DNA 
fragments, acquiring the characteristic comet shape. After the staining of DNA 
with Sybr Green, cells were analyzed by fluorescence microscopy and images 
were acquired and analyzed by the COMET SCORETM freeware (Figure 7a). To 
quantify the amount of damaged DNA, we evaluated the “tail moment” (a 
parameter that keeps in count the comet length, the tail length, and the percentage 
of DNA contained in the head and in the tail of the comet) of comets. Hmga1 -/-, 
Hmga2 -/- and Hmga1/2 DKO MEFs displayed similar levels of DNA damage 
before and immediately after the treatment with IR compared to wild-type MEFs 
(Figure 7b). However, after 3h, wild-type MEFs almost completely recovered the 
damage, while Hmga1/2 DKO still showed significant levels of damaged DNA. In 
contrast, Hmga1 -/- and Hmga2 -/- MEFs did not significantly differ from wild-
type controls. These observations suggest that absence of both HMGA proteins 
determines a significant impairment of the DNA-damage repair machinery, 
probably because of the reduced cellular levels of ATM. However, the presence of 
only one of the two HMGA genes is sufficient to sustain enough levels of ATM 
that, in turn, promotes DNA damage repair. 
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Figure 7. Impaired DNA damage repair in MEFs lacking HMGA1 and HMGA2. (a) Wild 
type, Hmga1-null, Hmga2-null and Hmga1/Hmga2-null MEFs, exposed or not to 4 Gy of IR, 
were allowed to repair for 0 h and 3 h and processed for COMET assay. Cells were stained 
with SYBR Green, visualized by fluorescence microscopy and then analyzed by COMET 
Score. A representative comet is shown.(b) DNA damage was quantified analyzing comet tail 
moment using COMET Score. The bars represent the mean tail moment values ± S.D. of 
three independent experiments (100 comets were measured per experimental point in each 
experiment).  
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4.6 Impaired expression of HMGA proteins prevents stress-induced 
senescence 
 
As previously described, ATM also plays a key role in cellular senescence, 
and several recent reports has demonstrated that stress- and oncogene-induced 
senescence has a key role in the process of transformation and in the acquisition of 
resistance to genotoxic therapies (d'Adda di Fagagna 2008, Crescenzi et al. 2008, 
Viale et al. 2009). Moreover, our previous data indicated that Hmga1/2 DKO 
MEFs undergo replicative senescence more rapidly than wild-type MEFs (De 
Martino et al. manuscript in preparation). Therefore, we decided to investigate 
whether absence of HMGA proteins can affect stress-induced senescence in early-
passage MEFs. Wild-type, Hmga1 -/-, Hmga2 -/- and Hmga1/2 DKO MEFs were 
treated with sub-lethal doses of IR (1-2Gy) and senescence-associated β-
galactosidase (SA β-gal), a marker of cellular senescence, was assessed 72 h after 
the treatment. As shown in Figure 8a, untreated MEFs, regardless of the genotype, 
showed similar levels of SA β-gal positive cells. Conversely, following IR 
exposure, we observed a significant increase in SA β-gal positive cells only in 
wild-type and Hmga2 -/- MEFs, while Hmga1 -/- and Hmga1/2 DKO MEFs were 
almost refractory to the stress-induced senescence. Figure 8b shows a 
quantification of SA β-gal positive cells for wild-type, Hmga1 -/-, Hmga2 -/- and 
Hmga1/2 DKO MEFs, untreated or following IR exposure. This result suggests 
that absence of both HMGA1 and HMGA2 prevents stress-induced senescence, 
probably because of their low levels of ATM. Moreover, HMGA1 seems to be 
more involved than HMGA2 in this process, because only Hmga1 -/-, and not 
Hmga2 -/- cells, were resistant to stress-induced senescence. Therefore, other 
ATM-independent pathways, involved in IR-induced senescence, are likely to be 
affected by the absence of HMGA1. 
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Figure 8. Absence of HMGA proteins impairs DNA damage induced senescence. (a) Early-
passage wild type, Hmga1-null, Hmga2-null and Hmga1/Hmga2-null MEFs were treated or 
not with different doses (1-2 Gy) of IR. 96 h after IR exposure, Senescence-Associated β-
galtactosidase (SA-β-gal)-staining was performed and light microscope cell images acquired. 
A representative image of each experimental point is reported. (b) Quantification of SA-β-gal 
positive cells. Values are the mean ± S.D. of three independent experiments. At least 20 
different fields were analyzed for each experimental point. 
 44 
4.7 Impaired expression of HMGA proteins prevents oncogene-induced DDR 
 
Activation of oncogenes such as H-RAS, BRAF, E2F1 and MYC drives an 
initial hyperproliferation phase, but this burst is quickly followed by cell cycle 
slowing down and establishment of ATM-dependent DDR, that results in 
oncogene-induced senescence (OIS). OIS is a tumor suppressor mechanism that 
impedes the proliferation of a cell overexpressing an aggressive oncogene (d'Adda 
di Fagagna 2008). Then, adaptive mechanisms, such as inactivation of tumor 
suppressor genes, allow the restart of DNA replication and cell proliferation 
(d'Adda di Fagagna 2008). However the mechanisms of senescence allow 
transformed cells to slow down their cell cycle in order to prevent accumulation of 
high levels of DNA damage and exhaustion of cancer stem cells (Viale et al. 
2009). 
To assess the role of HMGA protein in OIS, we used a cell system originally 
developed in our laboratories consisting in a rat thyroid epithelial cell line (FRTL-
5), stably expressing or not an HMGA1-antisense construct that impairs both 
HMGA1 and HMGA2 expressions (FRTL-5-asHMGI) (Berlingieri et al. 1995), 
and infected with the murine transforming retrovirus KiMSV carrying the 
oncogene Ki-Ras. As previously demonstrated (Berlingieri et al. 1995), following 
the infection with KiMSV, the cells (FRTL-5-Ki cells) acquired a fully 
transformed phenotype and overexpressed HMGA proteins. Conversely, 
prevention of HMGA expression (FRTL-5-asHMGI-Ki cells) impaired the 
acquisition of the fully transformed phenotype. Here we show, by western blot 
analysis of FRTL-5-Ki and FRTL-5-asHMGI-Ki cells, that absence of HMGA 
proteins determined a reduction in ATM cellular levels (Figure 9a). We then 
analyzed the amount of SA β-gal positive cells and found that, as shown in Figures 
9b and 9c, prevention of HMGA1 and HMGA2 expression strongly reduced the 
senescence induced by the infection with KiMSV, confirming the role of HMGA 
proteins in OIS. Next, we investigated whether prevention of HMGA proteins 
expression increases cell sensitivity to genotoxic treatments such as IR exposure. 
To this aim we performed a clonogenic assay in FRTL-5-Ki and FRTL-5-
asHMGI-Ki cells after treatement with increasing amounts of IR (1-3 Gy). As 
shown in Figure 9d, the number of colonies formed by FRTL-5-asHMGI-Ki 
following IR exposure, normalized for the number of colonies obtained from 
untreated cells, was significantly reduced compared to FRTL-5-Ki cells. 
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Figure 9. Inhibition of HMGA protein expression prevents ATM-dependent OIS and 
enhances radiosensitivity of transformed cells. (a) Total cell extracts from FRTL-5, FRTL-5-
Ki and FRTL-5-asHMGI-Ki cells were analyzed by western blot using the indicated 
antibodies. (b) Senescence-Associated β-galtactosidase (SA-β-gal)-staining performed on 
FRTL-5, FRTL-5-Ki and FRTL-5-asHMGI-Ki cells. A representative image of each 
experimental point is reported. (c) Quantification of SA-β-gal positive cells. Values are the 
mean ± S.D. of three independent experiments. At least 20 different fields were analyzed for 
each experimental point. (d) Clonogenic assay following IR exposure on FRTL-5, FRTL-5-Ki 
and FRTL-5-asHMGI-Ki cells. Cells were cultured for 2 weeks after an exposure to 1 or 3 Gy 
of IR. Colonies were stained using Crystal Violet staining. The results were normalized with 
respect to the untreated cells. Values are the mean ± S.D. of three independent experiments. 
 
 
One possible explanation of these observations is that HMGA1 and HMGA2, 
enhancing ATM expression, increase cellular DDR levels. Increased DDR slows 
down cell cycle following oncogene overexpression or DNA-damaging-agents 
treatment, allowing transformed cells to have the time to repair (not necessarily in 
correct manner) DNA damage and thus survive. Conversely, inhibition of HMGA 
proteins expression impairs the ATM-dependent DDR, thus enhancing sensitivity 
of cancer cells to DNA-damaging agents. 
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4.8 Down-regulation of HMGA1 protein enhances cancer cell sensitivity to 
DNA damage 
 
Overexpression of HMGA1 is a common feature of human solid and 
haematological malignancies. The data here reported clearly indicate a critical role 
for HMGA proteins in the positive regulation of ATM expression and, 
consequently, in DDR. Over the last few years, an increasing body of evidence has 
accumulated to suggest that inhibition of ATM kinase activity can enhance cellular 
sensitivity to DNA-damaging agents (Jackson 2009). Our results suggested that 
inhibition of HMGA proteins affect ATM expression, resulting in the reduction of 
the ATM-mediated DDR and improvement of cell sensitity to DNA-damaging 
agents. Therefore, we further investigated whether inhibition of HMGA protein 
expression could represent a valid alternative to other chemical inhibitors of ATM 
kinase activity in human tumor cells. We used FRO anaplastic human thyroid 
cancer cells, which express high levels of HMGA1, and generated a FRO cell 
clone, stably expressing the previously mentioned anti-HMGI antisense construct 
(FRO-asHMGI). Western blot analysis (Figure 10a) confirmed the abrogation of  
both HMGA1 expression and, consistent with our previous data, ATM protein 
levels. 
 
 
Figure 10. Downregulation of HMGA1 proteins sensitizes cancer cells to DNAdamage. (a) 
Western blot analysis of total cell extracts from FRO and FRO-asHMGI, using the indicated 
antibodies. (b) Clonogenic assay following UV exposure on FRO and FRO-asHMGI cells. 
Cells were not treated or treated with 10 or 20 J/m2 and cultured for 10 days. Colonies were 
stained using Crystal Violet staining. The results showed are normalized with respect to the 
untreated cells. Values are the mean ± S.D. of three independent experiments. 
 
Then, we performed a clonogenic assay on FRO and FRO-asHMGI following the 
exposure to different amount (10-20 J/m2) of UV light, a DNA-damage that 
activates both ATR and ATM, inducing G1/S and intra-S phase checkpoints. In 
agreement with the reduction of ATM in FRO-asHMGI, these cells formed a 
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strongly reduced number of colonies, normalized for the colonies obtained from 
untreated cells, respect to wild-type FRO (Figure 10b).  This result indicates that 
down-regulation of HMGA proteins affects cell proliferation and/or apoptosis 
following DNAdamage. 
Next, we analyzed cell cycle following the UV exposure, in order to evaluate the 
ATM-dependent slowing down in response to DNA damage. At 0, 8, 16 ad 24 h 
after exposure to 20 J/m2 of UV-light, asynchronously growing FRO and FRO-
asHMGI cells were harvested, fixed and stained with propidium iodide, to be 
assayd by flow cytometry. As shown in Figure 11a, FRO cells, expressing high 
levels of ATM, arrested cell cycle progression in G1 and S phase 16 h after UV 
treatment, consistent with the triggering of cell cycle checkpoints by ATM kinase. 
Conversely, FRO-asHMGI failed to arrest cell cycle in G1 and accumulated in 
G2/M phase, where other ATM-independent checkpoint could be active. This 
result is consistent with other previous data (Rainey et al. 2008) showing the G1/S 
arrest failure following chemical inhibition of ATM. To focus our attention on 
G1/S and intra-S checkpoints, immediately after exposure of FRO and FRO-
asHMGI to 20 J/m2 of UV-light, cells were treated with 0.2 µg/ml of nocodazole. 
This treatment prevents cells from exiting G2/M phase and entering G1, allowing 
us to analyze the cell cycle progression and the G1- and S-phases checkpoints 
without the bias of cells that, having accomplished their cycle, start a new cell 
division. Moreover, wild-type FRO were also treated with 10 µM of KU-55933 to 
assess the effect of ATM inhibition. Cells were harvested 8 h after the nocodazole 
treatment, and analyzed by flow cytometry. Figure 11b shows that wild-type FRO, 
both treated and not treated with KU-55933, and FRO-asHMGI had a similar cell 
cycle distribution. Conversely, following nocodazole treatment, FRO-asHMGI 
cells accumulated in G2/M faster than FRO cells, suggesting that block of HMGA 
expression may have led the G1/S checkpoint to be constitutively less active then 
parental cells. Following the UV treatment, cell cycle progression from G1 to G2 
was significantly slower in FRO cells than in both FRO cells treated with KU-
55933 and FRO-asHMGI cells. These results indicate that impairment of HMGA1 
expression in thyroid cancer cells prevent ATM induced G1/S checkpoint. It is 
reasonable to hypothesize that HMGA1, sustaining the expression levels of ATM, 
promotes the activation of G1/S checkpoint, which is necessary for cancer cells to 
slow down their cell cycle progression in order to repair DNA and prevent DNA-
damaging agents-induced apoptosis. 
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Figure 11. Inhibition of HMGA1 affects G1/S cell cycle checkpoints in response to DNA 
damage. (a) Cell cycle analysis of FRO and FRO-asHMGI cells. Cells were not treated (NT) 
or treated with 20 J/m2, harvested 8, 16 and 24 h after the treatment, fixed and analyzed by 
flow cytometry. The data obtained were analyzed using ModFit software. Cells in G1 and in 
G2 phase of cell cycle are reported in red, cells in S phase are indicated with white and blu 
bars. (b) Flow cytometric analysis of FRO and FRO-asHMGI, treated or not as in (a), with 
the supplement of 0.2 ug/ml nocodazole, to impair cell cycle progression and induce 
accumulation in G2 phase, and KU-55933 in FRO cells, to inhibit ATM kinase activity. Cells 
were harvested immmediately or after 8 h and analyzed as in (a). Data reported are 
representative of three independent experiments. 
 
 
To verify this hypothesis, we analyzed apoptotic markers such as caspases 3/7 
activation and annexin-V staining in FRO and FRO-asHMGI cells, following UV 
treatment (Figure 12). 
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Figure 12. HMGA1 inhibition enhances DNA-damage-dependent apoptosis. (a) FRO and 
FRO-asHMGI cells were treated or not with 10 and 20 J/m2 of UV, harvested 24 h after the 
exposure and stained with anti-annexin V antibody. Flow citometry analysis was performed 
to quantify the amount of apoptotic-annexin V positive cells. The results reported are 
representative of three independent experiments. (b) Colorimetric Caspase 3/7 activity assay, 
performed on cells treated as in (a) and harvested at different time points (8, 16 and 24 h). 
Values are the mean ± S.D. of three independent experiments performed in triplicate. 
 
Parental FRO and FRO-asHMGI cells were treated with different amount (10-20 
J/m2) of UV light, harvested after 24 h, stained with anti-annexin-V fluorescent 
antibody and analyzed by flow cytometry. As shown in Figure 12a, Annexin V 
staining confirmed that inhibition of HMGA1 increases cancer cell predisposition 
to apoptosis. Indeed, FRO-asHMGI cells displayed a higher percentage of 
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apoptotic cells already in untreated cells, compared to wild-type FRO. However, 
following UV exposure, both FRO and FRO-asHMGI cells underwent apoptosis, 
but a significant higher percentage of annexin-V positive cells was found in FRO-
asHMGI then parental cells (Figure 12a). To further confirm this observation, we 
evaluated caspase 3 and 7 activities in both cell lines following UV exposure, 
using a colorimetric assay. Consistent with the results obtained with annexin-V 
staining, FRO-asHMGI cells displayed an increased basal activation of caspases 3 
and 7 compared to parental cells. However, 8 h after UV-treatment, we observed a 
significant activation of caspases 3 and 7, which increased until 24 h after the 
exposure, only in FRO-asHMGI cells. Conversely, FRO cells showed a slower and 
less intense activation of apoptotic pathways, which became significant only 16 h 
after the exposure to UV light (Figure 12b).  Therefore, these data clearly indicate 
that HMGA1 inhibition effectively enhances DNA-damage-dependent apoptosis. 
In conclusion, our results demonstrate that abrogation of HMGA1 expression in 
anaplastic thyroid cancer cells reduces ATM levels and enhances cell sensitivity to 
DNA damage, by preventing the activation of cell cycle checkpoints necessary to 
activate an efficient DDR. The final effect is reduction of proliferation and 
increase of apoptotic pathways in HMGA1-overexpressing cancer cells, following 
DNA-damaging agents exposure, suggesting that HMGA1 may be a valid target to 
improve the efficacy of conventional genotoxic therapies. 
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5. CONCLUSIONS 
 
 
HMGA overexpression is a common feature of human benign and 
malignant neoplasias. Despite their well-defined role in processes such as 
proliferation, apoptosis and cellular trasformation, HMGA proteins involvement in 
DNA repair and cancer resistance to genotoxic therapies still remains 
controversial. Previous studies mostly analyzed HMGA role in cell lines 
engineered to overexpress HMGA proteins (Fusco and Fedele 2007). Here we first 
report the identification of a novel role of HMGA proteins in DNA repair in 
cellular systems that normally express one or both HMGA proteins. In particular 
we identified, in MEFs derived from wild-type, Hmga1 knock-out, Hmga2 knock-
out and Hmga1/2 double knock out mice, a positive and partially redundant role 
for HMGA1 and HMGA2 in the cellular response to DNAdamage. In fact, in the 
absence of HMGA1 and HMGA2, DNA repair and stress-induced senescence is 
significantly impaired, indicating a physiologic positive role for HMGA proteins 
in DNA damage response. Moreover, absence of HMGA proteins in this cellular 
system significantly reduces the expression of ATM, the master regulator of 
DNArepair machinery. Luciferase and ChIP experiments demonstrated that 
HMGA proteins have a direct positive role in the regulation of ATM promoter. 
Moreover, we show that HMGA proteins, in response to DNA-damaging agents 
such as IR, are phosphorylated by ATM, and this phosphorylation event increases 
their activity on ATM promoter. These observations indicate that HMGA1 and 
HMGA2 are positively involved in DNAdamage response through their 
physiologic and DNAdamage-dependent role in the regulation of ATM expression. 
Our results have also interesting implications in the field of new potential 
therapeutic approaches to improve cellular sensitivity to anti-cancer drugs. In fact, 
it has been previously demonstrated that chemical inhibition of ATM enhances 
cell sensitivity to genotoxic drugs. Here we show that inhibition of HMGA1 in 
anaplastic thyroid cancer cells (FRO) led to down-regulation of ATM expression 
and, consequently, reduced cell proliferation and increased cell sensitivity 
following exposure to DNA-damaging agents, such as UV rays. Conversely, 
HMGA1-expressing cells, in response to DNA-damaging agents exposure, slowed 
down their cell cycle in order to improve DNA repair and reduce the treatment-
induced toxic effects. These data are consistent with the finding that HMGA 
proteins expression in human tumors is usually considered a poor prognostic 
marker, often correlated with a reduced survival and response to common 
therapies (Fusco and Fedele, 2007). 
Therefore, our previous and present results indicate that HMGA proteins could 
represent a novel target for cancer therapy. In fact, inhibition of HMGA1 and 
HMGA2 can affect cancer cell proliferation and apoptosis, inhibiting their effect 
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on p53 and E2F1 pathways. Moreover, as suggested here, HMGA proteins sustain 
ATM levels in cancer cells, improving cellular response to DNA damage and 
preventing the accumulation of fatal DNAlesions. The striking difference between 
the use of chemical inhibitors of ATM and HMGA-targeting drugs to enhance cell 
sensitivity to genotoxic drugs is that, while ATM is expressed in all cells, HMGA 
proteins are expressed at high levels only in cancer cells. Thus, HMGA1 and 
HMGA2 may represent new, cancer cell specific, targets for the treatment of 
human neoplasias. 
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Summary
HMGA2 gene amplification and overexpression in human prolactinomas and the development of pituitary adenomas in
HMGA2 transgenic mice showed that HMGA2 plays a crucial role in pituitary tumorigenesis. We have explored the pRB/
E2F1 pathway to investigate the mechanism by which HMGA2 acts. Here we show that HMGA2 interacts with pRB and in-
duces E2F1 activity in mouse pituitary adenomas by displacing HDAC1 from the pRB/E2F1 complex—a process that results
in E2F1 acetylation. We found that loss of E2F1 function (obtained bymatingHMGA2 and E2F12/2mice) suppressed pituitary
tumorigenesis in HMGA2 mice. Thus, HMGA2-mediated E2F1 activation is a crucial event in the onset of these tumors in
transgenic mice and probably also in human prolactinomas.Introduction
High mobility group A (HMGA) proteins are nonhistone nuclear
compounds known as architectural transcriptional factors be-
cause they mediate the assembly of multiprotein complexes in-
volved in gene transcription. In fact, by interacting with theminor
groove of many AT-rich promoters and enhancers, HMGA pro-
teins do not per se exert transcriptional activity, but organize
chromatin into the structure required by the transcription ma-
chinery to allow gene transcription. There are four HMGA pro-
teins: HMGA1a, HMGA1b, HMGA1c, and HMGA2. The first
three are encoded by the gene HMGA1, whereas HMGA2 is en-
coded by HMGA2. HMGA2 is almost ubiquitously expressed at
high levels during embryogenesis, whereas in adult tissues it
occurs only in CD34-positive hematopoietic stem cells, uterine
myoblasts, testicular cells, and proliferating preadipocytes. Its
function is critical for growth and adipocytic cell differentiation.
In fact, its impairment results in pygmymicewith greatly reduced
fat tissue, whereas its activation by truncation leads to giantCANCER CELL 9, 459–471, JUNE 2006 ª2006 ELSEVIER INC. DOI 10.10mice affected by lipomatosis. HMGA2 overexpression was first
demonstrated in rat thyroid transformed cells and experimental
thyroid tumors. Subsequent studies showed that HMGA2 ex-
pression is required for thyroid cell neoplastic transformation
and that HMGA2 expression is correlated with humanmalignant
tumors. HMGA2 rearrangements are frequent in benign tumors
ofmesenchymal origin (reviewed by Fedele et al., 2001).We pre-
viously found that the HMGA2 gene is amplified and overex-
pressed in most human prolactinomas characterized by chro-
mosome 12 trisomy and tetrasomy (Finelli et al., 2002) and that
transgenic mice expressing high levels of theHMGA2 transgene
in all tissues develop pituitary adenomas secreting prolactin and
growth hormone, thereby confirming thatHMGA2 plays a critical
role in human pituitary adenomas (Fedele et al., 2002).
The aim of our study was to investigate the mechanisms by
which HMGA2 leads to the onset of pituitary adenomas in
HMGA2 transgenic mice and probably also in humans.
There are striking phenotypic similarities between the pRB
and HMGA2 animal models. In fact, transgenic miceS I G N I F I C A N C E
Themolecular pathway leading to pituitary tumorigenesis is one of the challenges of endocrine oncology. Here, we describe amech-
anism by which HMGA2 induces pituitary adenomas in mice. This mechanism entails an HMGA2-dependent process that relieves
pRB-mediated repression of E2F1. It is likely that the same mechanism is involved in most of the human prolactinomas in which the
HMGA2 gene is amplified and overexpressed. Elucidation of the mechanism by which HMGA2 induces pituitary adenomas opens
up the possibility of intervening in this mechanism to prevent or halt the onset of these tumors.16/j.ccr.2006.04.024 459
A R T I C L EFigure 1. HMGA2 increases E2F1 DNA binding
activity in pituitary adenomas
A: EMSA with extracts from a pool of pituitary
glands (lanes 1–3) and two pituitary adenomas
(lanes 4–11) of HMGA2 transgenic mice using
an E2F-responsive element sequence (E2FRE) as
a probe. Samples were incubated with E2FRE
(lanes 1, 4, and 8) or were preincubated with
1003CD28 responsive element (CD28RE), which
is a specific competitor for HMGA2 binding
(lanes 3, 6, and 10), with 1003 E2FRE unlabeled
probe (lanes 2–5 and 9), and with specific poly-
clonal anti-HMGA2 antibody (lanes 7 and 11),
before the addition of the probe. Arrows indi-
cate specifc complexes DNA/proteins.
B: EMSA of pituitary extracts of adenomas from
HMGA2 transgenic mice with E2FRE (lanes 1
and 2) or E2FRE mutated in the region rich in AT
bases (AT-mut; lane 3). The samples in lanes 1
and 2 were incubated without (lane 1) or with
anti-E2F1 antibody (lane 2), before the addition
of the probe. His-HMGA2 (lanes 4–5) or GST-
E2F1 (lanes 6–7) recombinant proteins were incu-
bated with E2FRE or AT-mut, as indicated above.overexpressing pRB show a dwarf phenotype because of de-
fective cell proliferation (Bignon et al., 1993) as do HMGA2 null
mice. Conversely, Rb+/2 mice are larger than their littermates
(Jacks et al., 1992), as are transgenic mice carrying an activated
HMGA2 gene (Battista et al., 1999). Moreover, mice carrying
a germline mutation of one Rb allele are highly predisposed to
develop pituitary tumors (Jacks et al., 1992), and this occurs
also in mice with impaired functioning of p27 or p18, both of
which converge on pRB (Franklin et al., 1998).
The finding that loss of E2F1 reduced pituitary tumorigenesis
in Rb knockout mice suggests that loss of pRB induces the on-
set of pituitary tumors by activating E2F1 (Yamasaki et al., 1998).
We therefore investigated the role of the pRB pathway in the
onset of pituitary adenomas in transgenic mice overexpress-
ing HMGA2.
pRB and the related proteins p130 and p107 control cell cycle
progression through their interactions with the E2F family of
transcription factors. E2F1 is known to activate transcription
of a number of genes required for the S phase of the cell cycle.
Transcriptional repression of E2F1 target genes entails recruit-
ment of pRB by E2F1 to the gene promoters. This recruitment
masks the activation domain of E2F1 and prevents its interac-
tion with the general transcriptional machinery. Before cells
enter S phase, pRB is phosphorylated atmultiple sites by cyclin-
dependent kinases. This phosphorylation leads to pRB inactiva-
tion, release of E2F1, and transcriptional activation of its target
genes (reviewed by Seville et al., 2005). Moreover, pRB recruits
class I histone deacetylase proteins that repress transcription by
removing acetyl groups from the histones. Removal of the acetyl
groups facilitates the condensation of nucleosomes into chro-
matin, which in turn blocks access to transcription factors and
leads to gene repression (Magnaghi-Jaulin et al., 1998).
Here we report that HMGA2 binds to pRB and prevents it from
repressing the E2F1-responsive promoters mainly by displacing
HDAC1 from pRB. This results in enhanced acetylation of both
E2F1 and associated histones, which could account for the en-
hanced E2F1 activity observed in HMGA2-induced pituitary ad-
enomas and associated with the HMGA2 overexpression. To
verify the crucial role of enhanced E2F activity in the onset of460pituitary adenomas, we mated transgenic mice overexpressing
HMGA2with E2F1 knockoutmice (Field et al., 1996). The adeno-
matous phenotype was almost totally rescued in the double
mutant mice, which demonstrates that HMGA2-mediated E2F1
activation is a prerequisite for pituitary tumorigenesis.
Results
E2F1 DNA binding activity is increased in pituitary
adenomas of HMGA2 transgenic mice
To investigate whether the pRB/E2F1 pathway is involved in pi-
tuitary tumorigenesis in HMGA2 transgenic mice, we analyzed
E2F DNA binding activity in HMGA2 pituitary adenomas and
normal pituitary glands from control mice by electrophoretic
mobility shift assay (EMSA) using an E2F-responsive element
(E2FRE) as probe. As shown in Figure 1A, E2F1 DNA binding ac-
tivity was dramatically higher in HMGA2 pituitary adenomas
than in pituitary glands from control mice. A specific complex
containing E2F (complex A) was present in normal pituitary
gland (lane 1). Another, faster-migrating complex (complex B)
was associated with pituitary adenomas from HMGA2 mice
(lanes 4 and 8). Competition analyses with specific anti-E2F1
antibodies showed that this band corresponds to the free
E2F1-DNA complex (Figure 1B, lane 2). Band specificity was as-
sessed by adding a 1003molar excess of unlabeled probe (Fig-
ure 1A, lanes 2, 5, and 9). Preincubation with an oligonucleotide
(CD28RE) that specifically binds to HMGA2 (Baldassarre et al.,
2001) prevented the formation of this complex (Figure 1A, lanes
6 and 10). Moreover, an antibody against HMGA2 significantly
reduced the band corresponding to complex B (Figure 1A, lanes
7 and 11). These data show that HMGA2 plays a crucial role in
the formation of complex B.
HMGA2 binds to the E2F1 responsive element
and enhances the binding of E2F1 to DNA
HMGA proteins allow the assembly of multiprotein complexes
by directly binding to the DNA in AT-rich sequences. We used
an E2F consensus oligonucleotide (E2FRE) that has an AT
stretch compatible with HMGA binding in an EMSA assay withCANCER CELL JUNE 2006
A R T I C L Ea recombinant HMGA2 protein. As shown in lane 4 of Figure 1B,
HMGA2was able to bind to the E2F-responsive oligonucleotide,
but not to the same oligonucleotide mutated in the AT-stretch
flanking the E2F-consensus sequence (AT-mut). Interestingly,
the binding of free E2F1 to DNA in pituitary adenomas from
HMGA2 transgenic mice was considerably decreased on the
AT-mut probe (Figure 1B, lane 3). Because the binding of the re-
combinant E2F1 to its consensus DNA was not impaired by the
ATmutation (Figure 1B, lanes 6 and 7), we suggest that the bind-
ing of HMGA2 to its consensus sequence, flanking the E2F
binding site, is crucial for efficient E2F1/DNA binding.
HMGA2 interacts with the pRB protein
Since free E2F1/DNA binding depends essentially on E2F1 re-
lease from pRB, HMGA2 may interfere with the pRB pathway.
To investigate whether HMGA2 interacts with pRB, we coimmu-
noprecipitated protein lysates from twoHMGA2pituitary adeno-
mas and from a pool of pituitary glands from control mice.
Immunoprecipitation of the protein lysates with anti-pRB anti-
bodies resulted in the coimmunoprecipitation of HMGA2 from
pituitary adenomas (Figure 2A, left panels). Western blot analy-
sis showed that pRB was equally expressed in pituitary glands
and adenomas, whereas the HMGA2 protein was expressed
only in HMGA2 pituitary adenomas.
We next verified the HMGA2/pRB interaction in a heterolo-
gous cell system. HEK293 cells were transiently cotransfected
with hemagglutinin (HA)-tagged-HMGA2 and pRB expression
vectors. Protein lysates were immunoprecipitated with anti-
pRB or anti-HA antibodies and immunoblotted with anti-HA or
anti-pRB, respectively (Figure 2A, right panels). Coexpression
of pRB and HMGA2 resulted in coimmunoprecipitation of the
two proteins. Conversely, there was no coimmunoprecipitation
when HEK293 cells were transfected with HA-HMGA2 or pRB
expression vectors alone. Indeed, consistent with the endoge-
nous expression of pRB in HEK293 cells, longer exposure times
resulted in a faint band in HA-HMGA2 transfected cells (data not
shown).
The HMGA2/pRB interaction is direct and involves either
the pocket region or the N terminus of pRB
To determine whether HMGA2 interacts directly with pRB, we
carried out Far-Western analyses in which we probed HMGA2
on pRB immunoprecipitates from cell lysates overexpressing
wild-type and different mutant forms of the pRB protein (Figures
2B and 2C). Interestingly, HMGA2 was found to bind to the pRB
mutant expressing only the pocket region (lane 5) as efficiently
as to the wild-type pRB (lane 1). It did not bind to the naturally
occurring mutant pRBD21 that carries a deletion of exon 21
and encodes a portion of the pocket region (lane 4). pRB mu-
tants 661 and 13S, which carry a point mutation in the pRB
pocket region and amino acid substitutions and insertions in
the C-terminal region, respectively (lanes 2 and 3), did not affect
binding between pRB and HMGA2.
These results are supported by in vitro binding experiments in
which GST-pRB fusion proteins containing various pRB do-
mains (Figure 2B) were incubated with a lysate from cells over-
expressing HMGA2 (Figure 2D). pRB(379-928), which contains
the entire wild-type pocket region of pRB plus the C-terminal re-
gion, was able to bind efficiently to HMGA2 (lane 1). In con-
trast, pRB(379-928)D21, which lacks the region corresponding
to exon 21, only weakly associated with HMGA2 (lane 3).CANCER CELL JUNE 2006pRB(768-928) and pRB(834-928), which carry the C-terminal re-
gion plus a small region of the pocket and the C-terminal region
only, respectively, did not bind to HMGA2 at all (lanes 5 and 6).
Finally, pRB(1-379) and pRB(379-792), carrying the N-terminal
region and the pocket region, respectively, were able to bind ef-
ficiently to HMGA2 (lanes 2 and 4). These results indicate that
HMGA2 binds to pRB in two regions: the N terminus and the
pocket region between amino acids 703 and 737.
The second AT-hook of HMGA2 is required
for interaction with pRB
We next investigated the regions of HMGA2 that are required to
form a complex with pRB. HMGA2 contains three AT-hook do-
mains that are involved in both DNA and protein-protein interac-
tions, and an acidic C-terminal tail preceded by a spacer region
(Figure 2E). We used cell lysates expressing HA-HMGA2 mu-
tants carrying serial deletions at the N and C terminus regions
(Figure 2E) in a pull-down assay with a recombinant GST-pRB
protein (Figure 2F, lanes 1–6). The only mutant that lost the ca-
pacity to bind to pRB was A2(1-44), which contains the N termi-
nus, the first AT-hook, and the region preceding the second AT-
hook. Because all the other mutants, including A2(1-56), which
encodes the same protein portion as mutant A2(1-44) plus the
second AT-hook, were able to bind to pRB as efficiently as the
wild-type HMGA2, we suggest that the second AT-hook domain
of HMGA2 is principally involved in binding to pRB. Tomapmore
precisely the HMGA2 region involved in forming a complex with
pRB, we generated an HMGA2 mutant lacking only the second
AT-hook [A2(D45-56) ] (Figure 2E) and used it in a pull-down assay
with the GST-pRB protein (Figure 2F, lane 7). The A2(D45-56) mu-
tant was less able than wild-type HMGA2 to bind to pRB. This
confirms that the region of HMGA2 coding for the second AT-
hook is principally involved in binding pRB and suggests, how-
ever, that other regions of the HMGA2 protein might also be in-
volved in this binding.
HMGA2 overexpression counteracts pRB-mediated
inhibition of E2F activity and cell proliferation
To define better the role of the pRB/HMGA2 interaction in the
regulation of E2F1 transcriptional activity, we examined the ac-
tivity of two E2F1-responsive promoter genes, i.e., CDC25A and
CDC6, fused to a luciferase reporter gene, in the HEK293 cells
transiently transfected with plasmids expressing the pRB and
HMGA2 proteins. As shown in Figure 3A, pRB repressed
CDC6 and CDC25A promoter activity (3-fold decrease),
whereas HMGA2 increased these activities (up to 3-fold) in
a dose-dependent manner. When pRB was cotransfected with
increasing levels of HMGA2, pRB repression of CDC25A and
CDC6 promoter activity was significantly antagonized. In partic-
ular, 5 mg of transfected HMGA2 vector abolished repression,
and 10 mg of HMGA2 caused a switch from repression to activa-
tion (2.5-fold increase). Similar experiments were carried out in
pRB null Saos-2 cells by transfecting pRB, HMGA2, and mu-
tants A2(1-44) or A2(D45-56), as indicated in Figure 3B. In the
absence of pRB, HMGA2 does not affect E2F target gene
activation, and neither of the mutants antagonized the pRB-
mediated inhibition of the promoter-response activity, which
suggests that HMGA2 binding to pRB is required for this effect.
The results of a colony-forming assay of Saos-2 cells demon-
strate that HMGA2 antagonizes the pRB-mediated inhibition of
cell proliferation (Figure 3C). The expression of transfected461
A R T I C L EFigure 2. HMGA2 interacts with pRB
A: Left panels. Lysates from a pool of pituitary glands of control mice and from the pituitary adenomas shown in Figure 1 were subjected to Western blot anal-
ysis with either anti-pRB or anti-HMGA2 antibodies to verify protein expression. The expression of g-tubulin served to verify equal loading of proteins. The same
lysates were immunoprecipitated with anti-pRB antibody, resolved by SDS-PAGE, and analyzed by Western blot with anti-HMGA2 antibody. Immunoprecip-
itation in the presence of EtBr and with IgG were also performed as control of the specificity of the interaction. Right panels. Whole-cell lysates from HEK293
cells untransfected or transfected with the indicated expression plasmids were immunoprecipitated with anti-pRB (upper panel) or anti-HA (lower panel) an-
tibodies, run on an SDS-PAGE gel, and transferred to nitrocellulose. The blot was probed with anti-HA or anti-pRB antibodies, respectively.
B: Schematic representation of GST-pRB fusion proteins and pRB expressing plasmids used for the analysis.
C: Whole-cell lysates from HEK293 cells transfected with plasmids expressing pRB proteins, as described in (B) were immunoprecipitated with either anti-pRB
polyclonal antibody or preimmune serum. After being washed, samples were run on an SDS-PAGE gel and transferred to nitrocellulose. The blot was probed
with His-HMGA2 in a Far-Western assay as described in Experimental Procedures (upper panel). The membrane was stripped and probed with an anti-pRB
antibody (lower panel).
D: Whole-cell lysate from HEK293 cells transfected with a plasmid expressing HA-HMGA2 (5 mg) was subjected to GST pull-down analysis using the GST or GST-
pRB fusion proteins reported in (B). Binding reaction products were washed, and proteins were separated by SDS-PAGE. The membrane was probed with both
anti-HA and GST antibodies.
E: Schematic representation of plasmids expressing wild-type and mutant HA-HMGA2 proteins used for the analysis.
F: Whole-cell lysates from HEK293 cells transfected with the plasmids reported in (E) were subjected to GST pull-down analysis using GST-pRB protein beads
(upper panel) or GST protein beads (medium panel) as control. Aliquots of the same lysates were probed with anti-HA antibody to evaluate the comparable
expression of the transfected plasmids (lower panel).462 CANCER CELL JUNE 2006
A R T I C L EFigure 3. HMGA2 counteracts the pRB-mediated inhibition of E2F activity and cell proliferation
A: Luciferase activities of extracts from HEK293 cells cotransfected with CDC25A-luc or CDC6-luc reporter plasmids and increasing amounts of HMGA2 with or
without a pRB expression vector. The RSV-luc plasmid served as a negative control. Relative activities were calculated by dividing normalized activities with
the activity of cells transfected with the reporter plasmid alone. Aliquots of the same lysates were resolved by SDS-PAGE, transferred to Immobilion-P, and
immunoblotted with the indicate antibodies (lower panels).
B: Saos-2 cells were transiently transfected with plasmids expressing HA-HMGA2 wild-type and mutated proteins and subjected to luciferase assay on the
CDC6-luc reporter promoter. Relative activities were calculated as reported in (A). Aliquots of the same lysates were resolved by SDS-PAGE and immunoblot-
ted with the indicate antibodies (lower panels).
C: Saos-2 cells were transiently transfected with the expression plasmids indicated on the left and selected for 14 days in the appropriate antibiotic. Cell clones
were counted following staining with crystal violet.
D: Focusassay on Rat-2 cells transfected with the plasmids indicated on the left. The transforming efficiency was expressed as foci-forming units (f.f.u.)/pmol of
transfected DNA. All the data reported are the mean 6 SE of three independent experiments. *p < 0.05; **p < 0.01.pRB greatly reduced the colony-forming ability. Cell growth in-
hibition was significantly reduced in the presence of a coex-
pressed HMGA2 construct and was not affected by either the
A2(1-44) or A2(D45-56) mutant. Conversely, HMGA2 alone had
no significant effects on colony-forming ability. These results
suggest that HMGA2, by interacting with pRB, inhibits the
pRB negative regulation of E2F1 activity, thereby blocking its
growth-suppressing potential.
The binding of HMGA2 to pRB is crucial
for its transforming activity
It has been previously reported that HMGA2 induces neoplastic
transformation of cultured rat fibroblasts (Wood et al., 2000),
demonstrating its oncogenic potential. In order to verify whether
the binding between HMGA2 and pRB, with the resulting pRB
inactivation, might be responsible for the oncogenic properties
of HMGA2, we evaluated the focus-forming ability of HMGA2
and pRB binding mutants of HMGA2. To do this, we transfectedCANCER CELL JUNE 2006Rat-2 cells with either HMGA2 or each of the HMGA2 mutants
unable to efficiently bind to pRB. As shown in Figure 3D, the
wild-type HMGA2 was able to induce foci, whereas no foci
were observed in transfected cells with both the HMGA2 mu-
tants. High transforming efficiency was obtained by transfecting
the activated Ha-Ras gene (Ras 12V) that we used as a positive
control of the assay. These results suggest that the binding be-
tween HMGA2 and pRB is necessary for the HMGA2 oncoge-
nicity and that the mechanism by which HMGA2 is involved in
pituitary tumorigenesis may be generally involved in HMGA2-
mediated cell transformation.
HMGA2 displaces HDAC1 from the pRB/E2F complex
Many cellular and viral proteins have been shown to bind pRB
within the pocket region of pRB (Hu et al., 1990). Consequent
to this process, E2F1 is released from the binding to pRB and
becomes active. Because HMGA2 binds to pRB in this same
pocket region, we tested the hypothesis that the HMGA2/pRB463
A R T I C L EFigure 4. HMGA2 competes with HDAC1 but not
with E2F1 for pRb binding
A: HEK293 cell lysates coexpressing both E2F1
and pRB transiently transfected plasmids were
subjected to immunoprecipitation with anti-
pRB antibody after incubation with either
HMGA2 or E1A recombinant proteins, as indi-
cated above, and then blotted against either
E2F1 or HDAC1, as indicated on the left. pRB
Western blot served as a control of the equal
loading of the immunoprecipitated pRB protein.
B: Labeled HDAC1 and recombinant pRB were
coimmunoprecipitated with or without 5 or 10
mg of either recombinant HMGA2 or A2(1-44)
proteins. The samples were then blotted and
probed with either HDAC1 or pRB antibody, as in-
dicated on the left.
C: Lysates from Saos-2 cells, transiently trans-
fected with the plasmids indicated on the left
or with the empty vector, were incubated with
a recombinant pRB protein and immunoprecip-
itated with anti-pRB antibodies. The resulted im-
munoprecipitates were in part subjected to his-
tone deacetylase assay as described under
Experimental Procedures and in part run on
a SDS-PAGE for evaluation of the equal amount
of pRB immunoprecitated in each sample.
D: Lysates from a pool of pituitary glands of wild-
type mice and one pituitary adenoma of
HMGA2 transgenic mice were assayed as in
(C). The results reported in (C) and (D) are the
mean 6 SE of three independent experiments.
*p < 0.05; **p < 0.01.
E: Cell inputs from the experiments shown in (C)
and (D) were assayed by Western blot for the ex-
pression of the HDAC1 protein.interaction interferes with the binding between pRB and E2F1,
thereby inducing E2F1 activation. To this aim, we performed
coimmunoprecipitation experiments with HEK293 cells tran-
siently cotransfected with pRB and E2F1 expression plasmids
in the presence of E1A or HMGA2 recombinant proteins
(Figure 4A). As previously reported (Putzer et al., 1997), E1A pre-
vented the binding between pRB and E2F1 (lane 2), whereas
HMGA2 did not (lane 3). Thus, HMGA2 does not activate E2F1
by competing with it for binding to pRB.
Another mechanism by which the pRB/E2F complex re-
presses transcription entails recruitment of a histone deacety-
lase, the HDAC1 protein, to the E2F binding sites by pRB (Mag-
naghi-Jaulin et al., 1998). Histone acetyl transferases and
histone deacetylases acetylate and deacetylate, respectively,
core histone tails that protrude from the nucleosome. Histone
acetylation is thought to weaken the interaction between histone
N-terminal tails and DNA, thus opening up the chromatin and in-
creasing accessibility for activating transcription factors. There-
fore, the binding of the viral transforming proteins to the pRB-
pocket region results in the loss of E2F and HDAC1 binding.
We thus asked whether the HMGA2/pRB interaction could
displace HDAC1 from the pRB/E2F complex, and so account
for E2F1 activation. To this aim, we used the same immunopre-
cipitates described above to also analyze the binding of HDAC1
to pRB. As shown in Figure 4A, both E1A (lane 2) and HMGA2
(lane 3) reduced the binding of pRB to HDAC1. This shows
that, similarly to the E1A/pRB interaction, the HMGA2/pRB
complex can affect HDAC1 recruitment.464To verify this result, we used a cell-free system in which
pRB and HDAC1 recombinant proteins were incubated with or
without increasing amounts of a recombinant HMGA2 protein.
As shown in Figure 4B, HDAC1 was partially or completely dis-
placed by the binding to pRB in the presence of 5 mg and 10 mg
of HMGA2, respectively. This result demonstrates that HMGA2
directly interferes with the binding between HDAC1 and pRB.
Moreover, to correlate the effect of HMGA2 onHDAC1 displace-
ment from pRB with the HMGA2/pRB interaction, we also per-
formed the experiment by using the A2(1-44) mutant, unable
to bind pRB. As shown in the same Figure 4B, the binding be-
tween HDAC1 and pRB was not affected at all by the HMGA2
mutant, suggesting that the interaction between HMGA2 and
pRBplays a crucial role in the displacement of HDAC1 frompRB.
Because recruitment of HDAC1 by pRB to gene promoters
decreases their level of histone acetylation (Magnaghi-Jaulin
et al., 1998), we evaluated whether HMGA2 overexpression
was associated with decreased HDAC activity associated with
the pRB complexes. To this aim, lysates from Saos-2 cells, tran-
siently transfected with either HMGA2 or each of the two
mutants A2(1-44) and A2(D45-56), were incubated with a re-
combinant pRB protein and then immunoprecipitated with anti-
bodies against pRB. These immunoprecipitates were incubated
with a 3H-acetylated histone H4 peptide, and the released 3H-
acetate was measured (Figure 4C). The same assay was carried
out with mouse tissue lysates from wild-type pituitaries and
HMGA2 transgenic pituitary adenomas (Figure 4D). Consistent
with the HMGA2-induced displacement of HDAC1 from theCANCER CELL JUNE 2006
A R T I C L EFigure 5. HMGA2 displaces HDAC1 from E2F1 target promoters
A: Lysates from cells transfected with plasmids expressing pRB, E2F1, and HMGA2 or pRb, E2F1, and empty vector, as indicated above the panel, were sub-
jected to ChIP using specific polyclonal antibody, as indicated on the right. Before reversal of formaldehyde cross-linking, each precipitate was washed, re-
suspended, and subjected to re-ChIP using specific antibody as indicated on the top. Immunoprecipitates from each sample were analyzed by PCR, and
a sample representing linear amplification (0.25–1 ml) of the total input chromatin (Input) was included in the PCRs as a control.
B: Increasing amounts of input samples as described in (A) were used as template in PCR amplifications performed using primers specific for the different pro-
moters including E2F binding sites: CDC2, TK1, and cyclin E1.
C: Lysates from cells transiently transfected as described in (A) and indicated above the panel were subjected to Western blot analysis with anti-pRB, anti-Ha
(for HMGA2), or anti-E2F1 antibodies to verify protein expression. Tubulin expression served as a control of equal protein loading.
D: Tissue extracts from a pool of normal pituitary glands (PG) and a representative HMGA2-induced pituitary adenoma (PA) were assayed by ChIP using a spe-
cific polyclonal antibody anti-HDAC1. Immunoprecipitates from each sample were analyzed by PCR, and a sample representing linear amplification (0.25–
1 ml) of the Input was included in the PCRs as a control. Another control included precipitation performed without specific IgG.
E: Increasing amounts of input samples as described in (D) were used as template in PCR amplifications carried out with primers specific for the different pro-
moters: CDC2, TK1, and Gapdh.pRB active repressor complex, HDAC activity was significantly
lower in cells and pituitary adenomas overexpressing HMGA2
than in mock-transfected cells and normal pituitary, respec-
tively. To exclude that this effect could be due to a downregula-
tion of HDAC1 expression following HMGA2 overexpression, we
also monitored HDAC1 expression in the inputs of the experi-
ments shown in Figures 4C and 4D. As shown in Figure 4E, no
differences in HDAC1 expression were observed between
HMGA2-transfected and parental cells or between pituitary ad-
enoma and normal gland.
HMGA2 binds to E2F target promoters in vivo
and interferes with the association of the single
subcomplexes
We next evaluated whether HMGA2 is part of the complexes, in-
cluding pRB, E2F1, and HDAC1 that form at the E2F bindingCANCER CELL JUNE 2006sites of the E2F-responsive promoters in vivo, and whether it
can displace HDAC1. In a combination of chromatin immuno-
precipitation (ChIP) and Re-ChIP analyses, HEK293 cells were
transfected with pRB and E2F1 or pRB and E2F1 plus HMGA2
(Figure 5C), and crosslinked genomic DNA was immunoprecip-
itated in two rounds with two specific antibodies directed
against protein components of the complex (Figure 5A). Re-
ChIPed DNA was analyzed by PCR using promoter-specific
primers that encompass the E2F binding sites, under conditions
of linear amplification (Figure 5B). Figure 5A shows that HMGA2
can associate in vivo with three E2F-responsive promoters, i.e.,
those driving CDC2, TK1, and cyclin E1 gene transcription, and
is a component of a promoter-bound multimeric complex con-
taining E2F1, pRB, and HDAC1. A comparison of the subcom-
plexes with and without HMGA2 revealed three mechanisms
whereby HMGA2 can activate E2F1 in vivo. First, in agreement465
A R T I C L Ewith our in vitro results, HDAC1/pRB binding was decreased in
the presence of HMGA2 on all the promoters analyzed, espe-
cially the TK1 promoter. Second, pRB/E2F binding is decreased
in the presence of HMGA2 on the cyclin E1 promoter, suggest-
ing that HMGA2 can displace pRB from E2F1, at least on this
promoter. Finally, E2F1 binding on the TK1 promoter was signif-
icantly increased in the presence of HMGA2, suggesting that, at
least on this promoter, HMGA2 can directly enhance the binding
of free E2F1 to the DNA target. This effect was also observed in
the EMSA with an E2F consensus oligonucleotide (Figure 1).
Quantitative data of this experiment, evaluated by densitometric
analyses, are shown in the Figure S1 in the Supplemental Data
available online.
To improve the significance of the HMGA2-mediated dis-
placement of HDAC1 from the E2F-responsive promoters, we
performed ChIP analyses on tissue extracts from normal and
neoplastic pituitary tissues from wild-type and transgenic
mice, respectively, using specific anti-HDAC1 antibodies. The
DNA that was immunoprecipitated was analyzed by PCR using
promoter-specific primers that encompass the E2F binding
sites under conditions of linear amplification (Figure 5E). As
shown in Figure 5D, differently from what occurs in normal pitu-
itary glands from control mice, the binding of HDAC1 to the pro-
tein complex bound to the E2F-responsive promoters is much
more reduced compared to normal tissue.
Overexpression of HMGA2 promotes acetylation
of histones and E2F1 protein on E2F target promoters
in vivo
We have shown that HMGA2 can displace HDAC1 from pRB at
the E2F binding sites—a process that could account for the de-
creasedHDAC activity associatedwith HMGA2 overexpression.
HDAC can also affect proteins that can be acetylated. An exam-
ple of this is E2F1, whose acetylation augments DNA binding
and stabilizes the protein (Martinez-Balbas et al., 2000).
To analyze the acetylation status of histones and E2F1 on
E2F1 target promoters in vivo, we transfected Saos-2 cells
with pRB or pRB and HMGA2 (Figure 6A) and subjected the ly-
sates to a ChIP assay using specific anti-acetylated histone H3
antibodies (Figure 6B). Immunoprecipitated DNA was analyzed
by PCR using promoter-specific primers that encompass the
E2F binding sites under conditions of linear amplification
(Figure 6C). Control vector-transfected cells had high levels of
acetylated histone H3 in association with the E2F binding sites
of the analyzed promoters (Figure 6B). Overexpression of pRB
decreased the association of the acetylated histone H3 with
the same promoters, but not with the glyceraldehyde-3-phos-
phate dehydrogenase (Gapdh) unrelated promoter. In contrast,
coexpression of pRB and HMGA2 abolished the effects of pRB.
In order to investigate E2F1 acetylation on the same promoters
and correlate it with the HMGA2/pRB interaction, we trans-
fected HEK293 cells with either HMGA2 or A2(1-44) and sub-
jected the lysates to a ChIP assay with a specific anti-acetylated
E2F1 antibody. As shown in Figure 6D, E2F1 acetylation was en-
hanced by the HMGA2 overexpression, whereas it did not
change in cells transfected with the A2(1-44) mutant. This result,
consistent with our previous data demonstrating the role of the
HMGA2/pRB interaction in displacing HDAC1 from the E2F-re-
sponsive promoters, was also confirmed by an additional exper-
iment in which total lysates from cells transfected as in Figure 6D466were immunoprecipitated with the anti-acetylated E2F1 anti-
body and then blotted for E2F1 (Figure 6F).
Finally, to evaluate whether these results correspond to real
regulation of the expression of these genes in vivo, we carried
out a semiquantitative reverse transcriptase-PCR. The expres-
sion levels of CDC2 and TK1 mRNA were measured in Saos-2
cells upon overexpression of pRB or pRB andHMGA2. In agree-
ment with the results reported above, these genes were specif-
ically downregulated upon pRB expression, but not upon coex-
pression of pRB and HMGA2 (Figure 6G).
Loss of E2F1 suppresses the development of pituitary
tumors in HMGA2 transgenic mice
The afore-reported data demonstrate that HMGA2 induces
E2F1 activity in pituitary adenomas by enhancing E2F1 acetyla-
tion and the binding of free E2F to the target promoter. This sug-
gests that E2F1 activity is a critical event in pituitary tumorigen-
esis of HMGA2 mice.
To address this hypothesis, we crossed HMGA2 transgenic
mice (HMGA2TG) withE2f12/2mice to generate doublemutants.
We obtained HMGA2TG;E2f1+/2 and HMGA2TG;E2f12/2 in
a mixed 129/Sv3 C57BL/6 genetic background. We monitored
the female double mutants for the development of pituitary tu-
mors, using HMGA2TG;E2f1+/+ female mice as controls. All con-
trol animals (9/9) and nearly allHMGA2TG;E2f1+/2 (13/14) double
mutants developed grossly detectable pituitary tumors by the
age of 15 months (see arrow in Figure 7A). In contrast, only 4
of the 16 (25%) HMGA2TG;E2f12/2mice developed pituitary tu-
mors (Figures 7A and 7B) at the same age. The loss of E2F1
function significantly affected the penetrance of pituitary tumors
in HMGA2TG mice (p = 0.0121; log rank test). In addition, the tu-
mors in the HMGA2TG;E2f1+/+mice featured multiple neoplastic
nodules constituted by cords and solid nests of monomorphous
polygonal tumor that had a high mitotic activity and intense
PCNA labeling (Figures 7Cd and 7Ce); the nodules enlarged,
distorted or completely replaced the anterior pituitary lobe. In
contrast, the pituitary adenomas in the HMGA2TG;E2f12/2 ani-
mals were neither grossly enlarged nor distorted, and the ante-
rior lobe showed a normal acinar pattern, except for a small nod-
ule containing a few blood-filled spaces and rare mitotic figures
and PCNA labeling (Figures 7Cj and 7Ck). The Gordon-Sweet
silver method was used for the histological diagnosis of these
nodules (Figure 7Cl) and showed focal disruption of the reticulin
fiber network, which is pathognomic for the adenomatous trans-
formation of pituitary cells (Figures 7Cc and 7Cf). These results
provide strong evidence that E2F1 activation is required for
the development of pituitary adenomas in HMGA2 transgenic
mice.
In order to further investigate the molecular mechanisms in-
volved in the pituitary alterations of the few cases of HMGA2TG;
E2F12/2 mice that develop small adenomas, we analyzed the
status of pRB/HMGA2 complexes and E2F ‘‘free’’ activation in
these E2F1 null tumors. As shown in Figure 7D, HMGA2 and
pRB still retain their capacity to interact with each other. How-
ever, the E2F ‘‘free’’ DNA binding activity does not show any sig-
nificant increase in these tumors compared to control wild-type
pituitary glands (Figure 7E, lane 3). Conversely, a strong in-
crease in E2F free DNA binding was always observed in pituitar-
ies from HMGA2TG;E2f1+/+ mice even before the appearance of
the pituitary tumor (Figure 7E, lane 2). Thus, even though
HMGA2 is still able to bind pRB in absence of E2F1, there areCANCER CELL JUNE 2006
A R T I C L EFigure 6. HMGA2 overexpression increases acetylation of both histones and E2F1 protein on E2F target promoters
A: Western blot analysis showing the protein expression of pRB and HMGA2 in Saos-2 cells transiently transfected with the relative expression plasmids, as in-
dicated on the top. Tubulin expression served as a control of equal protein loading.
B and C: Lysates from Saos-2 cells transfected as described in (A) were subjected to ChIP using specific polyclonal antibodies anti-acetylated histone H3 (B).
Immunoprecipitates were analyzed by PCR, and a sample representing linear amplification (0.25–1 ml) of the Input was included in the PCRs as a control. An-
other control included precipitation performed without specific IgG. Increasing amounts of input samples (C) were used as template to verify the linear range
of amplification.
D: HEK293 cells transfected with E2F1, HMGA2, A2(1-44), or the backbone vector alone were assayed by ChIP using a specific polyclonal antibody anti-acet-
ylated E2F1 under the same conditions as described in (B).
E: Increasing amount of input samples from the experiment described in (D) were used as template to verify the linear range of amplification.
F: HEK293 cells transfected as described in (D) were immunoprecipitated with anti-acetylated E2F1 antibody and assayed by Western blot for E2F1 (upper
panel). The inputs were assayed by Western blot for the expression of endogenous pRB and transfected HMGA2 and A2(1-44) proteins (middle and lower
panels).
G: RNA from Saos-2 cells transiently transfected as described in (A) was analyzed by RT-PCR for the expression of CDC2, TK1, and Gapdh. The RT control lanes
represent RT-PCR without reverse transcription.no alternative E2F proteins whose DNA binding activity is en-
hanced following this interaction, suggesting that other E2F-in-
dependent mechanisms may be responsible for the pituitary
alterations in the minority of these mice.
Discussion
Tumors of the pituitary gland can be found in 20% of the popu-
lation, and at least one-third of these cause health complica-
tions. In fact, although not classified asmalignant, most pituitary
adenomas grow rapidly and can invade downward into the para-
nasal sinuses, laterally into the cavernous sinuses, and upward
into the parenchyma of the brain. Little is known about the mo-
lecular events responsible for pituitary transformation (reviewedCANCER CELL JUNE 2006by Asa and Ezzat, 2002). A large body of evidence implicates
HMGA2 in pituitary tumorigenesis (Fedele et al., 2002; Finelli
et al., 2002). In an attempt to identify the mechanism by which
HMGA2 acts, we explored the pRB pathway. We selected this
strategy because of experimental data indicating that the
HMGA2 gene interferes with this pathway (Bignon et al., 1993;
Fedele et al., 2002; Jacks et al., 1992). Moreover, the finding
that mice with heterozygous RB mutations develop pituitary tu-
mors (Jacks et al., 1992) suggests that impairment of the pRB/
E2F pathway is involved in pituitary tumorigenesis. Thus far,
RBmutations have not been identified in human pituitary adeno-
mas (Cryns et al., 1993). However, methylation of the RB gene-
promoter region at a CpG island in human pituitary tumor cells
resulted in loss of protein expression (Simpson et al., 2000),467
A R T I C L EFigure 7. The absence of E2F1 suppresses pituitary tumorigenesis in HMGA2 transgenic mice
A: MRI analysis of a representative 12-month-old transgenic mouse homozygous for the knockout mutation of E2F1 (right: HMGA2TG;E2f12/2), com-
pared with a sex-age matched control transgenic mouse (left: HMGA2TG; E2f1+/+). The arrow indicates the pituitary tumor that is absent in the E2f12/2
mouse.
B:HMGA2 transgenic mice and E2f12/2mice were crossed to generateHMGA2TG;E2f1+/+,HMGA2TG;E2f1+/2, andHMGA2TG;E2f12/2mice. The total number of
pituitary tumors developed by each genotype is shown.
C: Histological analysis (hematoxylin and eosin staining) of the anterior pituitary from a wild-type animal showing a normal architecture (Ca), absence of
PCNA labeling (Cb), and a normal acinar pattern and reticulin network (Gordon-Sweet silver stain) (Cc). HMGA2TG;E2f1+/+ mice had a very large tumor
that enlarged and completely replaced the anterior lobe (Cd); most neoplastic cells showed PCNA labeling (Ce), and the reticulin network was lost (Cf).
HMGA2TG;E2f12/2 mice showing either a morphology (Cg), PCNA labeling (Ch), and reticulin network (Ci) similar to wild-type mice, or neoplastic nodules468 CANCER CELL JUNE 2006
A R T I C L Ewhich confirms that pRB is important in human pituitary tumor-
igenesis.
By repressing E2F1 activity, the pRB protein prevents cells
from progressing beyond the G1 phase of the cell cycle. Phos-
phorylation of pRB by cyclin-cdk complexes or expression of vi-
ral transforming proteins relieves this repression and allows cells
to progress toward S phase (reviewed by Seville et al., 2005). In-
teraction of pRB with histone deacetylase HDAC1 is involved in
pRB repression of E2F1 activity, and this interaction is disrupted
by both phosphorylation and viral transforming proteins (Mag-
naghi-Jaulin et al., 1998).
Here we demonstrate that HMGA2 induces the development
of pituitary adenomas by enhancing E2F1 activity. In fact, E2F1
activity was drastically increased in all pituitary tumors analyzed.
Moreover, the absence of E2F1, obtained by mating HMGA2
transgenic with E2f1 knockout mice, greatly inhibited the forma-
tion of pituitary tumors. In fact, most HMGA2TG;E2f12/2 mice
did not develop tumors, and only a few had small, slow grow-
ing adenomas. The reduced severity of pituitary lesions in
HMGA2TG;E2f12/2 animals suggests that loss of E2F1 may de-
lay the onset or progression of these tumors. It is noteworthy
that the loss of one wild-type E2F1 allele did not alter the fre-
quency of pituitary tumors in HMGA2TG mice.
Themechanismbywhich the HMGA2protein affects the pRB/
E2F pathway and enhances E2F1 activity is quite unique. In fact,
although HMGA2 binds to the pRB pocket, it does not compete
with the E2F protein in pRB binding, unlike proteins encoded by
the adenovirus E1A gene. Conversely, our data show that
HMGA2 activates E2F by interfering with HDAC1 recruitment
by pRB on various E2F-responsive promoters (Figure 8). Dis-
placement of HDAC1 would result in acetylation of both
E2F1 and DNA-associated histones, thereby promoting E2F1
activation.
It would be worthwhile to investigate whether HMGA2 is able
to displace also the other HDAC members (as suggested by our
preliminary experiments) and any other protein associated to the
pRB/E2F complex.
HDAC1 displacement from pRB is not the only way by which
HMGA2 activates E2F1. HMGA2 also acts directly on the E2F-
responsive DNA elements, and at least on the TK1 promoter
causes enhanced E2F1 DNA binding (Figure 5A). Although we
do not demonstrate in vitro that HMGA2/pRB binding caused
displacement of E2F1 from pRB, we show that HMGA2, at least
on the cyclin E1 promoter, displaced pRB from the E2F1-DNA
complex (Figure 5A). On the basis of our results it is reasonable
to suppose that displacement of pRB from E2F1 does not occur
simply through competition between E2F1 and HMGA2 for the
A/B pocket of pRB, but through a more indirect mechanism
due to the enhanced E2F1 acetylation dependent upon the
HMGA2 overexpression. In fact, it has been proposed (Marti-
nez-Balbas et al., 2000) that acetylation stimulates the functions
of the non-RBbound ‘‘free’’ form of E2F1, including DNAbinding
and its protein stability.
In conclusion, HMGA2 induces pituitary adenomas by en-
hancing E2F1 activity through displacement of HDAC1 fromCANCER CELL JUNE 2006pRB and consequent induction of E2F1 acetylation. It is likely
that the same mechanism may be involved in most human pro-
lactinomas in which the HMGA2 gene is amplified and overex-
pressed. Should this be the case, onemay envisage a therapeu-
tic strategy aimed at disrupting this mechanism.
Experimental procedures
Electrophoretic mobility shift assay
Protein/DNA binding was determined by electrophoretic mobility shift assay
(EMSA), as previously described (Battista et al., 2005). The E2F1 oligonucle-
otide (Santa Cruz, CA; sc-2507) was mutated as follows (mutated bases in
bold) in the AT-mut oligonucleotide: 50-ACTTGGGTTTCGCGC
CCTTTCTCAA-30. The antibodies used were anti-HMGA2 (polyclonal Ab
raised against a synthetic peptide located in the NH2-terminal region) and
anti-E2F1 (sc-193, Santa-Cruz). The DNA-protein complexes were resolved
on 6% (w/v) nondenaturing acrylamide gels and visualized by exposure to
autoradiographic films. Binding reactions with the purified proteins were car-
ried out as previously described (Baldassarre et al., 2001).
Protein extraction, immunoblot analysis, and immunoprecipitation
Tissues were rapidly dissected, frozen on dry ice, and stored at280ºC. Pro-
tein extraction, Western blot, and immunoprecipitation were carried out as
previously described (Pierantoni et al., 2001). The antibodies used were
anti-HMGA2 (polyclonal antibody raised against a synthetic peptide located
in the NH2-terminal region), anti-pRB (C-15, Santa Cruz, CA), anti-HA (F-7;
Santa Cruz), anti-GST (B-14, Santa Cruz), anti-E2F1 (C-20, Santa Cruz),
and anti-HDAC1 (06-720, Upstate Biotechnology Inc., Lake Placid, NY).
Plasmids and recombinant proteins
HA-tagged HMGA2 expression plasmids containing the entire and various
separate portions of the HMGA2 coding sequence were obtained by PCR
amplification and subcloned into the pCEFL-HA expression vector. The ex-
pression vectors for pRB and all pRB mutants (each subcloned into the
CMV-neo-Bam vector) were kindly donated by G. Condorelli. CDC25A-luc
and CDC6-luc plasmids were already described (Hateboer et al., 1998;
Vigo et al., 1999). pRB(379-928), pRB(1-379), pRB(379-928)D21, pRB(379-
792), pRB(768-928), pRB(834-928), and E2F1 were expressed as GST fusion
proteins, whereas HMGA2 and E1A-12S were expressed as His fusion pro-
teins. pGEX2T plasmids carrying the different deletion mutants of pRB
were kindly provided by S. Soddu. The pCMVHAE2F1 and pGST20TE2F-1
vectors are described elsewhere (Helin et al., 1993; Helin and Harlow,
1994). The GST and His fusion proteins were expressed in Escherichia coli
strain BL21 (DE3) (Stratagene) and purified using glutathione sepharose or
nickel beads as previously described (Baldassarre et al., 2001; Pierantoni
et al., 2001). The pRB full-length recombinant protein was from Abcam (ab
1111).
Pull-down and Far-Western experiments
Pull-down analysis was carried out as previously described (Pierantoni et al.,
2001). For Far-Western analysis, 50 mg of cell lysates expressing pRBand dif-
ferent pRBmutants were separated by SDS PAGE and transferred to a nitro-
cellulosemembrane. Themembranewas air-dried, and the proteins were de-
naturated for 10 min in 6 M guanidine hydrochloride in HBB buffer (10 mM
HEPES, pH 7.5, 60 mM KCl, 1 mM EDTA, and 1 mM DTT). The proteins
were renaturated sequentially in 3, 1.5, 0.75, 0.38, and 0.19 M GuHCl in
the same buffer (10 min each step). The membrane was extensively rinsed
with HBB and blocked with HBB supplemented with 5% nonfat milk and
0.5% NP40 for 1 hr at 4ºC and for 30 min in HBB with 1% milk. The His-
HMGA2 protein was incubated with the membrane in PIB buffer (10 mM
HEPES, pH 7.5, 13 mM NaCl, 50 mM KCl, 1% milk, and 0.5% NP40, 1 mM
DTT) for 4 hr at 4ºC. The unbound material was removed with extensivethat differed from those in HMGA2TG;E2f1+/+ mice in that they were smaller (Cj), had less intense PCNA labeling (Ck), and only partial loss of the reticulin net-
work (Cl). Scale bars (in yellow): 100 mm H&E, 75 mm PCNA staining, 25 mm Gordon-Sweet silver stain.
D: Coimmunoprecipitation of HMGA2 and pRB in tissue extracts from pituitary glands and tumors from mice as indicated on the top.
E: EMSA analysis of wild-type (WT), HMGA2TG;E2f1+/+ (TG +/+), andHMGA2TG;E2f12/2 (TG2/2) pituitary samples, either normal (N) or adenomatous (PA), using
a consensus E2F as probe.469
A R T I C L Ewashes for 30 min in the same buffer. Binding was detected with Western
blot analysis and anti-His antibody (Santa Cruz).
Cell lines and transfections
The HEK293, Rat-2, and Saos-2 cell lines were grown in Dulbecco’smodified
Eagle medium (DMEM) (Gibco-BRL) supplemented with 10% fetal-calf se-
rum (Gibco-BRL). HEK293 cells were transfected by calcium phosphate pre-
cipitation by standard procedures. Rat-2 and Saos-2 cells were transfected
by lipofectamine-plus reagent (Invitrogen) according to the manufacturer’s
instructions. For the luciferase activity assay, cells were transfected with
0.2 mg of CDC25A-luc or CDC6-luc reporter plasmids with or without 0.2 mg
of pRB expression vector and increasing amounts (1 mg, 5 mg, and 10 mg)
of HA-HMGA2 expression vector or 1 mg of HA-A2(1-44) or HA-A2(D45-56)
plasmid. One microgram of pCMVbgal plasmid was cotransfected to verify
equal transfection efficiency in the cell lines tested. Cells were harvested
36 hr after transfection, and luciferase and b-galactosidase activities were
measured with a luminometer (Lumat LB9507, Berthold) with the Dual light
Figure 8. Model of E2F1 activation by HMGA2
Following HMGA2 overexpression, transcription through E2F1 sites switches
from repression to activation throughout four steps.
A: HMGA2 binds to pRB, which is complexed with E2F1 and HDAC1 to form
the active repression.
B: The interaction between HMGA2 and pRB displaces HDAC1.
C: In the absence of HDAC1, the histone acetylase enzymes are recruited
and, by acetylating histones, relieve transcriptional repression.
D: Histone acetylases also acetylate E2F1 causing the stabilization of its
‘‘free’’ active form.470kit (Tropix). The data represent the average of three independent experi-
ments, performed in duplicate, with standard errors. Colony and Focus as-
says were carried out as previously described (Pierantoni et al., 2001; Fedele
et al., 1998).
Competition experiments
Whole-cell lysates from HEK293 cells transiently cotransfected with HA-
E2F1 and pCMV-pRB were incubated for 1 hr with His-HMGA2 or His-E1A
recombinant proteins and subjected to immunoprecipitation with anti-pRB
antibody (C-15, Santa Cruz, CA), resolved by SDS-PAGE on a 12% gel,
and analyzed by Western blot with anti-E2F1 (C-20, Santa-Cruz), anti-
HDAC1 (06-720, Upstate Biotechnology), or anti-pRB antibodies (C-15,
Santa Cruz). In another experiment, labeled HDAC1 and a recombinant
GST protein were subjected to immunoprecipitation with or without 5 or
10 mg of recombinant His-HMGA2 or His-A2(1-44). The samples were re-
solved by 12% SDS-PAGE gel and probed with anti-pRB antybody (C-15,
Santa Cruz).
Deacetylase assay
Deacetylase assays were carried out with a histone deacetylase assay kit
(Upstate Biotechnology) according to the manufacturer’s instructions. All
experiments were carried out three times, and samples were assayed in
duplicate.
Chromatin immunoprecipitation and reprecipitation
Chromatin immunoprecipitation (ChIP) was carried out with an acetyl-histone
H3 immunoprecipitation assay kit (Upstate Biotechnology) according to the
manufacturer’s instruction. For ChIp experiments with the polyclonal anti-
body anti-HDAC1 (Upstate Biotechnology), anti-E2F1 (C-20 Santa Cruz),
anti-pRB (C-15 Santa Cruz), and anti-HMGA2 (polyclonal antibody raised
against a synthetic peptide located in the NH2-terminal region), conditions
were as previously reported (Shang et al., 2000). For Re-ChIP experiments,
complexes were eluted by incubation for 30 min at 37ºC in 250 ml of Re-
ChIP elution buffer (2 mM DTT, 1% Triton X-100, 2 mM EDTA, 150 mM
NaCl, 20 mM Tris-HCl, pH 8.1) and then diluted 4-fold in Re-ChIP dilution
buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH
8.1) and subject again to the ChIP procedure. Crosslinking was reversed
by incubating samples overnight at 65ºC with 20 ml of 5 M NaCl. Samples
were then incubated in proteinase K solution (10 mM EDTA, 40 mM Tris-
HCl, pH 6.5, 40 mg/ml of Proteinase K) for 1 hr at 45ºC. DNA was purified
with phenol/chloroform/isoamyl alcohol and precipitated by adding 2 vol-
umes of ethanol and tRNA. PCR reactions were carried out by standard pro-
cedures, for a number of cycles optimized to ensure product intensity within
the linear phase of amplification. The PCR products were separated on a 2%
agarose gel, stained with ethidium bromide, and either scanned using a Ty-
phoon 9200 scanner or blotted and hybridized with specific probes. Primer
sequences are available as Supplemental Data.
Reverse transcriptase-PCR
Total RNA was isolated using TRI-reagent solution (Sigma) according to the
manufacturer’s protocol and treated with DNase (Invitrogen). Reverse tran-
scription was performed by standard procedures. Primer sequences are
available as Supplemental Data.
Generation and genotyping of mutant mice
E2f1-deficient animals ofmixed 129/SvxC57BL/6 genetic background (Jack-
son Laboratory) were mated to HMGA2 transgenic (HMGA2TG) animals
(Fedele et al., 2002) to generate HMGA2TG;E2f1+/2 mice. Subsequent inter-
matingofHMGA2TG;E2f1+/2malesand femalesproducedHMGA2TG;E2f12/2
mice. Animals were genotyped from tail DNA using Southern blot and PCR as
previously described (Fedele et al., 2002) and according to the Jackson pro-
tocol. Mice were maintained under specific pathogen-free conditions in our
Laboratory Animal Facility (Istituto dei Tumori di Napoli, Naples, Italy), and
all studies were conducted in accordance with Italian regulations for
experimentations on animals.
Histological analyses
Paraffin-embedded sections 4–5 mm thickwere stainedwith hematoxylin and
eosin and with the Gordon-Sweet silver method for the reticulin matrix. Im-
munohistochemical staining to identify proliferating cells was carried outCANCER CELL JUNE 2006
A R T I C L Ewith the PCNA antibody (Novocastra) and the streptavidin-biotin peroxidase
technique (DAKO Corp., CA).
Magnetic resonance
Magnetic resonance imaging was carried out at the Istituto dei Tumori di Na-
poli G. Pascale with a 1.5-T magnet system using local receiver coils and an
8 cm field of view. Sagittal slices 3 mm thick were obtained with T1 weighting
(TR/TE = 400/11 ms).
Supplemental Data
The Supplemental data for this article can be found online at http://www.
cancercell.org/cgi/content/full/9/6/459/DC1/.
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SOM230, ANew Somatostatin Analogue, Is Highly Effective
in the Therapy of Growth Hormone/Prolactin-Secreting
PituitaryAdenomas
Monica Fedele,1Ivana DeMartino,1Rosario Pivonello,2 Andrea Ciarmiello,4 M. Laura Del Basso De Caro,3
RosaVisone,1Dario Palmieri,1GiovannaM. Pierantoni,1ClaudioArra,4 Herbert A. Schmid,6 Leo Hofland,7
Gaetano Lombardi,2 Annamaria Colao,2 and Alfredo Fusco1,5
Abstract Purpose:We have previously shown that transgenic mice ubiquitously overexpressing the
HMGA2 gene develop growth hormone/prolactin-secreting pituitary adenomas. This animal
model has been used to evaluate the therapeutic efficacy of SOM230, a somatostatin analogue
with high affinity for the somatostatin receptor subtypes 1, 2, 3, and 5, on the growth of the
pituitary adenomas.
Experimental Design: Four groups of 3- and 9-month-old HMGA2 transgenic mice were
treated for 3 months with a continuous s.c. injection of two different dosages of SOM230
(5 or 50 Ag/kg/h), one dose of octreotide, corresponding to that used in human therapy, and a
placebo, respectively. The development of the tumor before and after therapy was monitored by
magnetic resonance imaging of the pituitary region and evaluation of the serum prolactin levels.
Results: The highest dose of SOM230 induced a drastic regression of the tumor, whereas
octreotide was not able to induce any significant tumor regression, although tumor progression
was significantly slowed down. No significant differences were observed between the animals
treated with the lowest dose of SOM230 and those receiving placebo.
Conclusions: These results clearly support the efficacy of the SOM230 treatment in human
pituitary adenomas secreting prolactin basedon the dramatic tumor shrinkage and fall in prolactin
levels. This beneficial effect could be of crucial clinical usefulness in patients bearing tumors
resistant to dopaminergic drugs.
Pituitary tumors account for f15% of intracranial tumors.
Although they are usually benign adenomas, they are associated
with significant morbidity due to local compressive effects on
brain structures and cranial nerves, leading to headaches and
visual disturbances. Morbidity can also result from tumor-
derived hormonal hypersecretion or following treatment that
inadvertently damages adjacent normal pituitary hormone
secretion. About two thirds of pituitary tumors express and
secrete pituitary hormones. Among these, prolactinomas are the
most common lesions, representing f50% of all the clinically
diagnosed pituitary adenomas. The current strategy for treating
patients with functional pituitary tumors aims to normalize
excess pituitary hormone secretion, targeting neuroendocrine
receptors with dopamine agonists and somatostatin analogues
(1). This approach has the potential to abrogate or suppress
excess of hormone secretion. In addition, as pituitary cell
hormone secretion and proliferation are strictly linked, treat-
ment with dopamine and/or somatostatin agonists can also
inhibit pituitary tumor growth. Thus far, the only drugs widely
used to treat pituitary tumors over the past 2 decades are
somatostatin analogues, such as octreotide and lanreotide,
which have high affinity for somatostatin receptor (SSTR) 2.
They are effective in the tumor mass shrinkage of 20% to 50% of
treated patients depending on the receptor density and subtype
expression (2). Different somatostatin analogues have been
found to have SSTR subtype specificity and have revealed
functional interactions between somatostatin receptor subtypes.
In fact, in vitro experiments have shown that SSTR2-selective
ligands do not prevent prolactin release from prolactin-secreting
pituitary tumor cells, whereas a SSTR5-selective analogue
suppresses prolactin secretion by f40%, indicating divergent
roles for SSTR2- and SSTR5-mediated actions in prolactinomas
(3). By this point of view, the development of molecules that
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bind with high-affinity different SSTR subtypes should have a
superior therapeutic potential. SOM230 is a promising drug
candidate that fulfills these criteria because it exhibits an almost
universal binding to somatotropin release-inhibiting factor
receptor subtypes (SSTR1, SSTR2, SSTR3, and SSTR5) and exerts
potent inhibitory effects on the growth hormone/insulin-like
growth factor-I axis in several in vivo animal models (4, 5).
Preclinical studies on experimental models in vivo are needed to
elucidate the real efficacy of a therapy based on SOM230
administration for functional pituitary adenomas secreting
either growth hormone or prolactin or both of them. Since
the last decade, several transgenic mouse models of pituitary
adenomas have been generated by targeting expression of
oncogenic transgenes to anterior pituitary cells using pituitary-
specific promoters (6–8). Our group has recently developed a
genetically engineered mouse model for pituitary tumorigenesis
(9). These mice, overexpressing in all tissues the HMGA2 gene,
develop growth hormone/prolactin-secreting pituitary adeno-
mas by 6 months of age, with an almost total penetrance in the
female gender. This animal model represents an excellent model
for evaluating new therapies for pituitary adenomas. Therefore,
to evaluate the therapeutic efficacy of SOM230 on pituitary
tumor development and hormone secretion, and to compare
it with that of octreotide, four groups of 3- and 9-month-old
HMGA2 transgenic female mice were treated for 3 months with
SOM230 (at two different doses), octreotide, and a placebo,
respectively. SOM230, at the highest dose of 50 Ag/kg/h,
drastically affected the tumor progression and induced a
significant regression of the tumor. In contrast, the octreotide
at the same dose significantly slowed down the progression of
the tumor without inducing regression.
Therefore, these results indicate that administration of
SOM230 may represent an elective treatment for pituitary
adenomas secreting growth hormone and prolactin.
Materials andMethods
Mice and treatment. Two groups of 32 HMGA2 female transgenic
mice have been treated either at 9 months or at 3 months of age as
follows: 8 placebo, 8 octreotide (50 Ag/kg/h), 8 SOM230 (5 Ag/kg/h),
and 8 SOM230 (50 Ag/kg/h). The treatment was delivered by s.c.
injection, for 3 months, by using Alzet osmotic pumps model 2004. A
saline solution (0.9% NaCl) was used as placebo. All the mice have
been housed in the Animal facility of the Istituto dei Tumori di Napoli
G. Pascale.
Quantitative reverse transcription-PCR. To evaluate SOM230-
responsive SSTR expression in HMGA2 transgenic mice pituitary
tumors, the relative amount of sst1, sst2A, sst2B, sst3, and sst5 was
calculated in four tumors removed by the mice not treated by
somatostatin analogues by quantitative reverse transcription-PCR.
Quantitative PCR was done as described previously (10). Briefly,
polyadenylated mRNA was isolated during Dynabeads Oligo(dT)25
(Dynal AS, Oslo, Norway) from tumor tissue samples. cDNA was
synthesized using the polyadenylated mRNA, which was eluted from
the beads in 40 AL H2O for 2 min at 65jC, using Oligo(dT)12-18
Primer (Applied Biosystems, Foster City, CA). One twentieth of the
cDNA library was used for quantification of the SSTR subtype mRNA
levels. A quantitative reverse transcription-PCR was done by Taqman
Gold nuclease assay (Perkin-Elmer Corp., Foster City, CA) and the ABI
PRISM 7700 Sequence Detection System (Perkin-Elmer) for real-time
amplification according to the manufacturer’s instructions. The assay
was done using 15 AL Taqman Universal PCR Master Mix (Applied
Biosystems), 300 nmol/L forward primer, 300 nmol/L reverse primer,
200 nmol/L probe, and 10 AL cDNA template in a total reaction
volume of 25 AL. The detection of hypoxanthine phosphoribosyl
transferase (HPRT) mRNA served as a control and was used for
normalization of somatostatin subtype mRNA levels.
The specific mouse primer sequences (Biosource, Nivelles, Belgium)
that were used included the following: HPRT, 5¶-TGAAGAGCTACTG-
TAATGATCAGTCAAC-3¶ (forward) and 5¶-AGCAAGCTTGCAACCT-
TAACCA-3¶ (reverse); sst1, 5 ¶-TTGACTTGGGGATCTGAAGG-3 ¶
(forward) and 5¶-ATTAATAAGCGGCACCATCG-3¶ (reverse); sst2A,
5¶-TGAGTGGTACGGAGGATGGG-3¶ (forward) and 5¶-CTCCGTGGT-
CTCATTCAGCC-3¶ (reverse); sst2B, 5¶-CAAGGCAGACAATTCA-
CAATCC-3¶ (forward) and 5¶-GTTTCTGCCGGGCAGCT-3¶ (reverse);
sst3, 5¶-CCTCTGCAGCAACCCTGTA-3¶ (forward) and 5¶-CAGATGAAG-
GATAGGTAACAGTGG-3¶ (reverse); and sst5, 5¶-GCGCTCAGAACG-
CAAGGT-3¶ (forward) and 5¶-CAGCAGCCCACGAACACC-3¶ (reverse).
The probe sequences that were used included the following: HPRT,
5¶-FAM-TGCTTTCCCTGGTTAAGCAGTACAGCCC-TAMRA-3¶; sst1,
5¶-FAM-TGAAATCTCCAGGTACAGGTTTAAAGAACTGGCA-TAMRA-3¶;
sst2A, 5¶-FAM-AGAGGAGCGACAGTAAGCAGGACAAATCC-TAMRA-3¶;
sst2B, 5¶-FAM-ATTGCCTGGGTGTGACCTGGTGGA-TAMRA-3¶; sst3,
5 ¶-FAM-TTAGGGCTGGTTGGCTGCTGACTGATCCTCATCTCAG-
TAMRA-3¶; and sst5, 5¶-FAM-ACTCGCATGGTGGTGGTAGTGGTGC-
TAMRA-3¶.
The relative amount of SSTR mRNA was determined by means of a
standard curve generated in each experiment from known amounts of
mouse genomic DNA. For the determination of the amount of HPRT
mRNA, a standard curve was obtained by including dilutions of a pool
cDNAs known to contain HPRT. The amount of SSTRs mRNA was
calculated relative to the amount of HPRT and is given in arbitrary units.
Serum hormone measurements. Serum prolactin concentration was
measured before and after the treatment using mouse prolactin RIAs
consisting of reagents provided by Dr. A.F. Parlow (National Hormone
& Peptide Program, Harbor-UCLA Medical Center, Torrance, CA).
Magnetic resonance. Magnetic resonance imaging (MRI) analyses
have been done at the Istituto dei Tumori di Napoli G. Pascale on a
1.5-T magnet system using local receiver coils and an 8-cm field of
view. Sagittal slices (3 mm thick) have been obtained with T1-
weighting (repetition time/echo time = 400/11 ms). The images were
analyzed by Acrobat Photoshop; the tumor size, expressed in pixel, has
been obtained by the product of the two major diameters of the lesion
as appeared in the median sagittal section.
Histologic analysis. Histologic evaluation was done on 10% neutral
phosphate-buffered formaldehyde-fixed, paraffin-embedded pituitary
adenomas. Paraffin sections were stained with H&E and Gordon-Sweet
silver impregnation to assess reticulin fiber network, which is essential
Fig. 1. SSTR expression in pituitary adenomas from HMGA2 transgenic mice.
The results obtained from three independent real-time analyses of sst1, sst2A, sst2B,
sst3, and sst5 genes were plotted as a histogram, showing their relative copy
number compared with the housekeeping HPRT gene.
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for distinguishing normal adenohypophysial architecture, hyperplasia,
and adenoma.
Statistical analysis. For the comparison of statistical significance
between two groups, Student’s t test was used. A P value of <0.05 was
considered statistically significant.
Results
Characterization of SSTRs in pituitary tumors from HMGA2
transgenic mice. A significant relative amount of sst1, sst2A,
sst2B, sst3, and sst5 was found in the pituitary tumors removed
by HMGA2 mice. The number of sst2A and sst2B is significantly
higher than that of all the others, although a rather heteroge-
neous expression of the formers and a rather homogeneous
expression of the latters were found. The expression of SSTRs is
shown in Fig. 1.
Treatment of HMGA2 transgenic mice with SOM230 reduces
tumor proliferation. The expression of SSTR subtypes 1, 2, 3, and
5 by the pituitary adenomas occurring in the HMGA2 transgenic
mice might account for testing the SOM230 for their treatment.
Female HMGA2 transgenic mice were used for preclinical studies
with SOM230 because they develop growth hormone/prolactin-
secreting pituitary adenomas with an almost complete pene-
trance. SOM230 was given to 3- and 9-month-old mice by
continuous s.c. injection as indicated in Materials and Methods.
In parallel, we also used octreotide and a placebo as positive and
negative control of pituitary adenoma treatment, respectively.
Fig. 2. MRI of HMGA2 transgenicmice before and after the treatment at 9 to12months of age. Representativemouse for each treated group before (left) and after (right) the
treatment. Arrows, pituitary adenoma.
Cancer Therapy: Preclinical
www.aacrjournals.orgClin Cancer Res 2007;13(9) May 1, 2007 2740
In 9-month-old mice, tumor growth was monitored before
and after the treatment by MRI analysis (Fig. 2). The
comparison of the images clearly shows a decrease of tumor
size in mice treated with high dosage of SOM230 (50 Ag/kg/h).
Conversely, a clear increase in tumor size was observed in mice
treated with either a placebo (control) or a low dosage of
SOM230 (5 Ag/kg/h). Finally, no increase in tumor size was
shown in mice treated with octreotide. We measured tumor
size for each mouse before and after the treatment as indicated
in Materials and Methods and plotted the results as shown in
Fig. 3A. The comparison of groups revealed that the pituitary
tumors of HMGA2 transgenic mice significantly (P = 0.028)
slow down their growth in response to 50 Ag/kg/h octreotide.
Interestingly, 50 Ag/kg/h SOM230 significantly (P = 0.015)
affect the tumor progression of HMGA2 transgenic mice, even
better than octreotide does, resulting in a reduction of the
tumor size. In fact, the effect of SOM230 on tumor
proliferation is significantly stronger (P = 0.0017) than that
exerted by the octreotide.
In 3-month-old mice, tumor growth was monitored by MRI
(data not shown) only at 12 months of age (after 6 months
from the end of the treatment) to follow up the tumor growth
in mice that received the treatment before the onset of the
tumor. As shown in Fig. 3B, tumor size, as appeared by MRI
analysis at 12 months of age, was measured for each treated
mouse. The only group that showed a significant size reduction
compared with placebo-treated mice (P = 0.053) was that
treated with SOM230 at high dosage (50 Ag/kg/h). Conversely,
both octreotide and 5 Ag/kg/h SOM230 did not significantly
reduce the tumor size compared with a placebo (P = 0.23 and
0.35, respectively). Importantly, no side effects were observed
Fig. 3. Size analysis of tumors in treated mice. A, mice treated at 9 mo of age were
analyzed by MRIbefore treatment and 3 mo later at the end of the treatment.Tumor
size was evaluated as indicated in Materials and Methods. Columns, mean of the
size difference before and after the treatment for each animal group; bars, SE.
B, mice treated at 3 mo of age were analyzed byMRI only at12 mo of age and 6 mo
later at the end of the treatment when the tumor was easily detectable.Tumor size
was evaluated as before. Columns, mean tumor size for each treated group; bars,
SE.Top of the graphs, P value obtained by the comparison of the groups. Asterisks,
values that differ statistically from the placebo group.
Fig. 4. Serum prolactin concentration measurement in treated mice. A, columns,
mean prolactin levels before and after the treatment at 9 mo of age for each animal
group; bars, SE. B, columns, mean prolactin levels before and after the treatment
at 3 mo of age for each animal group; bars, SE.Top of the graphs, P value obtained
by the comparison of the value in each group. Asterisks, values obtained after the
treatment of each group, whose difference from the value of the same group
before the treatment is statistically different.
Table 1. Incidence of pituitary adenomas in
treated mice
Treatment Age at the time of treatment
3 mo, n (%) 9 mo, n (%)
Placebo 8/8 (100) 8/8 (100)
Octreotide 8/8 (100) 8/8 (100)
SOM230 (low dose) 6/8 (75) 8/8 (100)
SOM230 (high dose) 2/8 (25) 2/8 (25)
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in treated mice over the period they were infused and no
differences in terms of body weights were observed among the
animals at the end of the treatment.
HMGA2 transgenic mice treated with SOM230 show reduced
prolactin secretion. Plasma prolactin concentration in trans-
genic mice before and after the treatment was measured by RIA.
In mice treated at 9 to 12 months of age, prolactin levels were
significantly increased in both placebo-treated and SOM230-
treated (low dose) mice in comparison with the respective
control mice (placebo group: P = 0.09; SOM230 (low dose):
P = 0.03). Conversely, octreotide-treated mice did not increase
significantly their prolactin levels (P = 0.34) and SOM230-
treated (high dose) mice showed a trend to decrease prolactin
concentration following treatment, although it was not sta-
tistically relevant (P = 0.29; Fig. 4A). In mice at 3 to 6 months,
the prolactin levels were not significantly increased even in the
placebo-treated mice because of the still low tumor growth due
to the early stage at this age. Nevertheless, a trend versus a slower
increase or a mild decrease was observed in all the other treated
groups in comparison with the respective controls (Fig. 4B).
Fig. 5. Cytohistologic characterization of
the pituitary tumors in treated mice.
A, transgenic mice of the placebo group
developed sharp delineated pituitary
tumors with a follicular type architecture and
several blood lakes. B, a healthy pituitary
gland from a wild-type mouse is shown for
comparison. C, mice treated with octreotide
show the same phenotype as in (A).
D, in most neoplastic cells from octreotide-
treated mice, the reticulin network was
lost. E, mice treated with SOM230 (low
dose) show the same phenotype as in (A)
and (C). F, in most neoplastic cells from
SOM230-treated (low dose) mice, the
reticulin network was lost. G, total rescue of
the normal phenotype was observed in
mice treated with SOM230 (high dose).
H, intact reticulin network in pituitary cells
from SOM230-treated (high dose) mice.
A, B, C, E, andG, H&E staining.D, F, andH,
Gordon-Sweet silver stain. Original
magnifications,100 [A and B (main
images) and D-H] and 400 [A and B
(insets) and C].
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Decreased incidence of pituitary tumors in mice treated with
SOM230. All the pituitary glands and tumors from treated
mice were fixed in formalin and analyzed by H&E staining for
the characterization of the histologic phenotype and the
obtaining of the definitive diagnosis. The results of this analysis
are summarized in Table 1.
In Fig. 5, some representative histologic analyses are shown.
Most of mice treated with 50 Ag/kg/h SOM230, both at 3 and 9
months of age, reacted to the therapy with a complete rescue of
the normal phenotype (Fig. 5G). The same result was achieved
by only one fourth of the mice treated with 5 Ag/kg/h SOM230
at 3 months of age. All the other treated mice showed a clear
tumoral phenotype with histologic characteristics similar to the
placebo group (compare Fig. 5C and E with Fig. 5A), although
mice treated with either octreotide, both at 3 and 9 month of
age, or SOM230 (low dose), at 3 months of age, showed in
most cases smaller tumors compared with control transgenic
mice (data not shown). The Gordon-Sweet silver method was
used for the histologic diagnosis of these nodules and showed
focal disruption of the reticulin fiber network, which is
pathognomic for the adenomatous transformation of pituitary
cells (Fig. 5D and F).
Discussion
Our previous studies proposed a crucial role of the HMGA2
gene overexpression in pituitary tumorigenesis. In fact, HMGA2
was found amplified and overexpressed in human prolactino-
mas, and transgenic mice overexpressing the HMGA2 gene
developed pituitary adenomas secreting growth hormone and
prolactin. Therefore, this animal model may represent a unique
tool for testing the efficacy of new drugs for the therapy of
human pituitary adenomas. Currently available treatment for
human pituitary adenomas uses somatotropin release-inhibit-
ing factor analogues, such as octreotide and lanreotide, which
bind preferentially and with high affinity to sst2 (11).
Therefore, a research of new drugs able to compete with the
other receptors has been prosecuted. Recently, a new drug
molecule, SOM230, which binds with high affinity to all
human somatotropin release-inhibiting factor receptor sub-
types, except for sst4, has been identified and characterized (5).
It has the potential to act as a drug combination that contains
both sst2- and sst5-selective somatotropin release-inhibiting
factor analogue agonists and that was shown to inhibit growth
hormone release more potently than single-agent treatment in
pituitary adenoma cultures (3, 12). Moreover, the affinity of
SOM230 to sst5 suggests potential inhibitory effects on
prolactin secretion, given that it has been found that sst5-
selective agents inhibit prolactin secretion from prolactinomas,
whereas sst2-selective agonists were inactive (12).
A recent study by the group of Melmed compared the relative
efficacy of SOM230 and octreotide on hormone secretion from
primary cultures of rat pituitaries, human fetal pituitary tissues,
and pituitary adenomas, finding no significant improvement by
SOM230 on growth hormone and prolactin suppression
compared with octreotide, although a trend toward greater
efficacy of SOM230 in both growth hormone–secreting and
prolactin-secreting adenomas, compared with octreotide, was
suggested (13). In the current study, the relative efficacy of
octreotide and SOM230 on hormone secretion and tumor
growth was studied in our in vivo model of pituitary
tumorigenesis, such as the HMGA2 transgenic mice, by a
3-month continuous s.c. infusion of the different compounds.
Our results clearly show that the treatment with SOM230 at the
dose of 50 Ag/kg/h is extremely effective because it is able to
induce a drastic regression of the tumor when the treatment
was started while the tumor was already evident. When the
treatment was begun at the third month after birth, no pituitary
tumor being present, it gave rise to the prevention of the
neoplastic phenotype. Conversely, the treatment with octreo-
tide did not lead to the regression of the disease and could not
avoid the development of the tumor in mice treated for 3
months before the onset of the tumor. However, the compound
showed a certain efficacy because the growth of the tumor was
less rapid in the octreotide-treated compared with mock-treated
animals. Interestingly, no effect at all was achieved after the
treatment with SOM230 at the dosage of 5 Ag/kg/h, suggesting
that the treatment with SOM230 requires a minimal dosage to
get a valid effect.
The results of this study indicate the potential usefulness of
SOM230 in the treatment of human prolactinomas. It is widely
accepted that dopaminergic compounds, such as bromocriptine
and cabergoline, are extremely effective in normalizing
prolactin levels and reducing tumor mass, up to its disappear-
ance, in 80% to 90% of patients in different series (14–17).
The minority of patients with tumors resistant to dopaminergic
drugs are very difficult to treat and have potentially the risk of
further tumor progression with neurologic damage and even
death because of the tumor (18). The results of the current
study support the possible usefulness of SOM230 in patients
with prolactinomas, especially in those patients who are
resistant to cabergoline.
In conclusion, these results taken together propose the
treatment with SOM230 as a valid tool for the therapy of
human pituitary adenomas with an efficacy that it is higher in
comparison with that obtained with octreotide, currently used
for the treatment of human prolactinomas. However, our data
also show that the dosage of SOM230 must be appropriate
because a low dosage does not give any therapeutic effect.
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downregulated by the high-mobility group A
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(Correspondence should be addressed to A Fusco; Email: afusco@napoli.com)AbstractThe high-mobility group A (HMGA) family of proteins orchestrates the assembly of nucleoprotein
structures playing important roles in gene transcription, recombination, and chromatin structure
through a complex network of protein–DNA and protein–protein interactions. Recently, we have
generated transgenic mice carrying wild type or truncated HMGA2 genes under the transcriptional
control of the cytomegalovirus promoter. These mice developed pituitary adenomas secreting
prolactin and GH mainly due to an increased E2F1 activity, directly consequent to the HMGA2
overexpression. To identify other genes involved in the process of pituitary tumorigenesis induced
by the HMGA2 gene, in this study we have analyzed the gene expression profile of three HMGA2-
pituitary adenomas in comparison with a pool of ten normal pituitary glands from control mice,
using the Affymetrix MG MU11K oligonucleotide array representing w13 000 unique genes. We
have identified 82 transcripts that increased and 72 transcripts that decreased at least four-fold in
all the mice pituitary adenomas analyzed compared with normal pituitary glands. Among these
genes, we focused our attention on the Mia/Cd-rap gene, whose expression was essentially
suppressed in all of the pituitary adenomas tested by the microarray. We demonstrated that the
HMGA proteins directly bind to the promoter of the Mia/Cd-rap gene and are able to downregulate
its expression. In order to understand a possible role of Mia/Cd-rap in pituitary cell growth,
we performed a colony assay in GH3 and GH4 cells. Interestingly, Mia/Cd-rap expression inhibits
their proliferation, suggesting a potential tumor suppressor role of Mia/Cd-rap in pituitary cells.Endocrine-Related Cancer (2007) 14 875–886Introduction
The high-mobility group A (HMGA) family consists of
three proteins: HMGA1a and HMGA1b that result from
alternative splicing of the same gene, i.e. HMGA1
(Johnson et al. 1989), and HMGA2,which is encoded by
a different gene (Manfioletti et al. 1991). They are small
nuclear proteins that bind to the minor groove of DNA
through highly cationic regions called ‘AT-hooks’
(Reeves 2001). The HMGA proteins function as anEndocrine-Related Cancer (2007) 14 875–886
1351–0088/07/014–875 q 2007 Society for Endocrinology Printed in Greatarchitectural transcription factor: they do not indepen-
dently regulate gene transcription, but modulate gene
expression through the formation of stereospecific
complexes on the promoter/enhancer regions of genes
by direct interaction with other transcription factors and
through substrate interactions that bend, unwind, or
distort the structure of DNA (Thanos & Maniatis 1995).
Both the genes have a critical role in the development,
during which they are abundantly expressed. In fact,Britain
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I De Martino et al.: HMGA2-induced pituitary adenomasthe generation of HMGA2-knockout mice resulted in a
pygmy phenotype associated with a drastic reduction of
the fat tissue (Zhou et al. 1995), whereas HMGA1 null
mice showed cardiac hypertrophy and type 2 diabetes
(Foti et al. 2005, Fedele et al. 2006a).
Rearrangements of the HMGA2 gene have been
frequently found in human benign tumors, mainly of
mesenchymal origin, such as lipomas, lung hamartomas,
and uterine leiomyomas (Ashar et al. 1995, Schoenmakers
et al. 1995). Both the HMGA genes have a critical role in
the process of carcinogenesis because they are over-
expressed in most human malignant neoplasias (Melillo
et al. 2001) and the blockage of their expression has been
shown to prevent thyroid cell transformation and lead
malignant cells to death (Scala et al. 2000,Berlingieri et al.
2002). Moreover, both HMGA1 and HMGA2 behave as
classical oncogenes in focus assays on mouse and rat
fibroblasts (Fedele et al. 1998, Wood et al. 2000). The
generation of transgenic mice overexpressing either the
HMGA1or theHMGA2gene confirmed their oncogenicity
also in vivo. In fact, both the HMGA1 and HMGA2
transgenic mice develop growth hormone/prolactin
(GH/PRL)-secreting pituitary adenomas and T/NK lym-
phomas (Baldassarre et al. 2001, Fedele et al. 2002, Fedele
et al. 2005).
Consistently with the development of pituitary
adenomas in HMGA2 transgenic mice, HMGA2 gene
amplification and overexpression have been shown in a
large set of human prolactinomas supporting a critical
role of HMGA2 in this human neoplasia (Finelli et al.
2002). The mechanism by which HMGA2 is involved
in pituitary tumorigenesis is on the ability of the
HMGA2 to interfere with the pRB/E2F1 pathway.
In fact, we have recently shown that HMGA2 interacts
with retinoblastoma protein (pRB) and induces an
increased E2F1 activity in pituitary adenomas by
displacing histone deacetylase (HDAC1) from the
pRB/E2F1 complex and resulting in E2F1 acetylation
(Fedele et al. 2006b). The suppression of pituitary
tumorigenesis by mating HMGA2TG and E2F1K/K
mice demonstrates a critical role for the HMGA2-
mediated E2F1 activation in the onset of these tumors
in transgenic mice, and likely in human prolactinomas.
Although the E2F1 activation might represent a major
point in the generation of pituitary adenomas in transgenic
mice, we cannot exclude the fact that other comp-
lementary mechanisms may be envisaged for the role of
HMGA2 in pituitary tumorigenesis. In fact, also in the
E2F1 minus background, the HMGA2 mice develop a
certain number of pituitary neoplasias, even thoughwith a
lower frequency and a minor phenotype. Thus, the aim of
the present work has been to find out other molecular
changes that might contribute tothe development of the876HMGA2-induced pituitary tumors. Therefore, we
analyzed the expression profile of three pituitary
adenomas developed by HMGA2 transgenic mice in
comparison with a pool of normal pituitary glands from
wild-type animals. We screened an array in which
w13 000 were represented, and we identified 82
transcripts that increased and 72 that decreased with a
greater than or equal to four-fold change in pituitary
adenomas versus normal ones. These results were
validated by semiquantitative reverse transcription (RT)-
PCR performed on pituitary tumors originating from
different HMGA2 transgenic mice. Then, we focused our
attention on theMia/Cd-rap gene, whose expression was
drastically downregulated in HMGA2-induced pituitary
adenomas. Mia/Cd-rap is a small, secreted protein that is
expressed normally at the onset of chondrogenesis (Dietz
& Sandell 1996). Interestingly, it is secreted by malignant
melanoma cells and elicits growth inhibition ofmelanoma
cells in vitro (Blesch et al. 1994).
Here we report that the HMGA proteins are able to
bind to the promoter of the Mia/Cd-rap gene both
in vitro and in vivo indicating a direct role of HMGA
proteins in the regulation of the transcription of the
Mia/Cd-rap gene. Functional studies by luciferase
assays confirmed the critical role of the HMGA
proteins in the downregulation of the Mia/Cd-rap
promoter. To understand the relevance of Mia/Cd-rap
downregulation in pituitary adenoma cell growth, we
expressed Mia/Cd-rap in GH3 and GH4 cells and
performed colony assays. Consistently with a putative
tumor suppressor role for Mia/Cd-rap in pituitary cells,
we found that its expression causes growth inhibition.
Materials and methods
RNA extraction
Pituitary glands adenomas from wild type and HMGA2
mice (Fedele et al. 2002, 2006b) were snap-frozen in
liquid nitrogen and stored at K80 8C until use. Total
RNAs were extracted from tissues and cell lines using
TRI REAGENT (Molecular Research Center Inc.,
Cincinnati, OH, USA) solution, according to manufac-
turer’s instructions. The integrity of theRNAwasassessed
bydenaturingagarosegelelectrophoresis (virtualpresence
of sharp 28S and 18S bands) and spectrophotometry.
Microarray analysis
The Affymetrix standard protocol has been described
extensively elsewhere (Affymetrix GeneChip). Briefly,
cRNA was prepared from 8 mg total RNA, hybridized to
MG MU11K Affymetrix oligonucleotide arrays
(containing about 13 000 murine transcripts), scanned,
and analyzed according to Affymetrix (Santa Clara, CA,www.endocrinology-journals.org
Endocrine-Related Cancer (2007) 14 875–886USA) protocols. Scanned image files were visually
inspected for artifacts and normalized by using
GENECHIP 3.3 software (Affymetrix). The individual
gene expression levels for each of the three pituitary
adenomas arrays were divided by the expression level in
the normal pituitary tissue. Thus, the data were presented
as relative to the expression in normal pituitary tissue.
The fold change values, indicating the relative change in
the expression levels between mutated and wild-type
samples, were used to identify genes differentially
expressed between these conditions.
Cluster analysis byMultiexperiment Viewer (MeV)
Microarray data havebeen elaboratedby theMeVsystem
to get gene expression signature of the samples analyzed.
TheMeV is a system of cluster analysis for genomewide
expression data fromDNAmicroarray hybridization that
uses standard statistical algorithms to arrange genes
according to similarity in the pattern of gene expression.
In our analysis, we used a four-fold difference in
expression level between normal and tumoral samples.
Semiquantitative RT-PCR
RNAs were treated with DNaseI (Invitrogen) and reverse
transcribed using random exonucleotides and MuLV
reverse transcriptase (Perkin–Elmer, Waltham, MA,
USA). To ensure that RNA samples were not contami-
nated with DNA, negative controls were obtained by per-
formingPCRonsamples thatwere not reverse transcribed,
but otherwise identically processed. For semiquantitative
PCR, reactionswere optimized for the number of cycles to
ensure product intensity within the linear phase of
amplification. The PCR products were separated on a
2% agarose gel, stained with ethidium bromide, and
scanned using a Typhoon 9200 scanner. Digitized data
were analyzed using Imagequant (Molecular Dynamics,
Sunnyvale, CA, USA). Primers sequences and different
annealing conditions are available as supplemental data
(Supplemental Table 1, which can be viewed online at
http://erc.endocrinology-journals.org/supplemental/).
Cell cultures and transfections
All cell lines, except for aT3-1 (kindly provided by Dr P
Mellon, University of California, San Diego, CA, USA),
were purchased from ATCC. They were all cultured in
DMEM containing 10% fetal bovine serum (HyClone,
Logan, UT, USA) and 50 mg/ml gentamicin (Life
Technologies Inc.) in a humidified atmosphere of 95%
air and5%CO2.B16F0aremurinemelanomacells;AtT20
and aT3-1 are murine pituitary adenoma cells secreting
adrenocorticotrophin (ACTH) and gonadotropic hor-
mones, respectively; RC-4B/C are rat pituitary adenomawww.endocrinology-journals.orgcells secreting GH, follicle-stimulating hormone, lutei-
nizing hormone, gonadotrophin-releasing hormone,
ACTH, and thyrotrophin (TSHb); GH1, GH3, and GH4
are rat pituitary adenoma cells secreting PRL and GH.
Transfections were carried out by using Lipofecta-
mine 2000, according to manufacturer’s instructions.
Plasmids
The 5 0 flanking region of the mouse Mia/Cd-rap gene
spanning nucleic acid residues K1396 to K1 with
respect to the ATG protein start codon was amplified
by PCR and inserted into the promoterless luciferase
plasmid pGL3-basic (Promega) to obtain the MIA-luc
pGL3 plasmid. The human Mia/Cd-Rap expression
plasmid, pCMV6-XL4/Mia, was commercially avail-
able (TC116021 – OriGene Technologies, Rockville,
MD, USA). pBABE-puro had been already described
(Monaco et al. 2001).
Luciferase and colony assays
For the Luciferase assay, a total of 2!105 B16F0 cells
were seeded into each well of six-well plates and were
transiently transfected with 1 mg MIA-luc pGL3 and with
the indicate amounts of pCEFLHa-HMGA1(Melillo et al.
2001) and pCEFLHa-HMGA2 (Fedele et al. 2006b),
together with 0.5 mg Renilla and various amounts of the
pCEFLHa plasmid to keep the total DNA concentration
constant. Transfection efficiencies were normalized by
using Renilla luciferase expression assayed with the dual
luciferase system(Promega).All transfection experiments
were repeated at least three times.
For the colony assay, GH3 and GH4 cells were seeded
at a density of 2.5!106 per 10 mm dish. Two days after,
the cells were transfected with 10 mg pCMV6-XL4 plus
2 mg pBabe-puro, or 10 mg pCMV6-XL4/Mia plus 2 mg
pBabe-puro. After about 15 days, the cells were stained
with 500 mg/ml crystal violet in 20% methanol, and the
resulting colonies were counted.
Protein extraction and western blot
Tissues and cell culture were lysed in buffer 1% NP40,
1 mmol/l EDTA, 50 mmol/l Tris–HCl (pH 7.5), and
150 mmol/l NaCl, supplemented with complete protease
inhibitors mixture (Roche Diagnostic Corp). Total
proteins were separated by SDS-PAGE and transferred
to nitrocellulose membranes (Bio-Rad). Membranes
were blocked with 5% nonfat milk and incubated with
antibody against MIA (A-20 Santa Cruz Biotechnology,
Santa Cruz, CA, USA, sc-17047). Bound antibody was
detected by the appropriate secondary antibody and
revealed with an enhanced chemiluminescence system
(Amersham-Pharmacia Biotech).877
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Protein/DNA-binding was determined by EMSA, as
previously described (Battista et al. 1995). Briefly,
5–20 ng of recombinant protein were incubated in the
presence of a 32P-end-labeled double-strand oligonu-
cleotide (specific activity, 8000–20 000 c.p.m./fmol).
Spanning from base K1130 to K1100 of the mouse
Mia/Cd-rap promoter region (5 0-AAACCCTGAAA-
TAAATCTTTTTTTCCCCTT-3 0). The DNA–protein
complexes were resolved on 6% non-denaturing
acrylamide gels and visualized by exposure to
autoradiographic films.Figure 1 Gene expression profile of pituitary adenomas of
HMGA2 transgenic mice. The expression profile of three
HMGA2-induced pituitary adenomas was compared with that of
normal pituitary gland of wild-type mice. Transcripts are
grouped according to fold change.Chromatin immunoprecipitation (ChIP)
ChIP was carried out with an acetyl-histone H3
immunoprecipitation assay kit (Upstate Biotechnology,
Charlottesville, VA, USA) according to manufacture’s
instruction. Approximately, 3!107 cells of the NIH3T3
cell line were grown on 75 cm2 dishes and cross-linked by
the addition offormaldehyde (to 1%final concentration) to
the attached cells. Cross-linking was allowed to proceed at
room temperature for 5 min and was terminated with
glycine (final concentration, 0.125 mol/l). The cells were
collected and lysed in buffer containing 5 mmol/l
piperazine-N, N0-bis[2-ethanesulfonic acid] (PIPES); (pH
8.0), 85 mmol/l KCl, 0.5% NP40, and protease inhibi-
tors(1 mmol/l phenylmethylsulfonyl fluoride, 10 mg/ml
aprotinin, and 10 mg/ml leupeptin), on ice for 10 min.
Nuclei were pelleted by centrifugation at 2300g for 5 min
at 4 8C and resuspended in buffer containing 50 mmol/l
Tris–Cl (pH 8.1), 10 mmol/l EDTA, 1% SDS, the same
protease inhibitors, and incubated on ice for 10 min.
Chromatin was sonicated on ice to an average length of
about 400 bpwith aBranson sonicatormodel250. Samples
were centrifuged at 16 000g for 10 min at 4 8C.Chromatin
was pre-cleared with protein A Sepharose (blocked
previously with 1 mg/ml BSA) at 4 8C for 2 h. Pre-cleared
chromatin of each sample was incubated with 2 mg
antibody anti-HA (sc-7392, Santa Cruz Biotechnology)
at 4 8C overnight. An aliquot of wild-type sample was
incubated also with anti-IgG antibody. Next, 60 ml a 50%
slurry of blocked protein A Sepharose was added and
immune complexes were recovered. The supernatants
were saved as ‘input.’ Immunoprecipitates were washed
twice with 2 mmol/l EDTA, 50 mmol/l Tris–Cl (pH 8.0)
buffer and four times with 100 mmol/l Tris–Cl (pH 8.0),
500 mmol/l LiCl, 1% NP40, and 1% deoxycholicacid
buffer. The antibody-bound chromatin was eluted from
the beads with 200 ml elution buffer (50 mmol/l NaHCO3,
1% SDS). The samples were incubated at 67 8C for 5 h
in thepresence of 10 mg RNase and NaCl to a final
concentration of 0.3 mol/l to reverse formaldehyde878cross-links. The samples were then precipitated with
ethanol at K20 8C overnight. The pellets were resus-
pended in 10 mmol/l Tris (pH 8)K1 mM EDTA and
treated with proteinase K to a final concentration of
0.5 mg/ml at 45 8C for 1 h. DNA was extracted with
phenol/chloroform/isoamylalcohol, ethanol precipitated,
and resuspended in water. Input DNA and immuno-
precipitatedDNAswere analyzed by PCR for the presence
of Mia/Cd-rap promoter sequence. The PCR were
performed with AmpliTaq gold DNA polymerase
(Perkin–Elmer). The primers used to amplify the sequence
of the Mia/Cd-rap promoter were 50-TTGCTGGTGCA-
TGCCTTA-3 0 (forward) and 5 0-TCTTAACCGCT-
GAGCCATCT-30(reverse). The PCR products were
resolved on a 2% agarose gel, stained with ethidium
bromide, and scanned using a Typhoon 9200 scanner.Results
Gene expression profile analysis
RNAs were extracted from a pool of normal pituitary
glands and from three pituitary adenomas developed in
three different HMGA2 transgenic mice, and were
hybridized to one MG Affymetrix MU11K-A oligonu-
cleotide array containing about 13 000 transcripts. The
number of transcripts that increased or decreased in all
pituitary adenomas versus normal gland is shown in the
Fig. 1. Of the 13.059 transcripts represented on the
array, 1560 had a one- to three-fold, 290 had a three- to
four-fold, 154 had a four- to ten-fold, and 11 had a
greater than ten-fold change. We examined the 154
transcripts that had a fold change R4 in all HMGA2-
induced pituitary adenomas versus normal pituitary
gland. Among these transcripts, 82 were increased and
72 were decreased, including 108 known genes, 30
expression sequence tags and 16 unknown genes. The
relative fold changes of these genes, grouped according
to their biological function, are shown in Table 1.www.endocrinology-journals.org
Table 1 Genes differentially expressed with a greater than or equal to four-fold change in high-mobility group A 2 (HMGA2)-induced
pituitary adenomas versus normal pituitary gland
Description GenBank accession no. FC Ad1 FC Ad2 FC Ad3
Immune function
Thy-1 X03151 4.0 1.3 5
Ob/Ob haptoglobin M96827 10.2 2.2 1.2
MRP8 M83218 107 3.7 1.3
Clon B6 myeloid second. granule prot L37297 105.1 2.2 1.7
Interferon inducible protein 1-8U W12941 K2.25 K2.7 K3.3
VCAM-1 X67783 32.6 3.7 4.1
Il-6 receptor X51975 K3.7 K2.6 K4.3
Ig-k chain (HyHEL-10) M35667 3.2 7.5 1.9
G protein-g 3 subunit AA049022 K2.5 K1.5 K7.9
GM-CSF X03019 K4.1 K4.9 K5
Myelopeptide-2 M23236 9.2 10.6 9.5
IFN-g AA015168 K7.5 K10.2 K13
Antigen pB7 M55561 5.5 K5.2 K5.6
Cell proliferation
b-Enolase W33721 K1.5 K2.2 K1.3
CAD protein AA466758 2.1 3 5.3
dUTPase AA110424 1.1 1.4 5.2
Galectin-3 W10936 14.3 8.2 6.3
Signal transduction
PKC-a M25811 2 1.8 6.6
FKBP65 binding protein L07063 6.3 8.3 12.2
mR-PTPm X58287 2.7 2.8 4
GTP-binding protein Gb4 M63658 2.4 3.7 6.8
p36 D10024 K4 K4.4 K11
AEBP1 X80478 K12.6 K3.3 K36.9
AP-2 NM_011547 8.4 12.5 4.4
A-RAF AA060840 K11.5 K11.7 K12.2
Vitronectin m77123 21.7 10.5 6.1
STEP61 U28217 K5.4 K9.9 K18.2
Cell cycle
CycD3 AA266783 4.4 6.1 3.5
CycB2 X66032 5.6 8 6.1
CycB X58708 4.5 6.3 4.4
cdc2 U58633 4 11.2 3.6
GADD-45 l28177 K2.6 K5.9 K3.9
Antigens
SSAV provirus polygene C76668 2.1 1.6 5.1
(Emv-3) gag gene U63133 K1.1 K1.4 K2
Mitochondrial proteins
Heme oxygenase M33203 30.5 3.2 2
Fosfadilserine decarb. Proenzime AA162205 23.9 40.8 36
Creatine kinase W50891 8 6.8 9.3
HMG proteins
HMGA1 AA290110 2.3 1.2 5.6
HMG2 Z46757 10.7 4.4 23.1
Enzymes
Argininosuccinate synthetase M31690 K5.6 K4.5 K6
PAF-acetylhydrolase U34277 K5.9 K6.7 K8.6
Transglutaminase Tgase M55154 K1.1 K5.8 K5.3
Aldehyde dehydrogenase ALDH2 U07235 K1.3 K3.2 K5.3
Rib-1 X60103 K16 K16.9 K18.5
Dipeptidase D13139 K4 K3.8 K3.9
Aldolase 3, isoform C W53351 K11.5 K5.5 K9.4
Cytochrome P-450 Naphthalene Hydrox. M77497 K13 K21 K12.2
11b HSDH X83202 K5.5 K7.2 K7.9
Ubiquitin-conjugating enzyme E2 W99019 5.6 8.6 3.1
Endocrine-Related Cancer (2007) 14 875–886
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Table 1 (continued)
Description GenBank accession no. FC Ad1 FC Ad2 FC Ad3
Retinaldehyde-specific dehydrogenase X99273 K7.2 K6.7 K6.2
Membrane-type matrix metalloproteinase
1
U54984 K1.8 K3.1 K6
CAMK2 b subunit X63615 K22.6 K22.7 K31.1
Acetylcholinesterase X56518 18.1 4.3 9.6
DNA topoisomerase II d12513 6 9.1 5.1
Ribonucleotide reductase M2 subunit m14223 4.4 7.9 5
Transcriptional factors
ID4 X75018 1.4 1.6 1.9
ID1 M31885 K4.5 K6.6 K7.5
Zif 268 M22326 K8.3 K1.4 K14.1
SOX-2 U31967 K8.8 K7 K10.6
d-like 1 protein X80903 4.3 6.7 6
MLZ4 zinc protein AA015118 6.4 4.6 9.1
SOX-11 AF009414 7.4 9.3 11.2
Hormones
FSH-b U12932 K9.6 K5.3 K7.9
LH-b U25145 K14 K2 K1.2
GH Z46663 15.3 18.7 22.1
Pituitary glycoprotein hormone M22992 K1.7 K1.1 K10.6
Thyroid-stimulating hormone M54943 K7.1 K7.7 K7.3
Oncogenes and oncoproteins
PTTG AA711028 K1.2 K5.6 K2.4
GARG-16 U43084 K3.6 K5.6 K10.4
Bcl3 W62846 9.1 8.3 6.1
IFC oncogene U28495 11.2 11 10.3
Lipidic metabolism
Choline Chinase AK078101 1.3 1.9 4.4
APOBEC-1 W29206 4.2 1.6 4.6
ALBP (adipocyte lipid-binding protein) K02109 10.8 6.1 9.6
Allergic disease and inflammation
IgE receptor W41745 9.2 1.2 K1.1
Extensin precursor AA031158 34 12.2 3.8
Mouse complement component C3 k02782 9.6 5.8 4.6
Extracellular matrix and cellular-structure
Laminin b-3 U43298 K3.8 K9.2 K14.3
Decorin X53929 K4.6 K4.6 K5.4
Tubulin b2 AA030364 7.1 9.3 11.3
Vsm a-ACTIN X13297 26.4 9.9 2.8
Reelin U24703 K6.2 K12 K32.7
E-chaderin X06115 K5.4 K6.2 K5.1
Tubulin b4 AA030364 9.9 4.3 11.3
Semaphorin H Z80941 K12.1 K8.6 K7.6
ATP-binding cassette trasp.(ABCR) AF000149 K9.9 K10.5 K12.3
Syntaxin 1A D45208 K5.6 K4.9 K5.6
Folate-binding protein 1 M64782 K10.1 K14.1 K16
Growth factors
Igf2 U71085 8.6 3.5 2.8
MIA/CD-RAP X97965 K106.6 K126.6 K121
Peroxisome membrane protein (PMP22) L28835 6.5 9.6 4.1
Development
Raly L17076 K5.4 K3 K3
Noggin U79163 7.5 8.3 10.3
NFI-b U57634 K4.5 K4.2 K7.5
Receptors
Nicotinic Acetyl Choline rec. b subunit M14537 K13.4 K15 K24.8
FGR receptor M33760 K5.9 K3.1 K12.5
T-cell receptor b chain M26417 K7.2 K5.6 K6.6
continued
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Table 1 (continued)
Description GenBank accession no. FC Ad1 FC Ad2 FC Ad3
RIP140 W85018 K6.8 K4.9 K7.1
Serotonin 4L receptor W85018 K4.1 K5.6 K4.9
Fc-g receptor m14215 31.6 7.4 6
Other functions
ANKT AA266783 4.4 6.1 7.5
g-casein D10215 1 1.1 1.1
EN7 X53247 13.4 1.4 K1.7
DMR-N9 gene Z38011 K4.3 7.3 K4.5
Actin-2 W50919 K7 K4.4 K6.7
Dihydropyrimidinase related protein 4 ab006715 K10 K10.6 K12.1
Hoxc-5 U28071 K5.7 K6.6 K8.5
Prosurvival factors
BDNF X55573 4.1 5.9 4.9
FC, fold change, Ad, pituitary adenoma.
Endocrine-Related Cancer (2007) 14 875–886A natural basis for organizing gene expression data is
to group together genes with similar patterns of
expression. Using the MeV, a free Java application
which is used to compare datasets from microarray
expression experiments (Eisen et al. 1998), we clustered
the gene expression profile of HMGA2-induced pituitary
adenomas in comparison with the normal gland. The
results, illustrated in Fig. 2, clearly show the similar
pattern of expression of several genes in all pituitary
adenomas with respect to the normal pituitary gland.Validation of microarray data
To validate the results obtained by microarray analysis,
we evaluated the expression of about 100 transcripts,
whose expression differed of a fold changeO4 or%4
in all the three pituitary adenomas compared with
normal glands. To this aim, we performed semiquanti-
tative RT-PCRs in normal glands and HMGA2-
induced pituitary adenomas derived from mice
different from those used for the Gene Chip micro-
array. For all of these genes, we confirmed the
differential expression associated with the pituitary
tumors. The results of some representative RT-PCR
analyses are shown in Fig. 3A. Among these
differentially expressed genes, there are some upregu-
lated (e.g. Cyclin B2, ANKT and noggin) and other
downregulated (e.g. Rib-1, CamK2 and Mia/Cd-rap) in
pituitary tumors with respect to the normal gland. Most
of the genes analyzed show the same regulation in their
expression also in pituitary adenomas developed in
transgenic mice overexpressing the HMGA1 gene
(Fedele et al. 2005). Some of these representative
results are shown in the Fig. 3B.
Subsequently, we analyzed by RT-PCR the
expression of these genes also in murine and rat cellwww.endocrinology-journals.orglines derived by pituitary adenomas of different
histotype in comparison with normal mouse or rat
pituitary gland (Fig. 3C and data not shown). Some
genes, such as Mia/Cd-rap and CamK2, as for the
pituitary adenomas of HMGAmice, are downregulated
in all the cell lines, whereas other genes, such as
FKBP65 or reelin, change their expression depending
on the cellular histotype.HMGA proteins regulate Mia/Cd-rap expression
We concentrated our attention on theMia/Cd-rap gene
for two main reasons: i) it was the most downregulated
gene in all of the HMGA2-induced pituitary adenomas
analyzed and ii) it has been already associated with
tumor development, even though it is upregulated in
different human neoplasias such as chondrosarcoma,
melanoma, and breast cancer (Blesch et al. 1994,
Chansky et al. 1998).
Mia/Cd-rap protein is downregulated in mouse
pituitary adenomas
To further validate the microarray data obtained for the
Mia/Cd-rap gene, we also analyzed the Mia/Cd-rap
protein expression in tissue extracts of pituitaries and
pituitary adenomas from control and transgenic mice
(either HMGA1 or HMGA2) respectively. As shown in
Fig. 4A, normal pituitary from control mice show high
levels of Mia/Cd-rap protein expression, whereas it
was completely lost in pituitary adenomas from both
HMGA1 and HMGA2 transgenic mice.
HMGA proteins bind to the Mia/Cd-rap promoter
To investigate whether the HMGA proteins are directly
involved in Mia/Cd-rap transcriptional regulation,
we evaluated the HMGA-binding activity to the881
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882Mia/Cd-rap promoter in vitro using oligonucleotides
spanning from base K1130 to K1100 of the mouse
Mia/Cd-rap promoter region (Bosserhoff et al. 1997),
including AT-rich putative HMGA-binding sites. As
shown in Fig. 4B, lanes 1–2, increasing amounts (5 and
20 ng) of the recombinant HMGA2 protein were
capable of binding the 32P-end-labeled double-strand
oligonucleotide in EMSA. The binding specificity was
demonstrated by competition experiments showing
loss of binding with the addition of 100-fold molar
excess of the specific unlabeled oligonucleotide
(lane 3). We performed the same experiment with a
recombinant HMGA1 protein, and also in this case a
specific binding with the Mia/Cd-rap promoter
(Fig. 4B, lanes 5–7) was detected.
To verify that HMGA proteins are able to bind to
Mia/Cd-rap promoter in vivo,we performed experiments
of ChIP in the NIH3T3 cell line transiently transfected
with either the HA-HMGA2 or HA-HMGA1 expression
plasmids. Chromatin prepared as described under
Materials and methods was immunoprecipitated with
anti-HA or normal rabbit IgG antibody. The results,
shown in Fig. 4C, confirmed that both HMGA2 and
HMGA1 proteins bind to the promoter of Mia/Cd-rap
gene. In fact, the Mia/Cd-rap promoter region was
amplified from the DNA recovered with anti-HA
antibody in HA-HMGA1- and HA-HMGA2- but not in
mock-transfected cells. Moreover, no amplification was
observed in the samples immunoprecipitated with a
specific rabbit IgG.
HMGA proteins regulate the Mia/Cd-rap promoter
activity
To define the functional consequences of the interaction
between HMGA proteins andMia/Cd-rap promoter, we
co-transfected the B16F0 cell line, in which Mia/Cd-rap
protein is endogenously expressed, with a construct
expressing the luciferase reporter gene under the control
of themouseMia/Cd-rap promoter regionK1396 toC1
(mMIAprom-luc) and increasing the amounts of an
HMGA2 (or HMGA1) expression vector. As shown in
Fig. 4D, the overexpression of HMGA2 (or HMGA1)
resulted in a decreased activity of the Mia/Cd-rap
promoter in a dose-dependent manner. Interestingly,
the HMGA1 protein showed a significantly higherFigure 2 Clustered display of gene expression in three pituitary
adenomas developed in three HMGA2 transgenic mice when
compared with normal pituitary gland using the MEV program.
A four-fold difference in expression level between adenomas
and normal samples was used. The green and red colors show
downregulated and upregulated genes respectively. Each gene
is represented by a single row of colored boxes; each adenoma
is represented by a single column.
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Figure 3 Validation of microarray data by semiquantitative RT-PCR. (A) Representative RT-PCRs on a panel of three HMGA2-
induced pituitary adenomas and a pool of wild-type pituitary glands. (B) Representative RT-PCRs on a panel of two HMGA1-induced
pituitary adenomas and a pool of wild-type pituitary glands. (C) Some of the genes regulated in HMGA-induced pituitary adenomas
were assayed by semiquantitative RT-PCR on a panel of seven cell lines originating by rat and mouse pituitary adenomas of different
histotype in comparison with a pool of wild-type mouse pituitary glands. Amplification of the b-actin gene has been evaluated as a
control of the RNA amount used.
Endocrine-Related Cancer (2007) 14 875–886inhibitory effect on the Mia/Cd-rap promoter activity in
comparison with the HMGA2 protein (80% with 1 mg
HMGA1 versus 55% with 1 mg HMGA2).
Mia/Cd-rap expression inhibits growth of
pituitary adenoma cells
To investigate the functional role of Mia/Cd-rap in
pituitary cell growth, we performed colony assay
experiments by transfecting Mia/Cd-rap in pituitary
adenoma GH3 and GH4 cells. After puromycin
selection, the number and growth of the colonies
obtained by transfection with the Mia expression
plasmid decreased dramatically compared with empty
vector in both cell lines (Fig. 5). These results show
that Mia/Cd-rap inhibits the cell growth of rat pituitary
adenoma cells, suggesting it as a negative regulator of
pituitary cell proliferation.Discussion
Pituitary tumors constitute about 15% of intracranial
neoplasms and are mostly benign with slow growth.
Most pituitary neoplasms secrete hormone genewww.endocrinology-journals.orgproducts, leading to disturbed endocrine functions.
About two-thirds of pituitary tumors express and
secrete pituitary hormones. Among these, prolactino-
mas are the most common lesions, representing about
50% of all the clinically diagnosed pituitary adenomas.
The genesis of pituitary tumors remains still largely
unknown, and several factors, such as gene mutations,
locally produced growth factors, and hypothalamic
dysregulation, play a critical role in the transformation
of pituitary cells. A crucial role for the HMGA2 gene
in the process leading to the generation of human
pituitary adenomas was first suggested by the
phenotype of transgenic mice overexpressing a
truncated or a wild-type HMGA2 gene under the
transcriptional control of the strong and ubiquitous
promoter of the cytomegalovirus. Most of these mice
(85% of females and 40% of males), in fact, developed
pituitary adenomas secreting PRL and GH
(Fedele et al. 2002). After these findings, we
investigated the role of the HMGA2 gene in human
prolactinomas. Interestingly, cytogenetic analysis of
prolactinomas revealed not only an increased dosage of
the HMGA2 gene, which resulted from multiple883
Figure 4 HMGA proteins regulate the murine Mia/Cd-rap promoter. (A) Mia/Cd-rap protein expression in pituitary adenomas and
normal pituitary glands from HMGA (both HMGA1 and HMGA2) transgenic mice and wild-type animals respectively. (B) EMSA
performed with a radiolabeled oligonucleotide spanning from baseK1130 toK1100 of the mouse Mia/Cd-rap promoter region, and
incubated with 5 ng (lanes 5) and 20 ng (lanes 6) of the recombinant HMGA1-His protein or with 5 ng (lane 1) and 20 ng (lanes 2) of
the recombinant HMGA2-His protein. Where indicated, a 100-fold molar excess of unlabelled MIApr oligonucleotide was added as a
specific competitor. (C) Chromatin immunoprecipitation assay performed on NIH3T3 cells transfected with pCEFLHA, pCEFLHa-
HMGA1, or pCEFLHa-HMGA2. The recovered DNA was used as a template for PCR with primers that specifically amplify the murine
Mia/Cd-rap promoter. Input indicates PCR products with chromosomal DNA without immunoprecipitation. As an immunoprecipi-
tation control, IgG was used. (D) Luciferase activity (fold of activation) of the Mia/Cd-rap promoter in the B16F0 murine melanoma
cell line. Where indicated 0.5 and 1 mg of either HMGA1 or HMGA2 expression vectors were cotransfected with the Mia-luc plasmid.
Figure 5 Effect of Mia/Cd-rap expression on pituitary adenoma
cell proliferation. Colony forming assay experiment performed
on GH3 (black bars) and GH4 (gray bars) cells transfected with
a vector expressing Mia/Cd-rap. As a control the empty vector
(mock) was used. The reported results are the mean of three
experiments and error bars show S.D.
I De Martino et al.: HMGA2-induced pituitary adenomasmechanisms, mainly simple chromosome gain
(trisomy or tetrasomy of chromosome 12), but also
over-representation of the HMGA2 gene through der
(12) chromosomes (Finelli et al. 2002). The strong
correlation between the phenotype of the HMGA2
transgenic mice and the HMGA2 overexpression in
human prolactinomas suggested that this animal model
might represent a unique tool for studying the
molecular mechanisms underlying the generation of
pituitary adenomas induced by the HMGA2 over-
expression. In fact, these mice allowed us to
demonstrate that the mechanism of the HMGA2-
induced pituitary adenoma development is based on
the increased E2F1 activity (Fedele et al. 2006b). Since
other additional mechanisms can be envisaged on the
base of a minimal residual tumoral phenotype showed
by some HMGA2 transgenic mice lacking a functional
E2F1 gene (Fedele et al. 2006c), in the present study
we have analyzed the gene expression profile of three
HMGA2-pituitary adenomas in comparison with a
pool of ten normal pituitary glands in order to identify
other genes involved in the process of pituitary884tumorigenesis induced by the HMGA2 gene. The
results of our analysis led to the identification of 82
transcripts that increased and 72 transcripts that
decreased at least fourfold in all mice pituitary
adenomas analyzed when compared with normalwww.endocrinology-journals.org
Endocrine-Related Cancer (2007) 14 875–886pituitary gland. It is noteworthy that among the
overexpressed genes, we found galectin-3. This is
consistent with previous reports showing a role for the
galectin-3 protein in pituitary cell proliferation and
tumor progression (Riss et al. 2003). Here we focused
on the Mia/Cd-rap gene because its expression was
essentially suppressed in all of the mouse pituitary
adenomas analyzed and, even though it has been
already associated with a neoplastic phenotype (Blesch
et al. 1994, Chansky et al. 1998), it has been never
described in pituitary tumorigenesis so far. We
demonstrated, by EMSA and ChIP, that both
HMGA1 and HMGA2 proteins directly bind to the
promoter of this gene and downregulate its expression
in transcription assays. It is noteworthy to observe that
even though both the HMGA proteins are able to
regulate the Mia/Cd-rap gene, this effect is more
pronounced with HMGA2 than with HMGA1. Finally,
by colony assays in GH3 and GH4 cells we were able
to demonstrate that re-expression of Mia in this
pituitary adenoma cell line dramatically reduces their
proliferative potential, indicating a potential tumor
suppressor role for this gene in pituitary tumors.
The protein Mia/Cd-rap is mainly expressed in
cartilage during embryogenesis (Dietz & Sandell
1996), and is related to cellular motility, metastasis,
and modulation of immune responses in melanoma
cells. In fact, it has been shown that Mia/Cd-rap
interacts with components of the extracellular matrix,
such as laminin and fibronectin, suggesting that it may
have a function in regulating detachment of melanoma
and possibly other cells from the extracellular matrix,
which is an important step in metastasis (Bosserhoff
et al. 1997).
Therefore, the previous published data about the
Mia/Cd-rap gene appear in contrast with those reported
here which suggest a tumor suppressor function of this
gene rather than an oncogenic function. It is reasonable
to retain that, as it occurs for other proteins, such as
HMGA1 (Martinez Hoyos et al. 2004), the Mia/Cd-rap
protein function may depend on the cellular context.
Interestingly, a recent study proves that HMG1,
another member of the HMG family, is an important
factor in MIA regulation and melanoma progression. In
fact, a sequence-specific DNA motif in the highly
conserved region of the Mia/Cd-rap promoter is
recognized by HMG1 (Golob et al. 2000). Besides,
recent data showed that HMG1 is upregulated in
malignant melanoma cell lines compared with normal
human embryonal melanocytes (NHEM) normal skin
cell line and that it plays a pivotal role in Mia/Cd-rap
transcriptional activation (Poser et al. 2003). Consist-
ently, the promoter sequence of Mia/Cd-rapwww.endocrinology-journals.orgcontains many potential regulatory domains
including an AT-rich domain, which are known as
DNA-binding sites for the HMGA proteins (Bosserhoff
et al. 1997).
In conclusion, in this study we have identified
Mia/Cd-rap as a gene directly downregulated by the
HMGA proteins in HMGA-induced pituitary adeno-
mas. Moreover, we showed that Mia/Cd-rap
expression is inversely correlated with the proliferative
potential of pituitary adenoma cells, thereby
suggesting a relevant role of its downregulation in
the generation of pituitary adenomas.Acknowledgements
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The HMGA1 proteins have a critical role in the process of carcinogenesis. They are overex-
pressed in most human malignant neoplasias, and the inhibition of their expression has been
shown to prevent cell transformation and results in malignant cell death. To determine
whether HMGA1 proteins are also required for in vivo carcinogenesis, we compared the
tumour susceptibility of mice wild-type or knockout for the Hmga1-null allele using a two-
stage chemical skin carcinogenesis protocol. Hmga1)/) mice exhibited a decreased number
and a delayed onset of skin papillomas in comparison with wild-type mice. Moreover, the pro-
gression of skin papillomas to carcinomas was observed in only 5% of Hmga1)/) compared to
18% of wild-type mice. These results suggest a lower susceptibility of Hmga1)/) mice to skin
carcinogenesis induced by chemical agents.
 2007 Published by Elsevier Ltd.1. Introduction
The HMGA family of mammalian high mobility group con-
sists of three related members: HMGA1a, HMGA1b (encoded
by the same gene and generated by alternative splicing),
and HMGA2 (derived from a different gene).1 They are small
nuclear polypeptides that bind to the minor groove of DNA
through highly cationic regions called ‘AT-hooks’.2 HMGA pro-
teins function as architectural transcription factors: they dohed by Elsevier Ltd.
to di Biologia e Patologia
39 81 3737857; fax: +39 8
sco).not independently regulate gene transcription, but modulate
gene expression through the formation of stereospecific com-
plexes on the promoter/enhancer regions of genes. These
complexes are formed by direct interaction with other tran-
scription factors and through DNA-protein interactions that
bend, unwind or distort the structure of DNA.3 HMGA pro-
teins seem to play their major physiologic role during embry-
onic development. In fact, HMGA is abundantly expressed
during embryogenesis, while their expression is negligibleCellulare e Molecolare, Universita` degli Studi di Napoli ‘‘Federico
1 3737808.
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cently reported by our group,5 has revealed the critical func-
tion of this gene in development. Cardiac hypertrophy and
type 2 diabetes were observed in Hmga1-ko mice,5,6 even in
mice heterozygous for the gene, suggesting that a quantita-
tively appropriate HMGA1 expression is required for normal
development. Interestingly, the severe insulin resistance of
Hmga1-null mice resembles that shown by three diabetic pa-
tients with impaired HMGA1 function.6
Alterations in the structure and/or the expression of the
HMGA proteins play an important role in benign and malig-
nant tumours. In fact, HMGA gene rearrangements, due to
chromosomal translocation, are frequently detected in hu-
man benign tumours of mesenchymal origin.7,8 Moreover,
HMGA1 overexpression was first documented in transformed
thyroid cells,9 then in experimental carcinomas,10 and subse-
quently in human thyroid,11 colorectal,12 pancreatic duct
cell,13 uterine,14 breast,15 ovarian cancers,16 and in glioblasto-
mas.17 Thus, HMGA1 protein overexpression appears to be a
constant feature of malignant human neoplasias. The onco-
genic activity of HMGA1 gene overexpression has been dem-
onstrated in vitro and in vivo.18,19 Moreover, blocking HMGA1
synthesis prevents malignant transformation of rat thyroid
cells by murine transforming retroviruses,20 and an adenovi-
rus carrying the HMGA1 gene in antisense orientation induces
apoptotic cell death of anaplastic human thyroid carcinoma
cell lines but not of normal thyroid cells.21 These findings
demonstrate that HMGA proteins have a causal role in neo-
plastic transformation. Furthermore, the development of hae-
matological malignancies, including B cell lymphoma and
myeloid granuloerythroblastic leukaemia in Hmga1-knockout
mice also revealed an unsuspected tumour suppressor role
for this gene.5
To verify whether Hmga1 gene plays a pivotal role in in vivo
transformation, we evaluated the susceptibility of Hmga1-ko
mice to chemically induced skin neoplasias. For this purpose,
we used Hmga1-ko mice in a two-stage skin carcinogenesis
protocol based on initiation with 7,12-dimethylbenz[a]anthra-
cene (DMBA) followed by promotion with 12-O-tetradecanoyl-
phorbol-13-acetate (TPA). Overexpression of HMGA1 in
murine skin carcinomas22 and regulation of HMGA1-specific
transcription start sites by TPA23 led us to choose this model
of carcinogenesis. Moreover, this animal model of carcino-
genesis allowed us to determine whether the Hmga1 gene
had a role in the early or late steps of tumour development.
In the present study we report that mice homozygous for
the Hmga1-null allele develop fewer papillomas compared to
wild-type mice, and fewer of these lesions progress to carci-
nomas. Moreover, we document reduced expression of c-Fos
protein in the Hmga1)/) mice, suggesting an explanation of
the decreased sensitivity of these mice to chemically induced
skin carcinogenesis.
2. Materials and methods
2.1. Experimental skin carcinogenesis
Mice carrying a disrupted Hmga1 gene were generated by
homologous recombination in an ES cell line, as described;5
the disrupted Hmga1 gene was subsequently transferred intoan inbred C57Bl/6J genetic background. Mice 6–7 weeks old
were used. Each mouse was identified with an ear tag and
genotyped by Southern blot analysis. The dorsal skin was
shaved and treated with a single application of DMBA (7,12-
dimethylbenz[a]anthracene; Sigma, St Louis, MO) (25 lg in
200 ll acetone), followed by twice weekly application of TPA
(12-O-tetradecanoylphorbol-13-acetate; Sigma, St Louis, MO)
(200 ll of 10)4M in acetone). TPA treatment was stopped after
26 weeks. The number and size of skin tumours on each
mouse were recorded at regular intervals. Mice were sacri-
ficed after 32 weeks, and the neoplastic lesions were excised,
and frozen or fixed for histolologic, immunohistochemical
and molecular analysis. All the mice had been housed in
the Animal facility of the Comprehensive Cancer Center at
the Ohio State University, and their care was in accordance
with institution guidelines.
2.2. Histological and immunohistochemical procedures
For light microscopy, tissues were fixed by immersion for 24 h
in Bouin’s solution and embedded in paraffin using standard
procedures. Sections (5 lm) were stained with haematoxylin
and eosin or haematoxylin and periodic acid–Schiff (PAS) re-
agent. Frozen sections (4–8 lm) of normal and pathological
tissues were cut in a cryostat and allowed to dry for 1 h at
room temperature before fixation in acetone for 10 min. The
slides were air dried for 2 h at room temperature and then
placed in a buffer bath (phosphate buffered saline, PBS) for
5 min before immunohistochemistry.
For immunohistochemical studies of paraffin-embedded
samples, 3–4 lm paraffin sections were deparaffinised, placed
in a solution of absolute methanol and 0.3% hydrogen perox-
ide for 30 min and washed in PBS. The slides were incubated
overnight at 4 C in a humidified chamber with antibodies di-
luted 1:100 in PBS. The slides were subsequently incubated
with biotinylated goat anti-rabbit IgG for 20 min (Vectostain
ABC kits, Vector Laboratories) and then with premixed re-
agent ABC (Vector) for 20 min. The immunostaining was per-
formed by incubating the slides in diaminobenzidine (DAB-
DAKO) solution containing 0.06 mM DAB and 2 mM hydrogen
peroxide in 0.05% PBS (pH 7.6) for 5 min. After chromogen
development, the slides were washed, dehydrated with alco-
hol and xylene, and mounted with coverslips using a perma-
nent-mounting medium (Permount). Micrographs were taken
on Kodak Ektachrome film with a photo Zeiss system. The
antibodies used in this study were raised against the syn-
thetic peptide SSSKQQPLASKQ specific for the HMGA1 pro-
teins.11 For HMGA2 immunohistochemistry, antibodies
raised against the recombinant HMGA2 protein were used.24
The specificity of the reaction was validated by the absence
of staining when carcinoma samples were stained with anti-
bodies pre-incubated with the peptide against which the anti-
bodies were raised (data not shown). Similarly, no positivity
was observed when tumour samples were stained with a
pre-immune serum (data not shown).
2.3. Protein extraction and Western blot analysis
Frozen sections 10–15 lm thick from papillomas and carcino-
mas were resuspended in NIH lysis buffer [1% Nonidet P-40;
320 E U R O P E A N J O U R N A L O F C A N C E R x x x ( 2 0 0 8 ) x x x –x x x1 mM EDTA; 50 mM Tris-HCl (pH 8.0); 150 mM NaCl; 2 mM
phenylmethylsulfonyl fluoride (PMSF); 50 mM NaF; 10 mM
Na3V4; 20 mM NaPP; 1.5 mM aprotinin]. Tissue lysates were
clarified by centrifugation at 12,000 rpm for 20 min at 4 C.
The supernatant was then used for immunoblotting. Western
blotting was performed by standard procedures using the fol-
lowing antibodies: anti-c-Fos (Santa Cruz, sc-52-G), anti-vin-
culin (Santa Cruz, sc-7649), monoclonal anti-Rab11
(PharMingen/DB Biosciences) and mouse TrueBlot secondary
antibody (eBiosceince, San Diego, CA). Briefly, the protein ex-
tracts were separated by 4–20% SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to nitrocellulose
membranes (Biorad). Membranes were blocked with 5% non-
fat milk in TTBS and incubated with antibodies diluted in the
same solution. Bound antibodies were detected by the appro-
priate horseradish peroxidase-conjugated secondary antibod-
ies followed by enhanced chemiluminescence (Amersham).
2.4. Statistical analysis
Data are expressed as mean ± SEM. Differences were analysed
by Student’s t test. Kaplan–Meyer survival curves were used to
analyse the percentage of tumour-free mice in dependence of
the weeks of treatment. Differences were analysed by Log-
rank test. P values 6 0.05 were considered significant for both
statistical assays.
3. Results
3.1. The onset of papillomas is delayed in Hmga1-null
mice
To address the role of HMGA1 in cancer development, we ap-
plied a two-stage chemical skin carcinogenesis protocol to
Hmga1-null mice. Sixteen Hmga1+/+, 22 Hmga1+/) and 19
Hmga1)/) mice were given a single initiating treatment with
DMBA and tumour promotion was stimulated by TPA applica-
tion twice weekly. After 8 weeks, the number of Hmga1)/)
mice developing skin papillomas was 26%, which was signif-
icantly lower then the number of wild-type mice (68%)
(P < 0.01) (Fig. 1a). The Hmga1+/) mice showed an intermediate
phenotype, with a tumour incidence of 37%. A significant dif-
ference in the number of papillomas per mouse in Hmga1)/)
and Hmga1+/+ mice at specific time points was also observed
(Fig. 1b). These differences were statistically significant at
the 12th and 16th week, when the average number of
papillomas per mouse was reduced by approximately 60% in
Hmga1)/) mice compared to Hmga1+/+ mice [average ± SE:
1.2 ± 0.3 and 2.8 ± 0.4 (P < 0.05) after 12 weeks from the begin-
ning of the treatment; 2.1 ± 0.3 and 4.1 ± 0.4 (P < 0.001) after 16
weeks]. The Hmga1+/) mice again showed an intermediate
phenotype [average ± SE: 2.1 ± 0.3 at the 12th week; 2.4 ± 0.5
at the 16th week].
3.2. HMGA1 deficiency resulted in decreased malignant
transformation
In the two-stage mouse skin carcinogenesis, papilloma
regression is a common event; however, a small percentage
of benign lesions progress to form squamous cell carcinomas(SCC). At 32 weeks after DMBA treatment, the incidence of
mice bearing SCC was 18% ± 5 for wild-type mice and 5% ± 3
for Hmga1)/) mice with a significant P value of 0.0419; thus,
wild-type mice developed many more carcinomas than
Hmga1)/) mice (Fig. 2). Therefore, these data suggest that
HMGA1 proteins also have a role in the malignant progression
of skin tumours.
At the histological analysis, papillomas appeared as dis-
crete exophytic masses consisting of a central connective tis-
sue core forming papillae covered by thickened epithelium.
This epithelium showed orderly differentiation and was cov-
ered by a keratinised layer of variable thickness (Fig. 3a and
b). Some mice also developed, with a reduced incidence,
benign epidermal tumours resembling human keratoacan-
thomas. These tumours consisted of large cup-shaped, kera-
tin-filled central regions surrounded by a rim of very well
differentiated squamous epithelium, which formed a distinct
lip (data not shown). Conversely, SCC were composed of cords
and islands of well-differentiated keratinising neoplastic
epithelium that invaded the dermis and subcutis and pene-
trated the panniculus carnosus (Fig. 3c and d). No microscopic
or macroscopic differences in appearance were observed
between tumours of the same type in the different animal
groups.
3.3. Expression of Hmga1 and Hmga2 in the skin
papillomas and carcinomas induced in Hmga1-null mice
The expression of both HMGA1 and HMGA2 proteins is in-
duced during cell transformation in vitro and in vivo.24 As
shown in Fig. 4, we analysed the expression of the Hmga pro-
teins in papilloma and carcinoma samples originating from
wild-type and Hmga1-null mice. As expected, immunohisto-
chemical analysis of papilloma and carcinoma samples did
not show any expression of the Hmga1 protein in neoplasias
of the Hmga1-null mice (Fig. 4b and d, respectively), while its
induction was observed in all of the papillomas and carcino-
mas from the wild-type mice (Fig. 4a and c, respectively).
Hmga2 protein expression was also detected in the carcinoma
samples from both Hmga1+/+ and Hmga1)/) mice (Fig. 4g and
h, respectively), whereas it was absent in the papillomas from
the same groups (Fig. 4c and d). These findings suggest that
Hmga1 induction occurs earlier than Hmga2 induction during
the process of skin tumour development.
3.4. The expression of Rab11a and c-Fos is decreased
in normal skin and papillomas of Hmga1-null mice
Previous studies have demonstrated that HMGA1 enhances
c-fos transcription in eukaryotic cells.25 Moreover, in vivo car-
cinogenesis studies showed that c-Fos plays a crucial role in
the transition from benign to malignant skin tumours by reg-
ulating expression of Rab11a.26,27 Therefore, we analysed the
expression of c-Fos and Rab11a proteins first in the untreated
back skin of Hmga1)/), Hmga1+/) and Hmga1+/+ mice (Fig. 5a
and data not shown). The levels of c-Fos and Rab11a proteins
were significantly lower in Hmga1-null skin compared to that
of wild-type mice (Fig. 5b), and intermediate between Hmga1)/
) and Hmga1+/+ in heterozygous mice (data not shown).
Then, we analysed c-Fos and Rab11a expression in SCC and
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mice. As shown in Fig. 5b, Western blot analysis revealed low-
er levels of c-Fos in both Hmga1)/) SCC and papillomas than
in the corresponding tumours from wild-type mice. Interme-
diate levels were observed in the Hmga1+/) samples. Similarly,
Rab11a expression levels were decreased in Hmga1+/) SCC
and papillomas in comparison with wild-type samples, and
further decreased in Hmga1)/) papilloma but unexpectedly
increased in Hmga1)/) SCC compared to wild-type.This finding suggests that the lack of Hmga1 expression in
the keratinocytes of Hmga1)/) mice reduced malignant transi-
tion of papillomas to SCC by interfering with the c-Fos/
Rab11a pathway. It is likely that the increase of Rab11a
expression in SCC, in the absence of Hmga1 protein, must
be considered an epiphenomenon associated to the neoplas-
tic phenotype.
4. Discussion
It is widely accepted that the HMGA proteins play a crucial
role in the development of malignant tumours. HMGA pro-
teins have been found to be overexpressed in almost all of
the malignant neoplasias so far analysed, and there is a cor-
relation between HMGA expression levels and the grade of
malignancy.13,28 Moreover, a causal role in cell transformation
has been demonstrated for these proteins. In fact, HMGA
overexpression can transform cells in vitro and in vivo,18,19
and blocking HMGA2 expression by antisense methodology
prevents malignant transformation of rat thyroid cells by v-
mos and v-ras-Ki oncogenes.24 However, when mice carrying
a disrupted Hmga2 gene (pygmy mice) were either treated
with radioactive iodine or crossed with transgenic mice carry-
ing the E7 papilloma virus oncogene under the transcriptional
control of thyroglobulin gene promoter, they developed thy-
roid carcinomas with the same frequency as wild-type mice,
and the tumours they developed were indistinguishable from
tumours in wild type mice. Therefore, these results indicated
that HMGA2 gene expression is not required for in vivo thyroid
cell malignant transformation,29 suggesting that HMGA1 pro-
teins, rather than HMGA2, may be required for cell transfor-
mation. This hypothesis is also supported by the evidence
Fig. 3 – Histological examination of papillomas and carcinomas in Hmga1)/) and Hmga1+/+mice. (a,b) Papillomas (bar
scale = 100 lm). (c,d) Squamous cell carcinomas (bar scale = 50 lm). Pap = papillomas; SCC = squamous cell carcinomas.
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carrying HMGA1 antisense sequences prevents transformed
thyroid cell growth;21 in addition, rat thyroid cell transforma-
tion by the Kirsten murine sarcoma virus does not take place
in the absence of the HMGA1 protein induction.20 Alterna-
tively, the expression of only one of the HMGA genes may
be required to transform thyroid cells to the malignant phe-
notype. The absence of HMGA1 gene induction in HMGA2
antisense virally infected thyroid cells24 is consistent with
this hypothesis.
The recent generation of Hmga1-knockout mice5 offers an
excellent opportunity to define the role of individual HMGA
genes in the process of carcinogenesis in vivo. In the present
study, mice homozygous and heterozygous for the Hmga1-
null allele and wild-type mice were treated with DMBA and
TPA in a classical two-stage skin carcinogenesis protocol.
After 8 weeks of treatment Hmga1)/) mice had significantly
fewer skin tumours than wild-type mice. Moreover, at the
12th and 16th weeks of chemical treatment, the total number
of papillomas per mouse was significantly higher in wild-type
than Hmga1)/) mice. Taken together, these findings indicate
that HMGA1 plays a critical role in the development of chem-
ically induced skin tumours. Furthermore, malignant pro-
gression of papillomas to carcinomas was observed in only
5% of Hmga1)/) mice compared to 18% of wild-type mice, sug-
gesting a further role for HMGA1 in tumour malignant pro-
gression. This result is consistent with the literature data
that show a frequent association of HMGA1 expression and
the presence of a highly malignant phenotype.11–17
Although we show evidence that HMGA1 plays a critical
role in development of the malignant phenotype, our results
also demonstrate that malignant tumours can still arise inthe absence of the HMGA1 proteins. Thus, it is likely that
HMGA2, which we showed to be induced in skin carcinomas,
may substitute for HMGA1. Of course, we cannot exclude that
other genes, as yet unidentified, may duplicate some func-
tions of the HMGA1 proteins.
It has been demonstrated that benign skin tumours do not
progress to malignant skin tumours in mice lacking c-Fos pro-
tein and that this failure is due to Rab11a inactivation.26
Moreover, it has been shown that HMGA1 enhances SRF-
dependent activation of the c-fos promoter and that TPA
mediates the activation of Rab11a in mouse skin in a c-Fos-
dependent manner.25,26 We analysed Rab11a and c-Fos
expression in both Hmga1)/) and Hmga1+/+ mice. Notably, de-
creased expression of Rab11a and c-Fos was found in kerati-
nocytes and papillomas of the Hmga1)/) mice, in
comparison with the wild-type mice, suggesting that the re-
duced expression of c-Fos in Hmga1-null mice might contrib-
ute to the decreased susceptibility to the development of
malignant skin tumours.
The correlation among HMGA1, c-Fos and Rab11a expres-
sion suggests a mechanism by which HMGA1 could be in-
volved in malignant progression. Nevertheless, other
biological roles of the HMGA proteins, such as their reported
capacity to inhibit DNA repair,30,31 may be taken into consid-
eration. In fact, the results shown here could also be ex-
plained by considering that HMGA1 overexpression would
increase the incidence of mutations that facilitate the process
of carcinogenesis.
In conclusion, the data reported here indicate that the
expression of the HMGA1 gene plays a critical role in
the process of chemically induced skin cancer
development.
Fig. 4 – Immunohistochemical detection of Hmga1 and Hmga2 proteins in mouse skin tumours. Paraffin sections from benign
and malignant mouse skin tumours arising in mice subjected to the carcinogenesis protocol were analysed by
immunohistochemistry using antibodies raised against specific Hmga1 and Hmga2 peptides. (a) Immunostaining for
HMGA1 of a representative skin papilloma developed by a Hmga1+/+ mouse (bar scale = 50 lm). A positive nuclear
staining was observed. (b) Immunostaining for HMGA1 of a representative skin papilloma developed by a Hmga1)/) mouse
(bar scale = 50 lm). No immunoreactivity was observed. (c) Immunostaining for HMGA1 of a representative squamous
cell carcinoma developed by a Hmga1+/+ mouse (bar scale = 100 lm). A positive nuclear staining was observed.
(d) Immunostaining for HMGA1 of a representative squamous cell carcinoma developed by a Hmga1)/) mouse (bar
scale = 100 lm). No staining was observed. (e) Immunostaining for HMGA2 of a representative skin papilloma developed by a
Hmga1+/+ mouse (bar scale = 50 lm). No immunoreactivity was observed. (f) Immunostaining for HMGA2 of a representative
skin papilloma developed by a Hmga1)/) mouse (bar scale = 50 lm). No immunoreactivity was observed. (g) Immunostaining
for HMGA2 of a representative squamous cell carcinoma deriving from a Hmga1+/+ mouse. A positive nuclear staining was
observed (bar scale = 50 lm). (h) Immunostaining for HMGA2 of a representative squamous cell carcinoma deriving from a
Hmga1)/) mouse. A positive nuclear staining was observed (bar scale = 100 lm).
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The high mobility group HMGA1 protein belongs to a family of architectural factors that
play a role in chromosomal organisation and gene transcription regulation. HMGA1 overex-
pression represents a common feature of human malignant tumours and is causally asso-
ciated with neoplastic transformation and metastatic progression. Recently, HMGA1
expression has been correlated with the presence of chromosomal rearrangements and
suggested to promote genomic instability. Here, we report a novel interaction between
HMGA1 protein and the ataxia-telangiectasia mutated (ATM) kinase, the major key player
in the cellular response to DNA damage caused by several agents such as ionising radiation
(IR). We identified an SQ motif on HMGA1, which is effectively phosphorylated by ATM
in vitro and in vivo. Interestingly, confocal microscopy revealed that HMGA1 colocalises with
the activated form of ATM (ATM S1981p). Moreover, HMGA1 ectopic expression decreases
cell survival following exposure to IR as assessed by clonogenic survival in MCF-7 cells, fur-
ther supporting the hypothesis that HMGA1 might act as a downstream target of the ATM
pathway in response to DNA damage.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
The high molecular group A (HMGA) proteins are a class of
nuclear, non-histone proteins involved in a wide range of cel-er Ltd. All rights reserved
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usco@unina.it (A. Fusco)lular processes such as chromatin remodelling, gene tran-
scription, differentiation and neoplastic transformation.1
TheHMGA family consists of theHMGA1 gene,which codes
byalternativesplicing for twomajor isoforms, theHMGA1aand.
logia Sperimentale ‘Gaetano Salvatore’, Universita` degli Studi di
3602/7463749; fax: +39 081 2296674.
.
E U R O P E A N J O U R N A L O F C A N C E R 4 4 ( 2 0 0 8 ) 2 6 6 8 –2 6 7 9 2669HMGA1b proteins, and the HMGA2 gene. HMGA proteins con-
tain three DNAbinding domains, referred to as ‘AT-hooks’, that
allow thebinding to theminorgrooveofATrichDNAsequences
and a highly acidic carboxy-terminal region. HMGA proteins
behave as architectural factors of gene transcription,1 regulat-
ing, positivelyornegatively, theexpressionof a largenumberof
genes in a way dependent on the cellular context.2
HMGA proteins are highly expressed during embryogene-
sis, whilst they are expressed only at low levels in normal adult
tissues.3 HMGA1 overexpression represents a common feature
of human malignant tumours including thyroid,4 breast,5
ovary6 andprostate,7 and is causally associatedwith the acqui-
sitionof a transformedphenotype. In fact,HMGA1protein sup-
pression prevents thyroid cell transformation by the Kirsten
murine sarcoma virus,8 and an adenovirus carrying the
HMGA1 gene in the antisense orientation induces death of hu-
man thyroid carcinoma cells.9 Moreover, HMGA1 overexpres-
sion induces the neoplastic phenotype in Rat1a cells and
humanCB33 lymphoid cells10 and in the human breast epithe-
lial MCF-7 cells.11 Accordingly, transgenicmice overexpressing
thewild-type form of theHmga1 gene develop pituitary adeno-
mas and natural killer cell lymphomas.13 Interestingly, in sev-
eral human prostate cancer cell lines HMGA1 expression has
been positively correlated to the extent of chromosomal rear-
rangements,14 and its ectopic expression was able to enhance
the presence and heterogeneity of unbalanced chromosomal
rearrangements in LNCaP prostate cell line,14 suggesting a role
for HMGA1 proteins in the acquisition of genomic instability,
one of the hallmarks of cancer cells. In human breast tumours
HMGA1 overexpression has been correlated to the downregu-
lation of BRCA1,5 a gene involved in DNA repair following dif-
ferent types of DNA damage.15 Moreover, HMGA1
overexpression was found to decrease cell survival following
exposure to DNA-damaging agents of human breast cancer-
derived MCF-7 cells, by inhibition of nucleotide excision repair
(NER), through downregulation of XPA,16 or by inhibition of
double-strand breaks (DSBs) repair, through a mechanism
involving BRCA1 downregulation.5 Recently, also HMGA2
expression has been shown to promote enhanced sensitivity
in response to doxorubicin and other related DNA-damaging
agents, likely through modulation of the signalling pathway
responsible for the maintenance of genomic integrity.17
Genome stability is threatened by DNA-damaging agents
that can either be endogenous, deriving from normal cell
metabolism, or exogenous such as ionising radiation (IR). IR
induces DNA double-strand breaks (DSBs) that can potentially
lead to mutations, translocations, abnormal recombination
and chromosome breakage or loss. Detection of damaged
DNA triggers checkpoint pathways that prevent cell cycle pro-
gression and activate the DNA repair system. If the type or
amount of damage overwhelm the survival response machin-
ery, apoptosis is triggered.18
ATM, the genemutated in the human disease ataxia-telan-
giectasia (AT),19 is crucial for initiating signalling pathways
following exposure to IR or other agents that cause DSBs. Like
other syndromes that are caused by defects in the DNA-dam-
age response, AT patients show an increased risk for cancer,
chromosome fragility and radiosensitivity.20 Once activated
by DNA damage,21 ATM phosphorylates numerous substrates
to induce cell cycle arrest, to reduce chromosomal breakageand to enhance cell survival. ATM belongs to the ‘PI3K-like
protein kinases’ (PIKKs) family of proteins, which all contain
a domain with motifs typical of the phosphatidylinositol 3-ki-
nase (PI3K).18 ATM, similarly to other PIKKs, features a serine/
threonine kinase activity. In particular, ATM targets serine or
threonine residues followed by glutamine,22 named the SQ/
TQ (or S/TQ) motif, which is characteristic of DNA-damage re-
sponse proteins.
Since HMGA proteins have been recently shown to play a
role in the cellular response to DNA-damaging agents, we
hypothesised that HMGA might function as adaptor media-
tors of the ATM-induced signalling pathway following IR.
Our studies demonstrate the interaction between HMGA1b
and ATM proteins and identify the HMGA1 protein as a novel
target of the ATM kinase. Even though the physiological role
of this interaction needs further studies, we provide evidence
that HMGA play a role in the cellular response to DNA damage
caused by IR.
2. Materials and methods
2.1. Cell cultures
Human embryonic kidney 293T cells were cultured in DMEM
supplemented by 10% (v/v) foetal bovine serum (FBS), 2 mM L-
glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin
(GIBCO-BRL). Human lymphoblasts GM2184 and GM1526 were
obtained from Coriell Cell Repositories and cultured in RPMI
supplemented by 15% (v/v) FBS, 2 mM L-glutamine, 100 U/ml
penicillin and 0.1 mg/ml streptomycin (GIBCO-BRL). Wild-type
and Hmga1 –/– AB2.1 ES cells, described elsewhere,23 were cul-
tured on a layer of mitomycin C-inactivated fibroblasts. Before
c-irradiation fibroblasts were removed by three passages onto
0.1% (w/v) gelatin-treated plates, and the undifferentiated
statewasmaintainedby theadditionof103 units/ml leukaemia
inhibiting factor (Chemicon). Wild-type, Hmga1 +/– andHmga1
–/– mouse embryonic fibroblasts (MEFs) were established from
14.5 dpc embryos following the standard procedures. MEFs
were cultured in DMEM supplemented by 10% (v/v) FBS, 2 mM
L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin and
1% (v/v) non-essential aminoacids (GIBCO-BRL).
For c-irradiation experiments, cells were irradiated by
6 MV X-ray of a linear accelerator with doses ranging from 0
to 10 Gy.
2.2. Plasmid constructs and recombinant proteins
HMGA1b full-length and its deletionmutants were cloned into
pCEFL-HA, in frame with the HA epitope, as described else-
where.24 Wild-type HMGA1b full-length was also cloned into
pcDNA3.1/Hygro (Invitrogen) for co-immunoprecipitation
experiments. The pFLAG-ATM-wild-type (wt) and kinase-
dead (kd) expressing vectors previously described25 were
kindly provided by Dr. M.B. Kastan. The recombinant HMGA1b
full-length and truncated (aa 1–79) proteins were generated by
cloning the corresponding cDNAs in frame to the polyhisti-
dine tag in pET21c expression vector (Novagen). Serine 88 of
HMGA1b was mutated to alanine by PCR using pET-HMGA1b
wild-type as template, and the resulting cDNA was cloned
into pET21c vector in frame to the polyhistidine tag.
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HMGA1b, pET-HMGA1b (1–79), pET-HMGA1b S88A), grown in
Luria Broth (LB) and induced with isopropyl-b-D-thiogalacto-
side, then harvested and sonicated. Recombinant proteins
were purified using the His-Trap purification kit (Amersham
Biosciences), then dialysed and analysed by SDS–PAGE.
2.3. Transfections, immunoprecipitation and Western
blots
Transient transfections into 293T cells were performed with
FuGene6 (Roche) according to the manufacturers’ specifica-
tions. Mammalian cell extracts were prepared and co-immu-
noprecipitations were performed as previously described,23 in
the presence or absence of 100 ng/ll ethidium bromide. Anti-
FLAG M2 (Sigma) or anti-HA Clone 12CA5 (Roche) monoclonal
antibodies were used for co-immunoprecipitation experi-
ments along with protein A/G-sepharose (Amersham Biosci-
ences). Anti-ATM/ATR substrate (phospho-Ser/Thr antibody)
(Cell Signalling Technology) was used to evaluate the phos-
phorylation of HMGA proteins by ATM in vivo. Proteins were
resolved by 3–8% (v/v) NuPAGE (Invitrogen) or by 15% (v/v)
SDS–PAGE and transferred to high or low molecular weight
nitrocellulose, respectively. Western blots were performed
using the above-mentioned anti-FLAG and anti-HA antibod-
ies, or anti-ATM polyclonal antibody (Novus Biologicals) and
anti-HMGA1 polyclonal antibody (raised against the amino-
terminal region of the protein). All the antibodies were diluted
(1:200) in 5% (w/v) non-fat dry milk (Biorad).
2.4. In vitro kinase assays
For in vitro kinase assays, the ATM kinase was obtained by
immunoprecipitation with an anti-FLAG antibody from 293T
transfected cells or with an anti-ATM antibody (Novus Biolog-
icals) from human lymphoblasts. Beads were washed twice
with buffer A, twice with buffer A containing 0.5 M LiCl and
twice with kinase buffer as previously described.19 ATM ki-
nase reactions were carried out at 30 C for 15 min in 50 ll
of kinase buffer containing 10 lCi of [c-32P]ATP and 10 lg of
each substrate (for recombinant proteins) or 50 mM of cold
ATP and 200 lM of each substrate (for peptides). 5 mM caf-
feine (Sigma) was used as a specific kinase inhibitor. Follow-
ing the kinase reaction, HMGA1 peptides (produced by
Neosystem) were spotted onto P81 phosphocellulose squares
(Upstate) and washed extensively with 1% orthophosphoric
acid. 32P incorporation was measured by a b-counter scintilla-
tor (Beckman Coulter). Recombinant proteins, instead, were
resolved by 15% SDS–PAGE and phosphorylation was revealed
by autoradiography.
2.5. Immunofluorescence microscopy
Wild-type andHmga1 –/–MEFswere grown on glass coverslips,
then fixed for 20 min in 4% (v/v) paraformaldehyde in PBS fol-
lowing mock or c-irradiation. Cells were then permeabilised
with 0.2% (v/v) Triton X-100 in PBS for 5 min at room temper-
ature and blocked in PBS containing 1% (w/v) BSA for 20 min.
Cells were incubated with primary antibodies for 1 h at room
temperature in a humidified chamber, then washed with PBSand incubated for an additional hour with the secondary anti-
body. Primary antibodies used for immunostaining were: goat
anti-HMGA1b sc-1564 (Santa Cruz), rabbit anti-HMGA1 (raised
against the amino-terminal region of the protein), rabbit
anti-ATM S1981p (Rockland) and mouse anti-cH2AX (Cell
Signaling). As secondary antibodies we used anti-goat
rhodamine-conjugated, anti-rabbit fluorescein-conjugated
and anti-mouse rhodamine-conjugated (Jackson ImmunoRe-
search). All the antibodies were diluted (1:100) in PBS.
2.6. FACS analysis
Cells were plated in 6-well plates at a density of 2.5 · 105/well,
incubated for 24 h and then exposed to a range of ionising
radiations (0–10 Gy). Before harvesting at different timepoints
following IR (0, 12, 24, 48 h), cells were pulsed for an hour with
10 lM BrdU (BrdU Flow kit, BD Pharmingen), then fixed and
stained with a FITC-anti-BrdU antibody according to the man-
ufacturers’ instructions. 7-Amino-actinomycin D (7-AAD)
fluorescent dye was used to label DNA. Cells were sorted on
a FACScan flow cytometer (Becton Dickinson), and the results
were analysed with FlowJo software, 4.3 version (TreeStar).
2.7. Clonogenic assay
Cell lines were plated in 6-well plates at a density of 300–800
cells/well, incubated for 24 h and then exposed to a range of
doses of ionising radiations (0–10 Gy), followed by a two-week
incubation. Prior to counting colonies, cells were fixed and
stained with crystal violet. Populations of more than 50 cells
were scored as surviving colonies. The mean of colony counts
normalised for plating efficiency is reported.
3. Results
3.1. ATM and HMGA1 proteins interact in vivo
To determine whether ATM and HMGA1 interact in vivo, we
transiently transfected 293T cells with expression vectors
containing the full-length cDNAs for ATM and HMGA1b genes
fused to the FLAG or HA tag, respectively. Total cell lysates
were immunoprecipitated using an anti-HA antibody and
analysed by immunoblotting with an anti-ATM antibody. A
band corresponding to FLAG-ATM was effectively co-immu-
noprecipitated only in cells expressing HA-HMGA1b demon-
strating that the two proteins are able to interact in vivo
(Fig. 1a). Moreover, HA-HMGA1b is able to co-immunoprecip-
itate also the endogenous ATM protein, which is highly ex-
pressed in 293T cells21 (Fig. 1a, middle lane). Since both
ATM and HMGA1 are chromatin-associated proteins, we per-
formed a co-immunoprecipitation experiment in the pres-
ence of ethidium bromide to exclude that their co-
immunoprecipitation may be dependent on contaminating
DNA (Fig. 1a).
The reverse co-immmunoprecipitation was carried out
transfecting 293T cells with a vector containing the wild-type
HMGA1b cDNA along with the FLAG-ATM-wt vector or a ki-
nase-dead FLAG-ATM-kd mutant, in which the catalytic activ-
ity is impaired.24 The analysis by immunoblot revealed that
FLAG-ATM-wt is also able to co-immunoprecipitate the
Fig. 1 – HMGA1b and ATM protein interaction. (a) 293T cells were transiently transfected with a vector expressing HA-HMGA1b,
alone or along with a FLAG-ATM expression vector. Total cell lysates were immunoprecipitated with anti-HA antibody and
blotted with anti-ATM antibody (upper panel). To determine protein levels, Western blots were performed with anti-HA
antibody (middle panel) and with anti-ATM antibody (lower panel). Immunoprecipitation in the presence of EtBr was also
performed as a control of the specificity of the protein–protein interaction. (b) 293T cells were transiently transfected with
vectors expressing FLAG-ATM, wild-type (wt) or kinase-dead (kd), alone or in combination with a vector expressing HMGA1b
wild-type or HMGA1b S88A. Total cell lysates were immunoprecipitated with anti-FLAG antibody and blotted with anti-
HMGA1b antibody (upper panel). To determine protein levels, Western blots were performed with anti-FLAG antibody (middle
panel) and with anti-HMGA1b antibody (lower panel). (c) 293T cells were transiently transfected with a vector expressing
FLAG-ATM wt alone or along with vectors expressing either the wild-type form of HMGA1b (1-96) or deletion mutants
spanning several regions of the HMGA1b protein as shown in the diagram (AT-hooks (+) and the acidic tail (- ----) are
indicated). Total cell lysates were immunoprecipitated with anti-FLAG antibody and blotted with anti-HA antibody (upper
panel). To determine protein levels, Western blots were performed with anti-HA antibody (middle panel) and with anti-FLAG
antibody (lower panel). (d) 293T cells were transiently transfected with vectors expressing the wild-type form of HMGA1b or a
deletion mutant (D44–53) lacking the second AT-hook, as shown in the diagram. Cells were also transfected with a vector
expressing ATM wt and compared to cells not transfected. Total cell lysates were immunoprecipitated with anti-FLAG
antibody and blotted with anti-HA antibody (upper panel). To determine protein levels, Western blots were performed with
anti-HA antibody (middle panel) and with anti-FLAG antibody (lower panel).
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main do not seem to impair the interaction since the FLAG-
ATM-kd mutant retains its ability to co-immunoprecipitate
HMGA1b (Fig. 1b). Likewise, mutation of the putative ATM tar-
get site on HMGA1b, serine 88 to alanine, (see below), does not
affect the interaction (Fig. 1b).
3.2. The presence of at least two AT-hook domains of
HMGA1 is necessary for its interaction with ATM
To identify the region of HMGA1 required for ATM binding, we
used a series of amino- or carboxy-terminal deletion mutants
of the HMGA1 proteins, fused to the HA tag (Fig. 1c). 293T cells
were transiently transfected with each HMGA1 mutant along
with a FLAG-ATM-wt expression vector. Total cell lysates were
then immunoprecipitated with an anti-FLAG antibody and
analysed by immunoblotting using an anti-HA antibody. Nei-
ther the progressive carboxy-terminal (1–79, 1–63, 1–53) nor
the amino-terminal (23–96, 31–96) deletion mutants of
HMGA1 showed reduced ability to co-immunoprecipitate
ATM, compared with the full-length protein (1–96) (Fig. 1c).
Conversely, no interaction was observed between ATM and
the HMGA1 mutants 1–43 and 54–98, both containing just
one AT-hook domain and both lacking the second AT-hook
(Fig. 1c). To evaluate whether the second AT-hook domain of
HMGA1 is required for the interaction, we generated a HMGA1
mutant lacking the second AT-hook domain (D44–53) and
tested its ability to interact with FLAG-ATM. As shown in
Fig. 1d, this HMGA1 mutant retains the ability to interact with
ATM, indicating that the presence of at least two AT-hook do-
mains, rather than just the second AT-hook, is required for
HMGA1–ATM interaction.
3.3. HMGA1 is phosphorylated by ATM in vitro and
in vivo
Since HMGA proteins are extensively post-translationally
modified and phosphorylation has been frequently re-
ported,26–28 we decided to investigate whether HMGA1 is tar-
geted by ATM kinase activity. By sequence analysis we found
that HMGA1 contains in its COOH terminal region a consen-
sus site for ATM phosphorylation, an SQ motif (serine 88/glu-
tamine 89), which is highly conserved amongst different
species and the different HMGA family members (Fig. 2a).
We then tested a 20 amino acid peptide, corresponding to
the HMGA1 acidic tail (aa 77–96), which contains serine 88, as
a substrate for ATM kinase activity. The endogenous wild-
type ATM kinase was immunoprecipitated from the total pro-
tein extract of the human lymphoblastoid cell line GM2184.
Before harvesting, cells were treated with a 10 Gy dose of IR
to increase ATM kinase activation as previously described.21
As shown in Fig. 2b, ATM was able to phosphorylate in vitro
the C-terminal peptide of HMGA1. The phosphorylation was
highly specific as it was strongly inhibited by 5 mM caffeine
(1,3,7-trimethylxanthine), an ATM/ATR specific inhibitor,29
and was impaired from the substitution of serine 88 with an
alanine residue (Fig. 2b).
We then assayed the ability of ATM to phosphorylate the
full-length HMGA1 recombinant protein, fused to a six-histi-
dine tag. ATM kinase and its kinase-dead mutant were immu-noprecipitated from transiently transfected 293T cells.
HMGA1 was strongly phosphorylated by the FLAG-ATM-wt ki-
nase and only to a lesser extent by the FLAG-ATM-kd mutant,
in which the kinase activity is impaired. In both cases, the
phosphorylation was strongly decreased by 5 mM caffeine
and when serine 88 of HMGA1 was substituted by alanine
(Fig. 2c, upper panel). The same amount of ATM and ATM
kinase-dead proteins was used for the assays (Fig. 2c, lower
panel). The above data indicate that HMGA1 phosphorylation
by ATM is specific, as it is inhibited by both caffeine and a
mutation impairing ATM kinase activity. Interestingly, some
kinase activity was obtained when using an antibody cross-
reacting with both ATM and ATR to immunoprecipitate ex-
tracts from lymphoblasts wild-type for ATM (GM2184) or
ATM null (AT1526), respectively. In fact, a strong phosphoryla-
tion occurred to HMGA1 when the kinase was obtained from
GM2184 cells (Fig. 2d, upper panel) but a fainter phosphoryla-
tion also occurred when the kinase was immunoprecipitated
from AT1526 cells (Fig. 2d, middle panel). Western blot analy-
sis using an antibody against ATR confirmed that the endog-
enous kinase was effectively immunoprecipitated from
AT1526 cells (data not shown). Therefore, it is likely that also
the ATR kinase, another member of the PIKKs family, has the
ability to phosphorylate serine 88 of HMGA1. Phosphorylation
was inhibited in the HMGA1mutant in which serine 88 is mu-
tated to alanine and in the HMGA1mutant 1–79, that lacks the
C-terminal of the protein containing serine 88. Phosphoryla-
tion was inhibited by 5 mM caffeine as well (Fig. 2d). The
Coomassie staining indicates the amount of recombinant
proteins used as substrates for the kinase assays (Fig. 2d, low-
er panel).
To verify that HMGA1 is effectively a substrate of ATM ki-
nase activity in response to DNA damage in vivo, we treated
HA-HMGA1-transfected 293 cells with a 10 Gy dose of IR to in-
duce endogenous ATM activation. Cells were collected 5 min
after treatment and extracted proteins immunoprecipitated
with antibodies that recognise serine and threonine residues
phosphorylated by ATM (Anti-P-Sub-ATM). Analysis of the
immunoprecipitates through Western blot with an anti-HA
antibody showed a band corresponding to the HA-HMGA1
protein, indicating that, following IR exposure, HMGA1 is
phosphorylated in vivo by ATM (Fig. 2e). The specificity of
HMGA1 phosphorylation by ATMwas assessed by the absence
of HMGA1 immunoprecipitation in the presence of 5 mM caf-
feine (Fig. 2e).
3.4. Colocalisation of HMGA1b and ATMS1981p
To support further the hypothesis that HMGA1b is a target of
the ATM kinase we investigated whether the two proteins
colocalise to the same regions of the nuclear compartment
by double-immunofluorescence labelling. Mouse embryonic
fibroblasts (MEFs), wild-type for both ATM and Hmga1 genes,
were either treated or not treated with a 2 Gy dose of IR. Fol-
lowing double staining with antibodies against HMGA1b (red
channel) and against the activated, phosphorylated (serine
1981) form of ATM, ATMS1981p, (green channel), cells were
analysed by confocal microscopy (Fig. 3a). As expected, ATM
kinase was massively activated after irradiation and, intrigu-
ingly, it partially colocalises with the endogenous HMGA1b
Fig. 2 – HMGA1 phosphorylation by ATM kinase. (a) Amino acid sequence alignment of HMGA1b and HMGA2 from the indicated
species (AT-hooks are shown in bold, ATM consensus site is underlined and serine 88 is marked with an asterisk). (b) In vitro
kinase assay testing ATM kinase activity on the HMGA1 carboxy-terminal peptide (aa 77–96) wild-type or mutated (S88A).
Phosphorylation was assessed with or without caffeine (5 mM). A representative experiment (out of three different ones,
each performed in duplicate) is shown. (c) In vitro kinase assays using FLAG-ATM wild-type (wt) or its kinase-dead (kd)
mutant on the histidine-tagged HMGA1b recombinant proteins both wild-type (with or without 5 mM caffeine) and mutated
in the putative ATM consensus motif (S88A). Following the kinase reaction, proteins were resolved by SDS–PAGE and the
autoradiography of the dried gel is shown (upper panel). FLAG-ATM wt and kd were immunoprecipitated from transiently
transfected 293T cells with anti-FLAG antibody. One fifth of each immunoprecipitate was probed with anti-ATM antibody
(lower panel). (d) In vitro kinase assays were performed using the endogenous ATM kinase immunoprecipitated from human
GM2184 lymphoblasts or from AT1526 (ATM –/–) as negative control. Kinase activity was assayed on the histidine-tagged
HMGA1b recombinant proteins either wild-type (with or without 5 mM caffeine), mutated in serine 88 or deleted of the
carboxy-terminal tail containing serine 88. Following the kinase reaction, proteins were resolved by SDS–PAGE and the
autoradiography of the dried gel is shown (upper and middle panels). Similar amounts of recombinant proteins were used for
the assay as shown by Coomassie staining (lower panel). (e) 293T cells transfected with a vector expressing HMGA1b were
untreated or treated with a 10 Gy dose of IR to induce activation of endogenous ATM. Total cell extracts were
immunoprecipitated with an antibody able to recognise serine and threonine residues phosphorylated by activated ATM
(Anti-P-Sub-ATM). Immunoprecipitates were analysed by SDS–PAGE followed by Western blot with anti-HA antibody. 293T
cells were also treated with 5 mM caffeine as a control of the phosphorylation specificity.
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Fig. 3 – Colocalisation of HMGA1, ATM and cH2AX foci. (a) HMGA1 colocalises with the ATM active kinase. MEFs were untreated
or treated with a 2 Gy dose of IR, and then analysed by confocal microscopy following double-immunofluorescence staining
with antibodies against ATM S1981p (green channel) and HMGA1b (red channel). (b) cH2AX foci formation in Hmga1 null
MEFs. MEFs wt and –/– for Hmga1 were untreated or treated with a 4 Gy dose of IR. Immunofluorescence staining is with an
antibody against cH2AX (red channel). (c) HMGA1b does not colocalise with cH2AX foci. Wild-type MEFs were untreated or
treated with a 2 Gy dose of IR, and then analysed by confocal microscopy following double-immunofluorescence staining
with antibodies against HMGA1b (green channel) and cH2AX (red channel).
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Fig. 4 – Cell cycle checkpoints are not impaired in Hmga1 null cells following IR. (a) ES Hmga1 wt or Hmga1 –/– (Clones 95.3 and
95.14) were either untreated or treated with a 10 Gy dose of IR. Cells were harvested at different timepoints following BrdU
treatment and stained with a FITC-conjugated anti-BrdU antibody and 7-AAD. Cell cycle profiles were obtained by FACS
analysis and the distribution of the cells in each different phase is reported from a representative experiment (out of three
different ones, each performed in duplicate). (b) MEFs from Hmga1 wild-type, +/– and –/– embryos were either untreated or
treated with doses of 5 and 10 Gy IR. Cells were harvested at different timepoints following BrdU treatment and stained with a
FITC-conjugated anti-BrdU antibody and 7-AAD. Cell cycle profiles were obtained by FACS analysis and the distribution of the
cells in each different phase is reported from a representative experiment (out of two different ones, each performed in
triplicate).
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cells and when activated by c-irradiation. This colocalisation
provides additional evidence that HMGA1b may act in vivo
as a substrate of the functional ATM kinase.3.5. HMGA1 does not localise with IR-induced cH2AX foci
The phosphorylation of histone H2AX (cH2AX) is amongst the
earliest responses to DNA damage, and it is considered the
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volved in DNA repair quickly relocalise to the cH2AX nuclear
foci31, we sought to investigate first whether cH2AX effec-
tively forms foci in Hmga1 null cells, then if HMGA1 relocalis-
es to the cH2AX foci following DNA damage. Mouse
embryonic fibroblasts (MEFs) wild-type or null for the Hmga1
gene (Hmga1 –/– E8 and E9) were either untreated or exposed
to a 4 Gy dose of IR and after 3 h fixed and stained with an
antibody against the phosphorylated form of histone H2AX.
Immunofluorescence showed that, following IR treatment,
cH2AX foci are effectively induced in Hmga1 –/– as in wild-
type cells (Fig. 3b, red channel).
To assess if HMGA1 is recruited to the same DSBs sites
where cH2AX acts, we treated wild-type MEFs with a 2 Gy
dose of IR. After three hours IR-induced DNA damage cells
were fixed and double labelled with antibodies against
HMGA1b (green channel) and cH2AX (red channel). Confocal
microscopy revealed that in mouse embryonic fibroblasts
HMGA1b does not localise with IR-induced cH2AX foci at least
at the dose and timepoint used (Fig. 3c).Fig. 5 – Cell survival is decreased in HMGA1b expressing MCF-7
cells following IR. (a) Clonogenic survival assay of the indi-
cated MCF-7 clones exposed to 0, 2, 4, 8 Gy of IR. The
percentage of survival is reported from a representative
experiment (out of three independent ones, each performed
in triplicate). (b) Clonogenic survival assay of MCF-7 clones
exposed to a 4 Gy dose of IR and treated with the indicated
amount of caffeine. The percentage of survival represents
the mean of three different experiments (+s.d.), each
performed in triplicate.3.6. Cell cycle checkpoints are not impaired in Hmga1 null
cells following IR
The ATM-mediated pathway is responsible for the activation
of cell cycle checkpoints following DNA damage. The result-
ing process allows the proper assembly of the DNA repair
machinery. To investigate whether HMGA1 might be involved
in this pathway, we analysed the cell cycle profile of mouse
embryonic stem (ES) cells or fibroblasts (MEFs) null for Hmga1
in response to IR.
ES cells devoid of the feeder fibroblasts were exposed to a
10 Gy dose of IR and harvested at different timepoints (0, 12,
24 and 48 h) after 1 h of 5-bromo-2-deoxyuridine (BrdU) treat-
ment (Fig. 4a). At 12 h, following IR treatment, both Hmga1 –/–
clones (95.3 and 95.14) and wild-type ES cells accumulate in
G2/M. At 24 h cells restarted cycling or underwent apoptosis
that was massive at 48 h. Anyway, no significant differences
were observed between wild-type and Hmga1 –/– cells at least
at the IR dose tested.
We also analysed cell cycle profiles of MEFs obtained from
Hmga1 wild-type, +/– and –/– embryos at 14.5 dpc. MEFs at
early passages were exposed to doses of 5 and 10 Gy IR, then
treated with BrdU and analysed at 12, 24 and 48 h (Fig. 4b). At
12 h MEFs of all three genotypes arrested in G2/M in a dose-
dependent manner. At 24 and 48 h, the block was slowly
released and only a small percentage of cells underwent
apoptosis (less than 10%). As for the ES cells we did not
observe any statistically significant difference between wild-
type or Hmga1 null cells at the IR doses and timepoints
analysed. However, even though it seems that lack of HMGA1
does not affect the ability of ES cells and MEFs to activate cell
cycle checkpoints following IR, we cannot rule out the possi-
bility that the other member of the HMGA family, HMGA2,
might compensate for HMGA1 loss.
3.7. Cell survival is decreased in HMGA1b expressing
MCF-7 cells following IR
Cells defective in genes involved in the response to DNA dam-
age usually show an altered long-term survival following
exposure to the damaging agent. Therefore, we sought to
investigate whether HMGA1 was able to affect cell survival
following IR treatment. To this aim we used a different cellu-
lar system such as the human breast cancer cell line MCF-7,
in which neither HMGA1 nor HMGA2 genes are expressed.
Moreover, HMGA1b expression has been previously shown
to sensitise MCF-7 cells to damage-induced by UV and cis-
platin treatment.12 We compared two different clones of
MCF-7 stably transfected with an HMGA1b expressing vector
to the control cells, transfected with the empty vector (EV).
Cells were exposed to doses of 2, 4 and 8 Gy of IR and after
2 weeks clonogenic survival was evaluated by colony count-
ing. Both HMGA1b expressing clones (MCF-7 HA-HMGA1b
Cl1 and Cl3) showed a decrease in the percentage of cell sur-
vival compared to the control MCF-7 EV Cl3 (Fig. 5a). Interest-
ingly, this response was highly reproducible and described
also in response to the radiomimetic antibiotic bleomycin.12
To assess whether the enhanced radiosensitivity of HMGA1b
expressing cells was correlated to the ATM/ATR pathway, cells
were exposed to a 4 Gy IR dose, treated with two different
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after two weeks. Caffeine treatment effectively enhanced cell
radiosensitivity in a dose-dependent manner, but no signifi-
cant differences were observed between HMGA1b expressing
MCF-7 clones and MCF-7 EV Cl3 control cells (Fig. 5b).
4. Discussion
Recently, several works correlated HMGA expression to en-
hanced cell sensitivity in response to different DNA-damag-
ing agents.5,16,17 Here, we report a novel interaction between
the HMGA1 family member and the ATM protein kinase, the
major key player in the activation of the cellular response
aimed to safeguard genome integrity following DNA damage.
We show that HMGA1b and ATM are able to co-immunopre-
cipitate in 293T cells and that at least two AT-hook domains
of HMGA1 are necessary for this interaction. Since ATM phos-
phorylates its substrates on serine or threonine that precede a
glutamine residue, we looked for the presence of these S/TQ
motifs on the HMGA protein sequences. Interestingly, both
the HMGA1 and the HMGA2 members of the HMGA family
present suchmotifs in the carboxy-terminal region of the pro-
tein, and this SQ motif also appears to be highly conserved
amongst different species making it tempting to speculate
that it may be crucial to the protein function. Subsequently,
we demonstrated that HMGA1 is indeed an ATM target
in vitro using both the HMGA1 C-terminal peptide and the
full-length protein. HMGA1 phosphorylation was strongly re-
duced when using caffeine or the ATM kinase-dead mutant.
Moreover, we showed that HMGA1 phosphorylation was in-
deed site-specific since it was abolished when serine 88 was
mutated to alanine. Intriguingly, we found trace HMGA1b
phosphorylation when immunoprecipitating extracts from
ATM –/– cells with an antibody cross-reacting with the ATR ki-
nase. It is, therefore, likely that HMGA1 might be a target also
of the ATR kinase that shares with ATM the same consensus
sequence and several substrates,18 and it has been recently
shown to be activated by ATM following IR.32
Finally, using an antibody raised against a pool of ATM/
ATR substrates to immunoprecipitate HMGA1b after IR expo-
sure, we also demonstrated that ATM phosphorylates
HMGA1b in vivo. Accordingly, this phosphorylation was inhib-
ited by caffeine.
Following DNA damage, in fact, ATM is activated through
autophosphorylation at serine 1981 resulting in the dissocia-
tion of inactive dimers.21 The active ATM monomers in part
are free to move throughout the nucleus and in part are re-
cruited at the site of DNA damage.18 The M/R/N complex ap-
pears to be responsible for the initial recruitment of ATM at
DSBs sites,33–35 then MDC1 has been recently shown to bind
cH2AX and retain active ATM on the chromosome regions
adjacent to the break sites,36 leading to further expansion of
H2AX phosphorylation. The phosphorylation of H2AX by
ATM is amongst the earliest responses to DSBs and controls
the accumulation of checkpoint/repair proteins to large chro-
matin regions surrounding DNA damage sites. cH2AX has
been proposed to function as a docking protein for the reten-
tion of the DNA-damage response factors,37 or it may modu-
late the chromatin structure to facilitate the accumulation ofcheckpoint proteins.37 We observed efficient formation of
cH2AX foci following IR in Hmga1 –/– MEFs. Interestingly, as
assessed by immunofluorescence and confocal microscopy
there is no colocalisation between the HMGA1b and cH2AX
proteins. Since HMGA and H2AX are both chromatinic pro-
teins involved in chromatin remodelling it is tempting to
speculate that HMGA1 phosphorylation might serve to dis-
place HMGA and favour assembly of H2AX in the regions of
DNA damage. This may be consistent with the recent finding
that HMGA2 interferes with the basal H2AX phosphorylation
mechanism,17 but additional studies are needed to further ad-
dress this issue.
In an attempt to gain insight into the physiological role of
the HMGA1 and ATM interaction, we decided to investigate
whether IR-induced cell cycle checkpoint activation was
somehow impaired in cells lacking the Hmga1 gene. Following
the DNA damage, ATM triggers a complex regulatory pathway
aimed to allow for DNA repair before proceeding through the
cell cycle, and many proteins involved in this pathway show
defects in IR-induced checkpoints, MDC1,38 H2AX and
53BP1,37 CHK139 and CHK2.40,41 However, following IR treat-
ment, both Hmga1 –/– ES cells and MEFs did not show any de-
fects in cell cycle checkpoint activation relative to wild-type
cells under the conditions used in this study. One possible
explanation may lie in that both ES cells and MEFs express
the HMGA2member of the HMGA family, whichmay compen-
sate for HMGA1 loss. As a result, we are generating Hmga1/
Hmga2 double knock-out alleles in mice that will attempt to
address this issue. As an alternative means to investigate this
question, we used the human MCF-7 tumour-derived cell line
that does not express either HMGA family members and ana-
lysed the effect of ectopic HMGA1b overexpression following
IR-induced DNA damage. Interestingly, clonogenic survival
following IR treatment was decreased in the HMGA1b express-
ing MCF-7 clones. Consistently, the same effect has been de-
scribed in response to the radiomimetic antibiotic
bleomycin,12 suggesting that HMGA1 proteins play a role in
the cellular response to DSBs-causing agents. It is not yet clear
whether the ATM signalling pathway regulates HMGA1 in this
context, since ATM inhibition by caffeine does not rescue sur-
vival of HMGA1b expressing cells.
In conclusion, we report a novel interaction between the
HMGA1 and the ATM kinase and, whilst the physiological role
of this interaction remains to be assessed, we propose that
HMGA1 should be regarded as a potential ATM-downstream
target. These findings are likely to contribute to our under-
standing of HMGA1 function in the mechanism of tumouri-
genesis and reveal new insights into potential therapeutic
strategies. In fact, HMGA1 expression enhances sensitivity
of breast cancer cells to ionising radiation (as reported here)
or to other DNA-damaging agents such as bleomycin, cis-
platin and UV irradiation.12,16 Therefore, patients bearing
HMGA1 expressing tumours might benefit from adjuvant
therapy based on such DNA-damaging agents.
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The High Mobility Group proteins HMGA1 are nuclear
architectural factors that play a critical role in a wide
range of biological processes. Since recent studies have
identiﬁed the microRNAs (miRNAs) as important reg-
ulators of gene expression, modulating critical cellular
functions such as proliferation, apoptosis and differentia-
tion, the aim of our work was to identify the miRNAs that
are physiologically regulated by HMGA1 proteins. To
this purpose, we have analysed the miRNA expression
proﬁle of mouse embryonic ﬁbroblasts (MEFs) carrying
two, one or no Hmga1 functional alleles using a
microarray (miRNA microarray). By this approach, we
found a miRNA expression proﬁle that differentiates
Hmga1-null MEFs from the wild-type ones. In particular,
a signiﬁcant decrease in miR-196a-2, miR-101b, miR-331
and miR-29a was detected in homozygous Hmga1-knock-
out MEFs in comparison with wild-type cells. Consis-
tently, these miRNAs are downregulated in most of the
analysed tissues of Hmga1-null mice in comparison with
the wild-type mice. ChIP assay shows that HMGA1 is
able to bind regions upstream of these miRNAs. More-
over, we identiﬁed the HMGA2 gene product as a putative
target of miR-196a-2, suggesting that HMGA1 proteins
are able to downregulate the expression of the other
member of the HMGA family through the regulation of
the miR-196a-2 expression. Finally, ATXN1 and STC1
gene products have been identiﬁed as targets of miR-101b.
Therefore, it is reasonable to hypothesize that HMGA1
proteins are involved in several functions by regulating
miRNA expression.
Oncogene (2009) 28, 1432–1442; doi:10.1038/onc.2008.495;
published online 26 January 2009
Keywords: HMGA1; microRNA; MEF; ATXN1;
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Introduction
The High Mobility Group A (HMGA) protein family
includes HMGA1a and HMGA1b, which are encoded
by the HMGA1 gene through an alternative splicing
(Johnson et al., 1989), and the closely related HMGA2
protein, which is encoded by a different gene (Manﬁo-
letti et al., 1991). These proteins bind the minor groove
of AT-rich DNA sequences through three short basic
repeats, called ‘AT-hooks’, located at the NH2-terminal
region of the proteins. The mammalian HMGA proteins
play key roles in chromatin architecture and gene
control by serving as generalized chromatin effectors,
either enhancing or suppressing the ability of most usual
transcriptional activators and repressors to act within
the conﬁnes of chromatinized DNA (Reeves and Nissen,
1990; Thanos and Maniatis, 1995).
Both HMGA genes are widely expressed during
embryogenesis, whereas their expression is low or absent
in most of the normal adult tissues (Zhou et al., 1995;
Chiappetta et al., 1996). Conversely, their expression
again becomes abundant in most human malignant
neoplasias (Tallini and Dal Cin, 1999). Several studies
indicate that HMGA gene overexpression plays a
critical role in the process of carcinogenesis and their
oncogenic activity has been demonstrated in vitro and
in vivo (Fusco and Fedele, 2007). In fact, either HMGA1
or HMGA2 overexpression is able to transform mouse
and rat ﬁbroblasts (Fedele et al., 1998; Scala et al.,
2000), and transgenic mice overexpressing either
HMGA1 or HMGA2 develop natural killer-T lympho-
mas and pituitary adenomas (Baldassarre et al., 2001;
Fedele et al., 2002, 2005). Interestingly, the HMGA1
gene also seems to have a tumor suppressor role in
oncogenesis since the Hmga1-null mice, even at the
heterozygous state, develop B-cell lymphomas and
myeloid malignancies, other than cardiac hypertrophy
and type II diabetes (Foti et al., 2005; Fedele et al.,
2006).
In a previous work, we searched for genes regulated
by HMGA1 proteins, using microarray analysis in
embryonic stem cells bearing one or two disrupted
Hmga1 alleles. We identiﬁed that 87 transcripts
Received 24 July 2008; revised 28 November 2008; accepted 17
December 2008; published online 26 January 2009
Correspondence: Professor A Fusco, Istituto di Endocrinologia ed
Oncologia Sperimentale del CNR ‘Gaetano Salvatore’, Universita` di
Napoli Federico II, via Pansini 5, 80131 Napoli, Italy.
E-mail: afusco@napoli.com or alfusco@unina.it
Oncogene (2009) 28, 1432–1442
& 2009 Macmillan Publishers Limited All rights reserved 0950-9232/09 $32.00
www.nature.com/onc
increased and 163 transcripts decreased by at least
four-fold in Hmga1/ embryonic stem cells. For some
of them, a Hmga1-dose dependency was observed. For a
couple of analysed HMGA1-regulated genes, electro-
phoretic mobility shift assay and chromatin immuno-
precipitation (ChIP) revealed a direct binding of
HMGA1 proteins to their promoters, suggesting an
HMGA1-direct regulation of their expression (Martinez
Hoyos et al., 2004).
MicroRNAs (miRNAs) are a class of genes encoding
short RNAs, which control gene expression by inhibit-
ing translation or inducing cleavage of target mRNAs.
miRNAs are aberrantly expressed in cancer tissues, and
links between deregulated miRNAs and the molecular
pathways involved in carcinogenesis have been estab-
lished (Negrini et al., 2007). Several studies have shown
that miRNAs play important roles in essential processes
such as differentiation, cell growth and cell death
(Miska, 2005; Zamore and Haley, 2005). Recent
evidences indicate that miRNAs could contribute to
oncogenesis, participating as tumor suppressors or as
oncogenes (Kent and Mendell, 2006). In fact, miR-21
was shown to directly target the tumor suppressor
PTEN (encoding a phosphatase that can inhibit growth
and/or survival pathways) in cholangiocarcinoma cells
(Meng et al., 2007). Moreover, the miR-221/222 cluster,
upregulated in thyroid and prostate cancer, was shown
to target the p27kip1 protein, a critical negative regulator
of the cell cycle (Galardi et al., 2007; Visone et al., 2007).
Therefore, it is reasonable to hypothesize that HMGA1
proteins are involved in several functions regulating the
miRNA expression.
In the present work, we have carried out miRNA
expression proﬁling of mouse embryonic ﬁbroblasts
(MEFs) isolated from Hmga1-knockout and wild-type
mice to identify the miRNAs regulated by the HMGA1
proteins. Among the miRNAs differentially expressed
in wild-type and Hmga1-null MEFs, we focused our
attention on a subset of miRNAs, including the miR-
196a-2 and miR-101b, downregulated in homozygous
Hmga1-knockout MEFs with respect to the wild-type
ones. Finally, we identiﬁed the HMGA2 gene product as
a target of miR-196a-2 and the ATXN1 and STC1 gene
products as targets of miR-101b.
Results
miRNA expression proﬁle of embryonic ﬁbroblasts
isolated from Hmga1-knockout mice
We used a miRNA microarray (Liu et al., 2004) to
evaluate the miRNA expression proﬁle of MEFs
deriving from Hmga1-knockout mice. The wild-type
MEFs were matched with those bearing one or two
disrupted Hmga1 alleles. Applying the analysis of
variance, we obtained a list of differentially expressed
miRNAs (Po0.05) between wild-type and homozygous
mutants (Table 1). Six miRNAs (miR-196a-2, miR-
101b, miR-331, miR-29a, miR-346 and miR-130b) were
overexpressed with a fold-change equal or higher than
two in the wild-type samples versus homozygous
mutants. In contrast, none of the analysed miRNAs
showed more than two-fold reduction in its
expression in the wild-type compared to Hmga1/
Table 1 miRNAs differentially expressed between MEFs obtained from wild-type (MEFs+/+), heterozygous (MEFs+/) and homozygous
(MEFs/) mice for the Hmga1-null mutation
miRNA name Fold-change
(MEFs+/+ vs MEFs+/)
P-value Fold-change
(MEFs+/+ vs MEFs/)
P-value
1 mmu-mir-196a-2No2 1.89 0.00238 3.70 0.0471
2 mmu-mir-101bNo2 1.28 0.0491 2.43 0.0466
3 mmu-mir-331No2 1.19 0.00280 2.29 0.0364
4 mmu-mir-29aNo2 1.19 0.0471 2.28 0.0299
5 hsa-mir-346No1 1.07 0.0174 2.10 0.0275
6 mmu-mir-130bNo1 1.00 0.0167 2.00 0.0224
7 mmu-mir-199bNo2 0.97 0.0306 1.96 0.00879
8 hsa-mir-199b-precNo2 0.97 0.0178 1.96 0.0143
9 mmu-mir-194-2No2 0.95 0.0212 1.93 0.00535
10 mmu-mir-134-precNo2 0.93 0.0306 1.91 0.00435
11 mmu-mir-210No2 0.87 0.0158 1.82 0.00256
12 mmu-mir-130-prec 0.85 0.0197 1.80 0.00178
13 hsa-mir-016a-chr13 0.99 0.0483 0.51 0.000595
14 hsa-mir-222-precNo2 1.00 0.0479 0.50 0.00026
15 mmu-mir-321No2 1.01 0.0578 0.50 0.000247
16 mmu-mir-28No2 1.05 0.0986 0.48 0.00659
17 mmu-let-7bNo1 1.08 0.0489 0.47 0.0336
18 mmu-mir-125b-precNo1 1.10 0.0255 0.47 0.00745
19 mmu-mir-125b-1No1 1.11 0.0339 0.46 0.00447
20 mmu-mir-030e-prec 1.14 0.0787 0.45 0.00338
21 mmu-mir-218-2precNo1 1.21 0.0396 0.43 0.00774
22 hsa-mir-30c-1No1 1.21 0.0499 0.43 0.00554
23 mmu-mir-321No1 1.22 0.0458 0.43 0.00121
24 mmu-mir-299No1 1.30 0.0115 0.41 0.00114
Abbreviation: MEFs, mouse embryonic ﬁbroblasts.
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MEFs. Subsequently, we validated the results obtained
by miRNA microarray analysis by real-time PCR on
the miR-101b, miR-196a-2, miR-331 and miR-29a
(Figure 1).
Interestingly, for miR-196a-2 and miR-101b, the
differences in their expression between wild-type and
Hmga1-null MEFs were even higher than those shown
by the microarray analysis. Then, we decided to
concentrate on the miR-101b and miR-196a-2, which
showed the highest fold-change decrease in Hmga1-null
MEFs (Table 1).
Subsequently, we analysed miR-196a-2 and miR-101b
expressions by real-time RT-PCR on different tissues
from Hmga1þ /þ , Hmga1þ / and Hmga1/ mice. As
shown in the Figure 2a, miR-101b was downregulated,
as described for MEFs, in the spleen, heart, thymus and
brain of heterozygous and homozygous Hmga1-null
mice with respect to the wild-type tissues, whereas no
differences in its expression were observed in the liver,
and its expression was not detected in the lung. The
expression trend of miR-196a-2 in the liver, heart, lung
and brain was similar to that observed in Hmga1þ /þ
with respect to Hmga1/ MEFs, being signiﬁcantly
downregulated in heterozygous and homozygous
Hmga1-null mice. Conversely, no differences in miR-
196a-2 expression were observed in the spleen, and no
expression at all was observed in the thymus (Figure 2b).
In some cases, such as miR-196a-2 in the liver
(Figure 2b) and miR-101b in the spleen (Figure 2a),
the reduction of their expression was HMGA1-dose-
dependent. These results are consistent with our
previous ones showing that the gene expression regula-
tion by the HMGA1 proteins is dependent on the
cellular context (Martinez Hoyos et al., 2004).
HMGA1 proteins directly bind the miR-101b and
miR-196a-2 upstream regions
To verify that HMGA1 proteins are able to bind to the
miR-101b or miR-196a-2 upstream regions in vivo, we
performed ChIP experiments in Hmga1þ /þ , Hmga1þ /
and Hmga1/ MEFs. Chromatin prepared as described
under Materials and methods was immunoprecipitated
with anti-HMGA1 or rabbit IgG antibodies, used as
internal control. In particular, we analysed a region of
Figure 1 Validation of some miRNA microarray data by
quantitative real-time reverse transcription-PCR (qRT–PCR).
qRT–PCR analysis of miR-101b, miR-196a-2, miR-331 and miR-
29a precursors was carried out on MEFs obtained from wild-type
(MEFsþ /þ), heterozygous (MEFsþ /) and homozygous (MEFs/)
mice for the Hmga1-null mutation. The fold-change values indicate
the relative change in the expression levels between homozygous
and heterozygous samples and the wild-type sample, assuming
that the value of the wild-type sample was equal to 1. Each
bar represents the mean value±s.e. from three independent
experiments performed in triplicates *Po0.05, **Po0.01 vs
MEFsþ /þ .
Figure 2 Expression of miR-196a-2 and miR-101b in Hmga1-knockout mouse tissues. qRT–PCR analysis of (a) miR-101b and
(b) miR-196a-2 precursors was carried out on the spleen, liver, heart, thymus, lung and brain deriving from Hmga1þ /þ , Hmga1þ / and
Hmga1/ mice. Each bar represents the mean value±s.e. from three different mice. *Po0.05, **Po0.01 vs wild-type control.
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2,000 bp upstream of the precursor sequence of miR-
101b and miR-196a-2 to search for AT-rich putative
HMGA1-binding sites. The results shown in Figure 3
demonstrate that HMGA1 proteins bind to these
sequences. In fact, the miR-101b and miR-196a-2
upstream regions were ampliﬁed from the DNA
recovered with anti-HMGA1 antibody in wild-type
and Hmga1þ /, but not in Hmga1/ MEFs. Moreover,
no ampliﬁcation was observed in samples immuno-
precipitated with rabbit IgG.
ATXN1 and STC1 are targets of miR-101b
To search for potential mRNA targets of the HMGA1-
regulated miRNAs, we used the miRGen program
(http://www.diana.pcbi.upenn.edu/miRGen.html) as a
bioinformatic tool. Among the several genes predicted
as potential targets of the miR-101b, we selected
ATXN1 and STC1 because of their biological function
in development and cancer. The gene ATXN1, which is
mutated to contain an expanded CAG trinucleotide
repeat in spinocerebellar ataxia-1, encodes for the
protein Ataxin 1. Ataxin 1 is detected in various brain
regions and in non-neuronal tissues, such as the heart,
skeletal muscle and liver (Servadio et al., 1995; Tsai
et al., 2004). Stanniocalcin1, encoded by STC1 gene, is a
glycoprotein hormone and it has a role in many
physiological processes, including bone development,
reproduction, wound healing, angiogenesis and mod-
ulation of inﬂammatory response (Ishibashi and Imai,
2002; Chang et al., 2003). The STC1 gene is expressed in
a wide variety of tissues, including the kidney, prostate,
thyroid, bone and ovary (Chang et al., 1995; Olsen et al.,
1996; Varghese et al., 1998). Recently, STC1 over-
expression has been found in hepatocellular, colorectal,
breast and medullary thyroid carcinomas (Fujiwara
et al., 2000; Okabe et al., 2001; Watanabe et al., 2002;
McCudden et al., 2004).
Three sites in the 30-UTR of ATXN1 gene and three in
the 30-UTR of STC1 gene, that match the miR-101b
‘seed sequence’, were predicted (Figure 4a). To validate
the inﬂuence of miR-101b on the selected candidate
targets, we transfected the miR-101b or its inhibitor, 20-
O-Me-101b, into the NIH3T3 cells, and searched
for changes in ATXN1 and STC1 protein levels by
western blot analysis. Introduction of miR-101b
decreased the protein levels signiﬁcantly (Figures 4b
and c). Conversely, the inhibitor, 20-O-Me-101b, does
not change STC1 and ATXN1 protein amounts
signiﬁcantly.
Interestingly, no signiﬁcant changes in the ATXN1 or
STC1 mRNA levels were observed in the cells trans-
fected with the miR-101b or its inhibitor (Figure 4d).
This result indicates a role of miR-101b in STC1 and
ATXN1 post-transcriptional regulation, and excludes
that miR-101b may affect ATXN1 or STC1 mRNA
degradation.
Most miRNAs are thought to control gene expression
by base pairing with the miRNA-recognizing elements
(miR-RE) found in their messenger target. To demon-
strate that the direct interaction between the miR-101b
and STC1 or ATXN1 mRNA was responsible for
decreased expression of these proteins, we inserted
downstream of the luciferase ORF the 1310 bp (3390–
4680) of the 30-UTR of the ATXN1 mRNA, or the 988
bp (1029–1995) of the 30-UTR of the STC1 mRNA,
respectively. These reporter vectors were transfected
into NIH3T3 cells with (a) the miR-101b oligonucleo-
tide precursor, (b) the 20-O-Me-101b and (c) a control
not targeting scrambled oligonucleotide. The luciferase
activity was markedly diminished after miR-101b
transfection, as compared with the scrambled oligo-
nucleotide (Po0.05). Conversely, an increase in the
luciferase activity was observed after transfection with
the miR-101b inhibitor (Po0.01 for STC1 and Po0.05
for ATXN1) (Figure 5a). These results indicate that this
miR interferes with ATXN1 and STC1 translation
through direct interaction with their respective 30-UTRs.
This conclusion is further supported by similar experi-
ments in which we used as reporter construct the same
vector of the previous experiments, but carrying target
sites modiﬁed by introducing point deletion in one, two
or three sites together (Figure 5b). For both target
genes, only the reporter vector carrying deletion in all
target sites was insensitive to the effect of miR-101b
(Po0.01) (Figures 5c and d), proving that the modiﬁca-
tion in only one or two target sites of the 30-UTR is not
sufﬁcient to block the inhibitory function of this miR.
miR-196a-2 downregulates HMGA2
Using the same bioinformatic tool, we also searched for
potential mRNA targets of mouse miR-196a-2. This
analysis identiﬁed several candidate genes, but we put
our attention on Hmga2 (Figure 6a), another member of
HMGA family, which maps on chromosome 12q13-15
and is causally involved in a variety of benign and
malignant tumors (Ashar et al., 1995; Schoenmakers
et al., 1995; Fedele et al., 2001; Fusco and Fedele, 2007).
To better investigate the inﬂuence of miR-196a-2 on
Hmga2 expression, we searched for changes in HMGA2
protein and mRNA levels in NIH3T3 cells transfected
with the miR-196a-2 precursor (miR-196a-2) or its
Figure 3 HMGA1 bind to the promoter of miR-101b and miR-
196a-2. ChIP assay was carried out on wild-type and Hmga1-
knockout MEFs. The recovered DNA was used as a template for
PCR reactions with primers that amplify the upstream regions of
miR-101b and miR-196a-2.
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inhibitor (20-O-Me-196a-2) in comparison with
scrambled oligonucleotide-transfected cells. As shown
in Figures 6b and c, the introduction of the miR-196a-2
precursor signiﬁcantly decreased the HMGA2 protein
levels, differently from the 20-O-Me-196a-2, which does
not signiﬁcantly change the HMGA2 protein amounts
compared to the cells transfected with a scrambled
oligonucleotide.
No signiﬁcant changes in the HMGA2 mRNA levels
were observed in the cells transfected with the miR-
196a-2 or its inhibitors (Figure 6d). The inverse pattern
of expression of Hmga2 and miR-196a-2 suggested an in
vivo interaction that we further investigated by luciferase
assays. In fact, to show a direct interaction between the
30-UTR of Hmga2 and miR-196a-2, we inserted the
30-UTR region predicted to interact with this miR into
a luciferase vector. Then, we tested the activity of the
miR-196a-2 by cotransfecting the luciferase reporter
vector bearing the 30-UTR of Hmga2 with (a) the
miR-196a-2 oligonucleotide precursors, (b) the 20-O-Me-
196a-2 and (c) a control not targeting scrambled
oligonucleotide. Consistent with the above data, in-
dicating HMGA2 as a target of miR-196a-2, the relative
luciferase activity was markedly diminished in cells
transfected with miR-196a-2 compared to those trans-
fected with the scrambled oligonucleotide (Po0.05).
Conversely, a signiﬁcant increase in the luciferase
activity was observed after transfection with the miR-
196a-2 inhibitor (Figure 7a).
To show that the effect of miR-196a-2 on the
luciferase gene is dependent on the presence of the
miR-196a-2-binding sites, we generated a panel of
reporter constructs containing the HMGA2 30-UTR,
with the miR-196a-2-binding sites mutated individually
or in combination (Figure 7b). Although the mutation
of one site did not inﬂuence the inhibitory effect of miR-
196a-2 on reporter gene expression, mutation of two
sites together reduced the inhibitory effect to three-fold
(Po0.01), suggesting that these two sites function
cooperatively in mediating the inhibition of HMGA2
protein synthesis (Figure 7c).
Discussion
The aim of this study was to identify miRNAs that are
physiologically regulated by the HMGA1 proteins.
To this purpose, we analysed, using a miRNA micro-
array platform, the miRNA expression proﬁle of
the MEFs carrying two, one or no Hmga1 functional
alleles. We identiﬁed four miRNAs signiﬁcantly
downregulated in homozygous Hmga1-null MEFs
with respect to the wild-type samples. Their expression,
in particular that of miR-101b and miR-196a-2,
Figure 4 ATXN1 and STC1 are target genes of miR-101b. (a) Schematic representation of STC1 and ATXN1 genes 30-UTR target sites
for miR-101b. (b) Immunoblots for STC1 and ATXN1. Proteins were extracted from untransfected and miR-101b sense- or antisense-
transfected NIH3T3 cells 48h after transfection. Vinculin immunoblot was used as loading control. (c) Densitometric analysis of the
western blots shown in panel b. Each bar represents the mean ratio±s.e., between STC1 (or ATXN1) and vinculin, of three independent
experiments. (d) qRT–PCR analysis of ATXN1 and STC1 mRNA in the same samples shown in panel b. Fold-change values indicate the
relative change in STC1 and ATXN1 expression levels between miRNA-treated and scrambled oligonucleotide-treated cells, normalized
with GAPDH. The error bars represent the mean±s.e. (n¼ 3). *Po0.05 vs scrambled control.
HMGA1 regulate microRNA expression
I De Martino et al
1436
Oncogene
is regulated by HMGA1 in a dose-dependent manner,
with an intermediate expression level in MEFs carrying
only one Hmga1 functional allele. Interestingly, none of
the miRNAs analysed showed a signiﬁcant increase in
the MEFs null for Hmga1. This result would suggest
that, at least in MEFs, the HMGA1 proteins positively
regulate a limited number of miRNAs, whereas they do
not seem to have a signiﬁcant negative role in miRNA
transcription.
We focused our studies on miR-101b and miR-196a-2,
which showed the highest fold-change. This regulation
by HMGA1 was also conﬁrmed in other mouse tissues,
but not in all those analysed, conﬁrming that the
regulation of gene expression by the HMGA1 proteins
Figure 5 The 30-UTR of STC1 or of ATXN1, enables miR-101b regulation. (a) Relative luciferase activity in NIH3T3 cells transiently
transfected with miR-101b oligonucleotide (sense and antisense) and control scrambled oligonucleotide. Relative activity of ﬁreﬂy
luciferase expression was standardized to a transfection control, using Renilla luciferase. The scale bars represent the mean±s.e.
(n¼ 3). **Po0.01, *Po0.05 compared with the scrambled oligonucleotide. (b) Schematic representation of the miR-101b site regions
(bold and dashed) wild-type and mutated in the constructs used in the luciferase assays shown in c and d. (c and d) Relative luciferase
activity in NIH3T3 cells transfected with different constructs shown in panel a. Results are reported as mean expression values of three
independent experiments, with error bars indicating standard error. **Po0.01.
Figure 6 HMGA2 is target of miR-196a-2. (a) Schematic representation of HMGA2 gene 30-UTR target sites for miR-196a2.
(b) Immunoblots for HMGA2 and vinculin protein as loading control. Proteins were extracted from untransfected and miR-196a-2
sense- or antisense-transfected NIH3T3 cell 48 h after transfection. (c) Densitometric analysis of the western blots shown in panel b.
Each bar represents the mean ratio±s.e., between HMGA2 and vinculin, of three independent experiments. (d) qRT–PCR analysis in
HMGA2 mRNA in the same samples shown in panel b. Fold-change values indicate the relative change in HMGA2 expression levels
between miR-treated and scrambled oligonucleotide-treated cells, normalized with GAPDH. The error bars represent the mean±s.e.
(n¼ 3). *Po0.05 vs scrambled control.
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is dependent on the cellular context. ChIP analysis
conﬁrmed that HMGA1 was able to bind to the
upstream region of both these miRNAs, suggesting a
direct control of the miR-101b and miR-196a-2 expres-
sions by HMGA1.
We looked for possible targets of these miRNAs using
appropriate bioinformatic programs. As far as the miR-
101b is concerned, two potential targets were identiﬁed:
the Ataxin1 (ATXN1) and Stanniocalcin1 (STC1)
proteins. Overexpression of miR-101b in NIH3T3 cells
leads to a reduction of both these proteins, and to a
reduced luciferase activity of ATXN1, or STC1 gene
30-UTR-based reporter constructs. ATXN1 is an RNA-
binding protein thought to act as a transcriptional
repressor (Yue et al, 2001; Irwin et al., 2005). The
expression of pathogenic ATXN1 protein carrying
expanded tracts of polyQ results in Spinocerebellar
Ataxia type 1 (SCA1), a disease that decimates
cerebellar Purkinje cells and brain stem neurons
(Skinner et al., 1997). Therefore, it is likely that
HMGA1 might have a certain role in the development
of the cerebellum, even though Hmga1-null mice do not
show a gross impairment of the cerebellar functions.
Moreover, since HMGA1 is overexpressed in most
neuroblastoma tumors (Giannini et al., 1999, 2000), it is
reasonable to hypothesize that the HMGA1 protein
might contribute to the growth of the neuron stem cells,
and to their transformation by modulating the ATXN1
expression. Studies are in progress to evaluate ATXN1
protein levels in neuroblastomas. While this manuscript
was under submission for publication, a paper showing
that the ATXN1 is a target of miR-101b was being
published. The authors show that the miR-101b, together
with miR-19 and miR-130, cooperatively regulate
ATXN1 levels and their inhibition enhanced the cyto-
toxicity of polyglutamine-expanded ATXN1 in human
cells (Lee et al., 2008). They conﬁrm that miRNA-
mediated post-transcriptional regulation of ATXN1
modulates SCA1 neuropathology by affecting the
amount of the protein expressed. These data seem
completely consistent with the data reported in this paper.
Another target of the miR-101b is the STC1 gene. It
codes for a homodimeric glycoprotein hormone
(Wagner et al., 1986). The modulation of its expression
has been revealed in numerous developmental, physio-
logical and pathological processes. Recently, STC1 has
also been reported to be induced in a variety of tumors
including the breast (McCudden et al., 2004), colon
(Gerritsen et al., 2002), ovary (Ismail et al., 2000), lung
cancer (Garber et al., 2001), thyroid medullary carcino-
ma (Watanabe et al., 2002), hepatocarcinoma (Okabe
et al., 2001), pheochromocytoma (Eisenhofer et al.,
2004), neuroblastoma (Wong et al., 2002), osteosarcoma
and ﬁbrosarcoma (Jellinek et al., 2000). The possible use
of STC1 expression levels for the diagnosis of human
breast, hepatocellular and colorectal cancer has also
been proposed (Fujiwara et al., 2000; Wascher et al.,
2003). Moreover, it has been shown that the inherited
mutations of the RET gene, responsible for the MEN2A
and MEN2B, are able to induce STC1 expression
(Watanabe et al., 2002). Recently, a critical role of
STC1 expression in the formation of tumor vasculature
has been proposed. Indeed, it has been shown that STC1
expression is markedly increased in hypoxia, common
phenomenon that occurs in region of most solid human
tumor in the latter stage of carcinogenesis (Gerritsen
Figure 7 The 30-UTR of HMGA2 gene enables miR-196a-2 regulation. (a) Relative luciferase activity in NIH3T3 cells transiently
transfected with miR-196a-2 oligonucleotide (sense and antisense) and a control non-targeting scrambled oligonucleotide. Relative
activity of ﬁreﬂy luciferase expression was standardized to a transfection control, using Renilla luciferase. The scale bars represent the
mean±s.e. (n¼ 3).*Po0.05 compared with the scrambled oligonucleotide. (b) Schematic representation of the miR-196a-2 site regions
(bold and dashed) wild-type and mutated in the constructs used in the luciferase assays shown in panel c. (c) Relative luciferase activity
in NIH3T3 cells transfected with different constructs shown in panel a. Results are reported as mean expression values of three
independent experiments, with error bars indicating standard error. **Po0.01.
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et al., 2002). STC1 expression would be induced by
Hypoxia-inducible factor 1a (Yeung et al., 2005)
and by vascular endothelial growth factor (Holmes
and Zachary, 2008). Therefore, its increased level by
miR-101b downregulation after HMGA1 induction
might have an important role in the progression step
of carcinogenesis in several human neoplasias all
featured by HMGA1 overexpression. More recently
STC1 has been proposed as a putative proapoptotic
factor in the regulation of programmed cell death
induced by p53 (Lai et al., 2007).
As far as the miR-196a-2 is concerned, we have
identiﬁed as target the HMGA2 protein, the other
member of the HMGA family.
This protein is implicated, through different mechan-
isms, in both benign and malignant neoplasias. Re-
arrangements of HMGA genes are a feature of most
benign human mesenchymal tumors. Conversely, un-
rearranged HMGA overexpression is a feature of
malignant tumors and is also causally related to
neoplastic cell transformation. In fact, the block of the
HMGA2 protein synthesis prevents thyroid cell trans-
formation by acute murine retroviruses (Berlingieri
et al., 1995). Very recently, it has been shown that
HMGA2 promotes neural stem cell self-renewal in
young mice reducing p16 and p19 (Nishino et al.,
2008). Then, it is reasonable to hypothesize that the
downregulation of miR-196a-2 leading to increased
HMGA2 levels could represent a further mechanism
by which HMGA1 overexpression can contribute to cell
transformation. Also the HMGA2 gene has been found
overexpressed in a large variety of experimental and
human malignant neoplasias (Fusco and Fedele, 2007).
The identiﬁcation of HMGA2 as a target of miR-196a-2
might also have some interesting implications in
adipocytic cell growth and differentiation, in which
HMGA1 and HMGA2 seem to have opposite functions
(Battista et al., 1999; Melillo et al., 2001). Consistent
with the results reported here, we have recently found
that the HMGA2 expression is increased in the Hmga1-
null MEFs (De Martino, unpublished data). Moreover,
miR-196a-2 would represent the third miRNA able to
target the HMGA2 mRNA. In fact, it has been
previously shown that let-7 (Lee and Dutta, 2007) and
miR-98 (Hebert et al., 2007) negatively regulate
HMGA2 expression.
In conclusion, here we report that HMGA1 proteins
are able to positively regulate the expression of miR-
101b and miR-196a-2 that have ATXN1 and STC1, and
HMGA2 as genes target, respectively. This could
represent another mechanism by which HMGA1
proteins play a role in the processes of differentiation
and carcinogenesis.
Materials and methods
Cell lines and transfections
MEFs have been established from wild-type, Hmga1þ / and
Hmga1/ embryos 12.5 days post coitum following standard
procedures. Cells were grown in Dulbecco0s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% FCS (fetal calf
serum), glutamine and non-essential amino acids (Life
Technologies Inc., Rockville, MD, USA) in a 5% CO2
atmosphere. NIH3T3 were cultured at 37 1C (5% CO2) in
DMEM containing 10% FBS (fetal bovine serum) supple-
mented with penicillin and streptomycin in a humidiﬁed
atmosphere of 95% air and 5% CO2.
For transfection assay, NIH3T3 cells were plated at a
density of 2.5 105 cells/well, in six-well plates, with three
replicate wells for each condition, and transfected with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. 20-O-Me-101b (CUUC
AGCUAUCACAGUACUGUAL) and 20-O-Me-196a-2 (CC
AACAACAUGAAACUACCUAL) oligonucleotides were
used in the antisense experiments. All 20-O-methyl oligonu-
cleotides were synthesized by Fidelity Systems, Inc. (Gaithers-
burg, MD, USA) as described previously (Meister et al., 2004)
and were used at 200 nM concentration. RNA oligonucleotides
corresponding to pre-miR negative control (no. AM17110,
Ambion, Austin, TX, USA), pre-miR-101b (AM12364) and
pre-miR-196a-2AM10068) were used at 100 nM ﬁnal concen-
tration in the sense experiments.
RNA extraction and quantitative reverse transcription-PCR
Total RNA isolation from mouse tissues and cells was carried
out with Trizol (Invitrogen) according to the manufacturer’s
instructions. The integrity of the RNA was assessed by
denaturing agarose gel electrophoresis (virtual presence of
sharp 28S and 18S bands). Spectrophotometry qRT–PCRs
analysis were carried out on the RNA isolated from tissues and
MEFs of Hmga1-knockout mice and from transfected cells by
using AmpliTaq DNA polymerase (Applied Biosystems,
Foster City, CA, USA) and the mirVana qRT–PCR miRNA
Detection Kit (Ambion) following the manufacturer’s instruc-
tions. Reactions contained mirVana qRT–PCR Primer Sets
(Ambion), speciﬁc for miR-101b, miR-196a-2 and GAPDH
(used to normalize RNA levels). A qRT–PCR analysis for
ATXN1, STC1 and HMGA2 mRNA was carried out by using
TaqMan Gene Expression Assay (Ambion).
miRNA microarray
Microarray experimental procedures were performed as
described earlier (Liu et al., 2004). Brieﬂy, labeled targets
from 5mg of total RNA from each sample were biotin-labeled
during reverse transcription using random hexamers. Hybri-
dization was carried out on miRNA microarray (KCI version
1.0; (Liu et al., 2004)) containing 368 probes in triplicate,
corresponding to 245 human and mouse miRNA genes.
Hybridization signals were detected by biotin binding of a
Streptavidin-Alexa 647 conjugate using a Perkin-Elmer Sca-
nArray XL5K (Perkin-Elmer, Wellesley, MA, USA). Scanner
images were quantiﬁed by the Quantarray software. Raw data
were normalized and analysed in GENESPRING software,
version 7.2 (Silicon Genetics, Redwood City, CA, USA).
Expression data were median-centered by using the GENE-
SPRING normalization option.
Quantitative RT-PCR for miRNA precursors
Quantitative real-time PCR was performed as described by
(Schmittgen et al., 2004). Brieﬂy, RNA was reverse transcribed
to cDNA with gene-speciﬁc primers and Thermoscript
(Invitrogen), and the relative amount of each miRNA was
normalized to the GAPDH RNA using the equation 2DCT ,
where DCT¼ (CT miRNACT GAPDH RNA). PCR reactions were
carried out in triplicate using iCycler (Bio-Rad, Hercules, CA,
USA) with SYBR Green PCR Master Mix (Applied Biosys-
tems, Foster City, CA, USA) as follows: 95 1C for 10min and
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40 cycles (95 1C for 15 s and 60 1C for 1min). A dissociation
curve was run after each PCR reaction to verify ampliﬁcation
speciﬁcity. The miRNAs analysed included miR-196a-2 and
miR-101b precursors. The primers used were described in
Supplementary Table 1.
Plasmids and constructs
The 30-UTR region of STC1 and ATXN1 genes including
binding sites for miR-101b, and the 30-UTR region of
HMGA2 gene including binding sites for miR-196a-2, were
ampliﬁed by PCR from genomic DNA by using the primers
described in Supplementary Table 1.
The ampliﬁed fragments were cloned into pGL3-Control
ﬁreﬂy luciferase vector (Promega, Madison, WI, USA) at the
XbaI site immediately downstream from the stop codon of
luciferase.
Deletions into the miR-101b-binding sites of the ATXN1
gene or STC1 gene, 30-UTR or into the miR-196a-2-binding
sites of the Hmga2 gene, 30-UTR were introduced by using
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA) following the manufacturer’s instructions.
The primers used are listed in Supplementary Table 1.
Transfection efﬁciency was corrected by transfection of
Renilla luciferase vector (pRL-CMV, Promega).
Luciferase target assays
NIH3T3 cells were co-transfected in 12-well plates with the
modiﬁed ﬁreﬂy luciferase vector described above, the Renilla
luciferase reporter plasmid and with the RNA oligonucleo-
tides. Fireﬂy and Renilla luciferase activities were measured
24 h after transfection with the Dual-Luciferase Reporter
Assay System (Promega). Fireﬂy activity was normalized to
Renilla activity as control of the transfection efﬁciency.
Protein extraction, western blotting, and antibodies
Tissues and cells were lysed in lysis buffer containing 1% NP-
40, 1mM EDTA, 50mM Tris-HCl (pH 7.5) and 150mM NaCl,
supplemented with complete protease inhibitors mixture
(Roche Diagnostic Corp., Indianapolis, IN, USA). Total
proteins were separated by SDS-polyacrylamide gel electro-
phoresis and transferred to nitrocellulose membranes
(Bio-Rad). Membranes were blocked with 5% nonfat milk
and incubated with antibodies against STC1 (sc-14346, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA), ATXN1
(sc-8766, Santa Cruz Biotechnology Inc.), HMGA2
(polyclonal rabbit antibody raised against a synthetic peptide
located in the NH2-terminal region), vinculin (sc-7649, Santa
Cruz Biotechnology Inc.). Bound antibody was detected by the
appropriate secondary antibody and revealed with an en-
hanced chemiluminescence system (Amersham-Pharmacia
Biotech, Piscataway, NJ, USA). The level of expression of
different proteins was analysed by using the public domain
software Image J (a Java image processing program inspired
by National Institutes of Health (NIH) Image for Macintosh)
by working in a linear range. It can calculate area and pixel
value statistics of user-deﬁned selections. Brieﬂy, it was done as
follows: X-ray ﬁlms were scanned and saved as eight-bit
grayscale JPEG ﬁles. The percentage of measurable pixels in
the image was set (and highlighted in red) by using the adjust
image threshold command. The number of square pixels in the
section selected (the protein bands) was then counted by
measuring the area in the binary or threshold image.
ChIP
Approximately 3 107 Hmga1þ /þ , Hmga1þ / and Hmga1/
MEFs were grown on 75 cm2 dishes. ChIP was carried out with
a ChIP assay kit (Upstate Biotechnology, Lake Placid, NY,
USA) according to the manufacturer’s instruction. PCR
reactions were performed with AmpliTaq gold DNA polymerase
(Perkin-Elmer). The recovered DNA was PCR-ampliﬁed with
the primers described in Supplementary Table 1.
Statistical analysis
For the comparison between two groups of experiments,
Student’s t-test was used. The statistical signiﬁcant difference
was considered when P-value was less than 0.05. miRNA
microarray data were compared with the GENESPRING
ANOVA tool.
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Abstract
The high mobility group As (HMGAs) belong to a family of
nonhistone nuclear proteins that orchestrate the assembly
of nucleoprotein complexes. Through a complex network of
protein-DNA and protein-protein interaction, they play
important roles in gene transcription, recombination, and
chromatin structure. This protein family is involved, through
different mechanisms, in both benign and malignant neo-
plasias. We have recently reported that transgenic mice
carrying the Hmga1 or Hmga2 genes under transcriptional
control of the cytomegalovirus promoter develop pituitary
adenomas secreting prolactin and growth hormone. We have
shown that the mechanism of the HMGA2-induced pituitary
adenoma is based on the increased E2F1 activity. The
expression profile of mouse normal pituitary glands and
adenomas induced in HMGA transgenic mice revealed an
increased expression of the ccnb2 gene, coding for the cyclin
B2 protein, in the neoplastic tissues compared with the
normal pituitary gland. Here, we show, by electrophoretic
mobility shift assay and chromatin immunoprecipitation, a
direct binding of HMGA proteins to the promoter of ccnb2
gene, whereas luciferase assays showed that HMGAs are able
to up-regulate ccnb2 promoter activity. Finally, we report an
increased CCNB2 expression in human pituitary adenomas of
different histotypes that is directly correlated with HMGA1
and HMGA2 expression. Because cyclin B2 is involved in
the regulation of the cell cycle, these results taken together
indicate that HMGA-induced cyclin B2 overexpression gives
an important contribution to experimental and human
pituitary tumorigenesis. [Cancer Res 2009;69(5):1844–50]
Introduction
The high mobility group A (HMGA) protein family includes
HMGA1a and HMGA1b, which are encoded by the same gene
through alternative splicing (1), as well as the closely related
HMGA2 protein (2). These proteins are nonhistone architectural
nuclear factors, which bind the minor groove of AT-rich DNA
sequences through three short basic repeats, called ‘‘AT-hooks’’’,
located at the NH2- terminal region of the proteins. The
involvement of HMGA proteins in embryogenesis, cell proliferation,
differentiation, apoptosis and, above all, cancer development has
been extensively shown (3). In particular, HMGA proteins seem to
play their major physiologic role during embryonic development.
In fact, their expression is very high during embryogenesis, whereas
it is very low or negligible in normal adult tissues (4, 5). Conversely,
HMGA protein expression has been found abundant in several
malignant neoplasias, including pancreas, thyroid, colon, breast,
lung, ovary, prostate carcinomas, squamous carcinomas of the oral
cavity, and head and neck tumors (6).
Both HMGA1 and HMGA2 show oncogenic activity in vitro and
in vivo : they are able to transform mouse and rat fibroblasts in
culture (7, 8), and both the HMGA1 and HMGA2 transgenic mice
develop GH/PRL-secreting pituitary adenomas and T/NK lympho-
mas (9–11). Recently, we have reported that HMGA2-mediated
E2F1 activation is a crucial event in the onset of these tumors in
transgenic mice (12), and likely also in human prolactinomas where
HMGA2 gene amplification and overexpression have been shown
(13). To identify other genes involved in the process of pituitary
tumorigenesis induced by the HMGA genes, we have analyzed the
gene expression profile of two HMGA1- and three HMGA2-pituitary
adenomas in comparison with a pool of 10 normal pituitary glands
from control mice using the Affymetrix MG MU11K oligonucleotide
array representing f13,000 unique genes. Among these genes, we
previously focused our attention on the Mia/Cd-rap gene, whose
expression was essentially suppressed in all pituitary adenomas
tested by cDNA microarray. We showed that the HMGA proteins
directly bind to the promoter of the Mia/Cd-rap gene and are able
to down-regulate its expression (14).
Here, we focus our attention on the ccnb2 gene, coding for the
cyclin B2 protein, which showed an 8-fold change increase in the
pituitary adenomas in comparison with normal pituitary glands
from control mice (14). Cyclin B2 is a member of the B-type cyclin
family, including B1 and B2. The B-type cyclins associate with
p34cdc2 kinase and are essential components of the cell cycle
regulatory machinery, being directly involved in the G2-M
transition (15). Consistent with this finding, ccnb2-knockout mice,
although develop normally, are smaller than normal mice and
have reduced litter sizes, which suggests that cyclin B2 expression
gives some growth advantage (16). Moreover, several studies have
reported the accumulation of Cyclins B1 and B2 in human
malignant tumors, such as colorectal and lung cancer (17–20).
Also, in human pituitary adenomas cyclins amplification and
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overexpression have been observed (21–23). More specifically, in
human prolactinomas, an increase of CCNB1 mRNA expression,
related to aggressiveness, has been recently reported (24).
Here, we report that HMGA proteins are able to bind in vitro
and in vivo the promoter of cyclin B2 gene, and to up-regulate
its activity. Furthermore, an increased expression of Cyclin B2,
correlated with HMGA1 and HMGA2 expression, has been shown
in human pituitary adenomas of different histotypes, suggesting its
contribution to the process of human pituitary tumorigenesis
where HMGA proteins are involved.
Materials and Methods
Cell cultures. NIH3T3 cells were grown in DMEM supplemented with
10% FCS. AtT20 and aT3-1 are murine pituitary adenoma cells secreting
adrenocorticorticotropic hormone (ACTH) and gonadotroph hormones,
respectively. RC-4B/C are rat pituitary adenoma cells secreting GH, follicle-
stimulating hormone (FSH), luteinizing hormone, GnRH, ACTH, and TSHb,
whereas GH1, GH3, and GH4c1 are rat pituitary adenoma cells secreting
prolactin and growth hormone. All these cell lines, purchased from
American Type Culture Collection, were cultured in DMEM containing 10%
fetal bovine serum (HyClone) and 50 Ag/mL gentamicin (Life Technologies,
Inc.) in a humidified atmosphere of 95% air and 5% CO2.
Cyclin B2 promoter construct, transient transfection, and luciferase
assay. The wild-type cyclin B2-luciferase vector (B2-luci) was generously
provided by Giulia Piaggio (25). Transfections for luciferase assays were
carried out in NIH3T3 mouse fibroblasts and GH3 rat pituitary adenoma
cells by using Lipofectamine 2000 method (Invitrogen) and microporator
MP-100 (Digital Bio), respectively, according to the manufacturer’s
instructions. A total of 2  105 NIH3T3 cells and 4  106 GH3 cells were
transiently transfected with 1 Ag of B2-luci and with the indicate amounts of
pCEFLHa-HMGA1 (26) and pCEFLHa-HMGA2 (12), together with 0.5 Ag of
Renilla and various amounts of the pCEFLHa plasmid to keep the total DNA
concentration constant. Transfection efficiencies were normalized by using
Renilla luciferase expression assayed with the dual luciferase system
(Promega). All tranfection experiments were repeated at least thrice.
Protein extraction and Western blot. Tissues and cell culture were
lysed in buffer 1% NP40, 1 mmol/L EDTA, 50 mmol/L Tris-HCl (pH 7.5), and
150 mmol/L NaCl, supplemented with complete protease inhibitors mixture
(Roche Diagnostic Corp.). Total proteins were separated by SDS-PAGE and
transferred to nitrocellulose membranes (Bio-Rad). Membranes were
blocked with 5% nonfat milk and incubated with antibody against Cyclin
B2 (N-20 Santa Cruz, sc-5235). Bound antibody was detected by the
appropriate secondary antibody and revealed with an enhanced chemilu-
minescence system (Amersham-Pharmacia Biotech).
Tissue samples. The human samples were obtained from 45 patients as
surgical excision biopsies from patients of ‘‘Federico II’’ University (Naples)
and ‘‘Faculte´ de Me´decine Lyon-RTH Laennec’’ (Lyon). One part of pituitary
adenoma was saved for routine histopathology evaluation and the other one
taken from each patient was immediately frozen at 80jC until the
extraction of nucleic acids. All tissue samples were fixed immediately after
surgical removal in a solution of 4% paraformaldehyde in PBS w/v. The
criteria for inclusion in the study were that the routinely processed paraffin
blocks were suitable for immunohistochemistry and adequate clinical
information.
Immunohistochemical analysis. Paraffin sections (5–6 Am) were
deparaffinized, placed in a solution of absolute methanol and 0.3%
hydrogen peroxide v/v for 30 min, and then washed in PBS before
immunoperoxidase staining. The slides were subsequently incubated with
biotinylated goat anti-rabbit/anti-mouse IgG for 20 min (Dako LSAB2
System) and then with streptavidin horseradish peroxidase for 20 more min.
For immunostaining, the slides were incubated in diaminobenzidine (DAB-
DAKO) solution containing 0.06 mmol/L DAB and 2 mmol/L hydrogen
peroxide in 0.05% PBS v/v (pH 7.6) for 5 min. After chromogen
development, the slides were washed, dehydrated with alcohol and xylene,
and mounted with coverslips using a permanent mounting medium
(Permount). Micrographs were taken on Kodak Ektachrome film with a
photo Zeiss system. For Cyclin B2 immunohistochemistry, antibodies
(2 Ag/mL) raised against the recombinant Cyclin B2 protein were used. The
specificity of the reaction was validated by the absence of staining when
carcinoma samples were stained with antibodies preincubated with the
peptide against which the antibodies were raised. Similarly, no positivity
was observed when tumor samples were stained with a preimmune serum.
RNA extraction, cDNA preparation, semiquantitative and quantita-
tive reverse transcription-PCR. Total RNA isolation from human tissues
was performed with Trizol (Invitrogen) according to the manufacturer’s
instructions. RNA was extracted from fresh specimens after pulverizing the
Figure 1. Cyclin B2 expression in pituitary
adenomas developing in HMGA-transgenic
mice and pituitary adenoma cell lines.
The expression of ccnb2 gene has been
studied by semi–qRT-PCR (A) and
qRT-PCR (B) on a panel of HMGA2- and
HMGA1-induced pituitary adenomas as
well as on a pool of wild-type pituitary
glands (NG ). C, cyclin B2 protein
expression in pituitary adenomas and
normal pituitary glands from HMGA- (both
HMGA1 and HMGA2) transgenic and
wild-type mice, respectively. D, Ccnb2
gene expression was assayed by
semi–qRT-PCR on a panel of seven cell
lines originating from rat and mouse
pituitary adenomas of different histotype in
comparison with a pool of wild-type mouse
and rat pituitary glands. Amplification of
the h-actin gene as well as incubation
with vinculin-specific antibodies have been
performed as controls for the RNA and
protein amounts used, respectively.
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tumors with a stainless steel mortar and pestle that were chilled on dry
ice. The integrity of the RNA was assessed by denaturing agarose gel
electrophoresis. One microgram of total RNA of each sample was reverse-
transcribed with the QuantiTect Reverse Transcription (QIAGEN group)
using an optimized blend of oligo-dT and random primers according to the
manufacturer’s instructions. One microgram of total RNA of each sample
was reverse-transcribed with the QuantiTect Reverse Transcription
(QIAGEN group) using an optimized blend of oligo-dT and random primers
according to the manufacturer’s instructions. To ensure that RNA samples
were not contaminated with DNA, negative controls were obtained by
performing the PCR on samples that were not reverse transcribed but
identically processed. For semiquantitative PCR, reactions were optimized
for the number of cycles to ensure product intensity within the linear phase
of amplification. The PCR products were separated on a 2% agarose gel,
stained with ethidium bromide, and scanned using a Typhoon 9200 scanner.
Digitized data were analyzed using Imagequant (Molecular Dynamics). The
primer sequences for the amplification of the murine cyclin B2 gene are as
follows: 5¶-CCTCAGAACACCAAAGTACC-3 ( forward) and 5¶-CTTCATGGA-
GACATCCTCAG-3¶ (reverse).
Quantitative PCR was performed with SYBR Green PCR Master Mix
(Applied Biosystems) as follows: 95jC 10 min and 40 cycles (95jC 15 s and
60jC 1 min). A dissociation curve was run after each PCR to verify
amplification specificity. Each reaction was performed in duplicate. To
calculate the relative expression levels, we used the 2DDCT method (27).
The primer sequences for the amplification of the human genes are:
Cyclin B2 forward: 5¶-TGGAAAAGTTGGCTCCAAAG-3¶,
Cyclin B2 reverse 5¶-TCAGAAAAAGCTTGGCAGAGA-3¶,
HMGA2 forward: 5¶-GCGCCTCAGAAGAGAGGAC-3¶,
HMGA2 reverse 5¶-GGTCTCTTAGGAGAGGGCTCA-3¶
HMGA1 forward 5¶-AAAAGGACGGCACTGAGAAG-3¶,
HMGA1 reverse 5¶-CTCTTAGGTGTTGGCACTTCG-3¶,
G6PDH forward: 5¶-ACAGAGTGAGCCCTTCTTCAA-3¶,
G6PDH reverse 5¶-GGAGGCTGCATCATCGTACT-3¶.
Electrophoretic mobility-shift assay. Protein/DNA-binding was deter-
mined by electrophoretic mobility shift assay (EMSA), as previously
described (28). Briefly, 5 to 20 ng of recombinant protein were incubated
in the presence of radiolabeled oligonucleotide (specific activity, 8,000–
20,000 cpm/fmol). A 200-fold excess of specific unlabeled competitor
oligonucleotide was added. The double-strand oligonucleotides used was a
region spanning from base 1189 to 69 of the mouse cyclin B2 promoter
(5¶-AGCAAATTGACAAGCAAATACAAGCCAGCCAATCAACGTG-3¶). For an-
tibody competition, analyses samples were preincubated, on ice for at least
30 min, with 0.5 Ag of previously described anti-HMGA1 (26) or anti-
HMGA2 antibodies (12). The DNA-protein complexes were resolved on 6%
nondenaturing acrylamide gels and visualized by exposure to autoradio-
graphic films.
Chromatin immunoprecipitation. Chromatin immunoprecipitation
(ChIP) was carried out with an acetyl-histone H3 imunoprecipitation assay
kit (Upstate Biotechnology) according to the manufacturer’s instruction.
Approximately 3  107 cells of the NIH3T3 cell line or f1 mg of chopped
HMGA-transgenic pituitary adenomas were cross-linked by the addition
of formaldehyde (1% final concentration). Cross-linking was allowed to
proceed at room temperature for 5 min and was terminated with glycine
(final concentration, 0.125 mol/L). Cells and tissues were lysed in buffer
containing 5 mmol/L PIPES (pH 8.0), 85 mmol/L KCl, 0.5% NP40, and
protease inhibitors (1 mmol/L phenylmethylsulfonyl fluoride, 10 Ag/mL
aprotinin, 10 Ag/mL leupeptin), on ice for 10 min. Nuclei were pelleted by
centrifugation at 5,000 rpm for 5 min at 4jC and resuspended in buffer
containing 50 mmol/L Tris-Cl (pH 8.1), 10 mmol/L EDTA, 1% SDS, the same
protease inhibitors, and incubated on ice for 10 min. Chromatin was
sonicated on ice to an average length off400 bp with a Branson sonicator
model 250. Samples were centrifuged at 14,000 rpm for 10 min at 4jC.
Chromatin was precleared with protein A-Sepharose (blocked previously
with 1 mg/mL bovine serum albumin) at 4jC for 2 h. Precleared chromatin
of each sample was incubated at 4jC overnight with 2 Ag of antibody anti-
HA (sc-7392; Santa Cruz Biotechnology), for transfected cells, anti-HMGA1
(26), for HMGA1-transgenic pituitary adenomas, and anti-HMGA2 (12), for
HMGA2-transgenic pituitary adenomas. An aliquot of wild-type samples
was incubated also with anti-IgG antibody. Next, 60 AL of a 50% slurry of
blocked protein G Sepharose were added, and immune complexes were
recovered. The supernatants were saved as ‘‘input.’’ Immunoprecipitates
were washed twice with 2 mmol/L EDTA, 50 mmol/L Tris-Cl (pH 8.0) buffer,
and 4 times with 100 mmol/L Tris-Cl (pH 8.0), 500 mmol/L LiCl, 1% NP40,
and 1% deoxycholic acid buffer. The antibody-bound chromatin was eluted
from the beads with 200 AL of elution buffer (50 mmol/L NaHCO3, 1% SDS).
Samples were incubated at 67jC for 5 h in the presence of 10 Ag RNase and
NaCl to a final concentration of 0.3 mol/L to reverse formaldehyde cross-
links. Samples were then precipitated with ethanol at 20jC overnight.
Pellets were resuspended in 10 mmol/L Tris (pH 8)-1 mmol/L EDTA and
treated with proteinase K to a final concentration of 0.5 mg/mL at 45jC for
1 h. DNA was extracted with phenol/chloroform/isoamyl alcohol, ethanol-
precipitated, and resuspended in water. Input DNA and immunoprecipi-
tated DNAs were analyzed by PCR for the presence of cyclin B2 promoter
sequence. PCR reactions were performed with AmpliTaq gold DNA
polymerase (Perkin-Elmer). The primers used to amplify the sequence of
the ccnb2 promoter were 5¶-TAAGGATGATGGACCAAGAG-3¶ ( forward)
and 5¶-CCCTCGACCTAAATTACACA-3¶ (reverse). PCR products were
Figure 2. HMGA proteins bind the ccnb2 promoter. A, EMSA performed
with a radiolabeled oligonucleotide spanning from base 1189 to 69 of the
mouse ccnb2 promoter region, and incubated with 5 ng (lane 1) and 20 ng
(lanes 2, 5, 8 , and 9) of the recombinant HMGA1-His protein or with 5 ng
(lanes 3, 6, 10 , and 11 ) and 20 ng (lane 4) of the recombinant HMGA2-His
protein. To assess the specificity of the binding, a 100 excess of unlabeled
oligonucleotides (lanes 5 and 6) or anti-HMGA1 (lane 9) and anti-HMGA2
(lane 11 ) antibodies were incubated as specific competitors. B, ChIP assay
performed on NIH3T3 cells transfected with pCEFLHA (HA ), pCEFLHA-HMGA1
(HA-A1 ), or pCEFLHA-HMGA2 (HA-A2 ). C, ChIP performed on pituitary
adenomas from HMGA1- and HMGA2-transgenic mice to detect the endogenous
in vivo binding of HMGA proteins to ccnb2 promoter gene. Input, PCR
products with chromosomal DNA without immunoprecipitation. As an
immunoprecipitation control, IgG was used.
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resolved on a 2% agarose gel, stained with ethidium bromide, and scanned
using a Typhoon 9200 scanner.
Statistical analysis. For the comparison between two groups of
experiments, Student’s t test was used. The statistical significant difference
was considered when P value was <0.05. The Pearson correlation was
performed to determine the association of CCNB2 with HMGA1 or HMGA2
expression levels in human pituitary adenomas. A correlation coefficient (r)
close to 1 was considerate indicative of a significant direct correlation.
Results
Cyclin B2 is overexpressed in pituitary adenoma developing
in HMGA-transgenic mice. The analysis of mRNA expression
profile of HMGA1- and HMGA2-induced pituitary adenomas
showed an 8-fold change increase expression of the ccnb2 gene
in the neoplastic tissues in comparison with the normal pituitary
from control mice (14). This result has been validated by
semiquantitative (Fig. 1A) and quantitative reverse transcription-
PCR (qRT-PCR; Fig. 1B) in two HMGA1- and three HMGA2
pituitary adenomas. In fact, the quantitative PCR showed a higher
than 20-fold increase in specific ccnb2 mRNA expression. Western
blot analysis showed the accumulation of cyclin B2 protein in
pituitary adenomas of the HMGA1 and HMGA2 transgenic mice
but not its presence in normal pituitary gland (Fig. 1C). However, in
the case of the pituitary adenoma sample PA2, no correlation has
been found between RNA and protein level. This could be due to
the possible action of some still unidentified microRNA/s in this
adenoma. Subsequently, we analyzed by RT-PCR the expression of
the ccnb2 gene also in murine and rat cell lines derived from
pituitary adenomas of different histotype. As shown in Fig. 1D , the
expression of ccnb2 is undetectable in normal pituitary (NG) gland,
both from mouse and rat, whereas it is expressed in all analyzed
cell lines. These results suggest cyclin B2 as a direct target of
HMGA proteins in pituitary tumorigenesis.
HMGA proteins bind to the ccnb2 promoter and positively
regulate its activity. To investigate whether the HMGA proteins
are directly involved in ccnb2 transcriptional regulation, we
evaluated the HMGA ability to bind the ccnb2-promoter in vitro
using oligonucleotides spanning from base 1189 to 69 of the
mouse ccnb2 promoter region (29) including AT-rich putative
HMGA-binding sites. As shown in Fig. 2A (lanes 1–2) increasing
amounts (5 and 20 ng) of the recombinant HMGA1 protein were
capable of binding the 32P-end–labeled double-strand oligonucleo-
tide in EMSA. The binding specificity was shown by competition
experiments showing loss of binding with the addition of 100-fold
molar excess of the specific unlabeled oligonucleotide (lane 5). In
addition, competition experiments with specific anti-HMGA1 and
anti-HMGA2 antibodies further confirmed the specificity of the
HMGA/DNA complexes (Fig. 2A, lanes 8–9). Analogous results were
obtained when the same experiments were performed using the
recombinant HMGA2 protein (Fig. 2A, lanes 3–4, 6 , and 10–11).
To verify that HMGA proteins are able to bind to ccnb2 promoter
also in vivo , we performed experiments of ChIP in the NIH3T3 cell
line transiently transfected with either the HA-HMGA1 or HA-
HMGA2 expression plasmids. Chromatin prepared as described
under Materials and Methods was immunoprecipitated with anti-
HA or rabbit IgG antibodies, used as internal control. The results,
shown in Fig. 2B , confirmed that both HMGA1 and HMGA2
proteins bind to the promoter of the ccnb2 gene. In fact, the ccnb2
promoter region was amplified from the DNA recovered with anti-
HA antibody in HA-HMGA1– and HA-HMGA2–transfected cells
but not in the cells transfected with the backbone vector. Moreover,
no amplification was observed in the same samples immunopre-
cipitated with rabbit IgG. To confirm this result in our in vivo
model system of pituitary adenoma, the ChIP of both HMGA1 and
HMGA2 was also analyzed in pituitary adenomas coming from
HMGA1 and HMGA2 transgenic mice, respectively. As shown in
Figure 3. HMGA proteins up-regulate the
ccnb2 gene. A to B, luciferase activity
(fold of activation ) of the ccnb2 promoter in
the NIH3T3 (A) and GH3 (B ) cell lines.
As indicated, growing amounts of either
HMGA1 or HMGA2, or both, expression
vectors were cotransfected with the B2-luci
plasmid. Columns, mean expression
values of three independent experiments;
bars, SD. P < 0.05 (*), P < 0.01 (**), versus
control (C ) ccnb2 mRNA expression in
MEFs derived from knockout mice for
Hmga1, Hmga2 , or both the genes. As a
control for equal mRNA loading, b-actin
was amplified on the same samples. D,
Cyclin B2 protein expression in extracts
from MEFs derived from knockout mice
for Hmga1, Hmga2, or both the genes.
As a control for equal protein loading,
the blotted proteins were incubated
with a vinculin-specific antibody.
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Fig. 2C , both the HMGA proteins do bind the ccnb2 promoter in
pituitary adenoma tissues.
To investigate the functional effect of the binding of HMGA
proteins to the ccnb2 promoter, we transiently transfected the
NIH3T3 cell line, which expresses low levels of HMGA proteins,
with a construct expressing the luciferase gene under the control of
the mouse ccnb2 promoter region (B2-luci). As shown in Fig. 3A ,
cotransfection with the HMGA1, or HMGA2 expression vectors,
led to a significant increase of the luciferase activity in a dose-
dependent manner. Neither synergistic nor additive effect on the
activity of the ccnb2 promoter was observed when both the HMGA1
and HMGA2 expression vectors were transfected together. To
confirm these results in a pituitary cell context, we also performed
analogous luciferase assays in the GH3 cell line. The results, shown
in Fig. 3B , are quite similar to those observed in the NIH3T3 cells.
To further validate that cyclin B2 expression is dependent on
HMGA proteins, we analyzed cyclin B2 mRNA and protein levels in
murine embryonic fibroblasts (MEF) derived from knockout mice
for Hmga1, Hmga2 , or both genes. As shown in Fig. 3C , the cyclin
B2 transcript is significantly lower in Hmga1 and Hmga2 minus
MEFs compared with the wild-type ones, and almost undetectable
in the MEFs where both members of the HMGA family have
been disrupted. Analogous results were obtained for the protein
levels (Fig. 3D).
Cyclin B2 is overexpressed in human pituitary adenomas.
The high expression of cyclin B2 in HMGA-induced mouse
pituitary adenomas and in murine and rat cell lines derived from
pituitary adenomas prompted us to verify whether cyclin B2
overexpression could be a feature also of human pituitary
adenomas. Therefore, we analyzed the expression of CCNB2 in a
panel of 45 human pituitary adenomas (including 15 nonfunc-
tioning adenomas, 6 somatotrophic adenomas GH-secreting, 16
prolactinomas, 2 mixed GH/PRL-cell adenomas, 6 gonadotrophic
adenomas FSH-secreting) by qRT-PCR. As shown in Fig. 4A , CCNB2
was expressed in all the adenomas analyzed at a much higher level
in comparison with the normal pituitary gland. Interestingly,
HMGA1 and HMGA2 expression was increased in all the tumors
analyzed when compared with normal tissue and a direct
correlation between HMGA1, HMGA2 , and CCNB2 mRNA levels
was observed. In fact, as shown in Fig. 4B and C , the correlation
coefficients for the fold changes between adenomas and normal
gland, calculated in both CCNB2 and HMGA1 , as well as CCNB2
and HMGA2 expression levels, were r = 0.80 (P < 0.001) and r = 0,90
(P < 0.001), respectively.
To verify whether the increase in Cyclin B2–specific mRNA levels
corresponded to an increase also in protein levels, we evaluated
Cyclin B2 protein expression in pituitary adenomas by Western blot
and immunohistochemistry. As shown in Fig. 5A , a band of 51 kDa
Figure 4. qRT-PCR analysis of CCNB2, HMGA1
and HMGA2 expression in human pituitary adenomas.
A, qRT-PCR analysis of CCNB2 (top ), HMGA1
(middle ), and HMGA2 (bottom ) was performed on a
panel of nonfunctioning (NF), somatotrophic (GH ),
prolactinoma (PRL ), mixed GH/PRL-cell (GH-PRL ),
and gonadotrophic (b-FSH ) pituitary adenoma samples
of human origin. The fold change values indicate the
relative change in expression levels between tumor
samples and a pool of normal pituitary tissues
assuming that the value of these normal samples
was equal to 1. B to C, statistical analysis of the
correlation between CCNB2 and HMGA1 (B) or
HMGA2 (C ) relative expression in pituitary
adenomas versus normal gland. r, Pearson
correlation coefficient.
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corresponding to the cyclin B2 protein was found in all 12 pituitary
tumors analyzed, independently from the hystotype, whereas it was
not detected in normal pituitary gland. Then, immunohistochem-
ical analysis was performed using antibodies raised versus the NH2-
terminal region of the Cyclin B2 protein. In Fig. 5B , we show a
representative case: no staining was detected in the normal gland
(a). Conversely, a specific cytoplasmic staining was found in all the
pituitary prolactinomas analyzed (b, c, d ; data not shown).
Discussion
A previous analysis of mRNA expression profiles showed an
8-fold increase in cyclin B2 gene (ccnb2) expression in pituitary
adenomas developing in Hmga1- and Hmga2-transgenic mice in
comparison with a pool of normal pituitary glands from control
mice (14). The B-type are the primary mitotic cyclins, although
several yeast B-type cyclins have been reported to function earlier
in the cell cycle, particularly in the S phase (30, 31). There are two
mammalian B-type cyclins, B1 and B2, which differ in their NH2
termini but have 57% similarity (32, 33). Both B-type cyclins, in
association with cdc2, play a critical role in regulating the G2-M
phase transition of the cell cycle (15). Consistent with a general role
in cell growth, several studies have reported the accumulation of
cyclins B in human tumors, including pituitary adenomas (17–21,
24). However, cyclin B2 involvement in pituitary tumorigenesis
has not emerged yet, and the molecular mechanisms underlying
its deregulation in cancer have not been definitively elucidated.
Indeed, it is known that CCNB2 promoter is activated by NF-Y (25),
but very little is known about its regulation in tumors (20).
Our above reported and previously published data suggested
that the increase in cyclin B2 expression might have a role in the
generation of pituitary adenomas in Hmga1- and Hmga2-
transgenic mice. Therefore, we considered interesting to evaluate
whether the induction of cyclin B2 was a direct or indirect effect of
HMGA overexpression, and if this was restricted to the experi-
mental pituitary adenomas, or was a general event occurring in
human pituitary adenomas as well. EMSA and ChIP revealed a
direct binding of HMGA proteins to the promoter of ccnb2 .
Moreover, luciferase assays showed that both the HMGA proteins
were able to up-regulate ccnb2 promoter activity. Finally, we
showed an increased expression of cyclin B2 in human pituitary
adenomas of different histotypes that is associated to HMGA1 and
HMGA2 expression.
A clear validation of the induction of the ccnb2 gene expression
comes from our analysis of ccnb2 mRNA levels in Hmga1- or
Hmga2-null MEFs. In fact, ccnb2 expression was reduced in MEFs
carrying a disrupted Hmga1 or Hmga2 gene, and was almost
undetectable in MEFs where neither Hmga gene was expressed.
It is reasonable to retain that the decreased cyclin B2 expression
in Hmga2-null and Hmga1/Hmga2-double-null mice may also
account for the pygmy phenotype of the mice knockout for Hmga2
and the very small size (less than half of that of the pygmy mice) of
the mice double-knockout for Hmga1 and Hmga2.7
We have previously shown that a critical mechanism in the
induction of pituitary adenomas by HMGA2 is the ability of
HMGA2 to interact with pRB and induce E2F1 activity in mouse
pituitary adenomas by displacing HDAC1 from the pRB/E2F1
complex—a process that results in E2F1 acetylation. Subsequently,
we showed that Mia/Cd-rap gene expression was suppressed in
HMGA-induced pituitary adenomas. Therefore, the induction of
cyclin B2 by HMGA2 could represent a further mechanism by
which HMGA2 would contribute to the development of pituitary
adenoma in mice and humans because HMGA2 gene amplification
and overexpression have been reported by our group in human
prolactinomas (13). It is reasonable to hypothesize that cyclin B2
induction by HMGA proteins may contribute to high-rate cell
proliferation of the malignant neoplasias where HMGA proteins are
abundantly expressed.
In conclusion, our data show that HMGA proteins positively
regulate cyclin B2 expression, indicating a new possible mechanism
by which they may be correlated to mouse and human pituitary
tumorigenesis.
Figure 5. Analysis of Cyclin B2 protein expression in human pituitary adenomas. A, cyclin B2 protein expression in extracts coming from pituitary adenomas of different
histotypes and normal pituitary gland. Blot against vinculin has been performed as control for equal protein loading. B, paraffin sections from a representative
prolactinoma and normal pituitary tissue were analyzed by immunohistochemistry using antibodies raised against Cyclin B2. a, immunostaining of a normal
hypophysis: no immunoreactivity was observed (200); b, immunostaining of a representative prolactinoma (200) showing a cytoplasmic positivity; c, immunostaining
of the same samples as in b , in the absence of the primary antibody: no immunoreactivity was observed; d, immunostaining of the same prolactinoma as in b at
a higher magnification (400). NP, normal pituitary gland; NF, nonfunctioning adenoma; GH, GH-secreting adenoma; GH/PRL, GH/prolactin-secreting adenoma;
PRL, prolactin-secreting adenoma.
7 I. De Martino et al., manuscript in preparation.
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Abstract
Background: We previously showed that mice lacking the high mobility group A1 gene (Hmga1-
knockout mice) developed a type 2-like diabetic phenotype, in which cell-surface insulin receptors
were dramatically reduced (below 10% of those in the controls) in the major targets of insulin
action, and glucose intolerance was associated with increased peripheral insulin sensitivity. This
particular phenotype supports the existence of compensatory mechanisms of insulin resistance that
promote glucose uptake and disposal in peripheral tissues by either insulin-dependent or insulin-
independent mechanisms. We explored the role of these mechanisms in the regulation of glucose
homeostasis by studying the Hmga1-knockout mouse model. Also, the hypothesis that increased
insulin sensitivity in Hmga1-deficient mice could be related to the deficit of an insulin resistance
factor is discussed.
Results: We first show that HMGA1 is needed for basal and cAMP-induced retinol-binding protein
4 (RBP4) gene and protein expression in living cells of both human and mouse origin. Then, by
employing the Hmga1-knockout mouse model, we provide evidence for the identification of a novel
biochemical pathway involving HMGA1 and the RBP4, whose activation by the cAMP-signaling
pathway may play an essential role for maintaining glucose metabolism homeostasis in vivo, in
certain adverse metabolic conditions in which insulin action is precluded. In comparative studies of
normal and mutant mice, glucagon administration caused a considerable upregulation of HMGA1
and RBP4 expression both at the mRNA and protein level in wild-type animals. Conversely, in
Hmga1-knockout mice, basal and glucagon-mediated expression of RBP4 was severely attenuated
and correlated inversely with increased Glut4 mRNA and protein abundance in skeletal muscle and
fat, in which the activation state of the protein kinase Akt, an important downstream mediator of
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BMC Biology 2009, 7:24 http://www.biomedcentral.com/1741-7007/7/24the metabolic effects of insulin on Glut4 translocation and carbohydrate metabolism, was
simultaneously increased.
Conclusion: These results indicate that HMGA1 is an important modulator of RBP4 gene
expression in vivo. Further, they provide evidence for the identification of a novel biochemical
pathway involving the cAMP-HMGA1-RBP4 system, whose activation may play a role in glucose
homeostasis in both rodents and humans. Elucidating these mechanisms has importance for both
fundamental biology and therapeutic implications.
Background
Insulin resistance is a metabolic condition found rela-
tively frequently among humans with chronic hyperin-
sulinemia and in experimental animal models with
defective insulin signaling [1-3]. Recently, a link has been
established between peripheral insulin sensitivity and the
retinol (vitamin A) metabolism, and insulin resistance in
rodents and humans has been linked to abnormalities of
the vitamin A signaling pathway [4-6]. According to these
studies, impaired glucose uptake in adipose tissue results
in secondary systemic insulin resistance through release of
the adipose-derived serum RBP4 [4,5]. However, it is
unknown whether RBP4 effects on insulin sensitivity are
vitamin A-dependent or vitamin A-independent. RBP4
(also called RBP) is mainly produced by the liver but also
by adipocytes [7]. In plasma, retinol-RBP4 is found in an
equimolar complex with transthyretin (TTR), which is a
thyroid hormone transport protein that is synthesized in
and secreted from the liver. This ternary complex prevents
retinol-RBP4 excretion by the kidney [8]. By impairing
insulin signaling in muscle, RBP4 inhibits glucose uptake
and interferes with insulin-mediated suppression of glu-
cose production in the liver, causing blood glucose levels
to rise [4]. Conversely, mice lacking the RBP4 gene show
increased insulin sensitivity, and normalizing increased
RBP4 serum levels improves insulin resistance and glu-
cose intolerance [4].
HMGA1 is a small basic protein that binds to adenine-
thymine (A-T) rich regions of DNA and functions mainly
as a specific cofactor for gene activation [9]. HMGA1 by
itself has no intrinsic transcriptional activity; rather, it can
transactivate promoters through mechanisms that facili-
tate the assembly and stability of a multicomponent
enhancer complex, the so-called enhanceosome, that
drives gene transcription [9,10].
As part of an investigation into the molecular basis regu-
lating the human insulin receptor gene, we previously
showed that HMGA1 is required for proper insulin recep-
tor gene transcription [11,12]. More recently, we showed
that loss of HMGA1 expression, induced in mice by dis-
rupting the HMGA1 gene, caused a type 2-like diabetic
phenotype, in which, however, impaired glucose toler-
ance and overt diabetes coexisted with a condition of
peripheral insulin hypersensitivity [13]. Concomitant
insulin resistance and insulin hypersensitivity in periph-
eral tissues may paradoxically coexist as observed in livers
of lipodystrophic and ob/ob mice [14], as well as in Cdk4
knockout mice with defective pancreatic beta cell develop-
ment and blunted insulin secretion [15]. The hypothesis
that the paradoxical insulin hypersensitivity of Hmga1-
deficient mice could be due to a deficit, in these animals,
of RBP4 is supported by our data. Herein, by employing
the Hmga1-knockout mouse model, we provide compel-
ling evidence for the identification of a novel biochemical
pathway involving HMGA1 and RBP4, whose activation
by the cAMP pathway may play an important role in
maintaining glucose metabolism homeostasis in vivo, in
both rodents and humans. The importance of HMGA1 in
RBP4 gene transcription was substantiated in Hmga1-defi-
cient mice, in which loss of HMGA1 expression consider-
ably decreased RBP4 mRNA abundance and RBP4 protein
production.
Results
RBP4 gene transcription is induced by HMGA1 and cAMP
We first performed experiments to see whether HMGA1
had a role in activating the mouse RBP4 gene promoter at
the transcriptional level. To test this possibility, HepG2
human hepatoma cells and mouse Hepa1 hepatoma cells
were cotransfected transiently with mouse RBP4-Luc
reporter plasmid plus increasing amounts of the HMGA1
expression vector. As shown in Figure 1, overexpression of
HMGA1 considerably increased RBP4-Luc activity in both
cell types and this effect occurred in a dose-dependent
manner. Consistent with these results, RBP4 mRNA abun-
dance was increased in cells overexpressing HMGA1 and
was reduced in cells pretreated with siRNA targeting
HMGA1 (Figure 1), indicating that activation of the RBP4
gene requires HMGA1. These data were substantiated by
chromatin immunoprecipitation (ChIP) assay, showing
that binding of HMGA1 to the endogenous RBP4 locus
was increased in whole, intact HepG2 and Hepa1 cells
naturally expressing HMGA1, and was decreased in cells
exposed to siRNA against HMGA1 (Figure 1). Based on
these results, in addition to previous observations indicat-
ing that cAMP, or agents which elevate intracellular cAMP,
increase RBP transcript levels [16], we were interested to
see whether a functional link could be establishedPage 2 of 13
(page number not for citation purposes)
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confirmed and extended the observation made by Jessen
and Satre [16] that RBP is induced by cAMP in Hepa1
cells. As measured by Northern blot analysis of total RNA
(Figure 2), RBP4 mRNA increased ≈ 5-fold over the basal
level in Hepa1 cells treated with 0.5 mM 8-bromo cAMP
(Br-cAMP), a standard concentration for c-AMP induction
experiments [16]. As shown in Figure 2, RBP4 mRNA lev-
els increased starting at 3 h, peaking at 24 h and then
declining, suggesting a transient transcriptional stimula-
tion. To establish whether HMGA1 was required for basal
and cAMP-dependent RBP4 transcription, we transfected
the HMGA1 expression vector in Hepa1 cells treated or
not with Br-cAMP and RBP4 protein levels were analyzed
48 h later by Western blot. As shown in Figure 2, RBP4
protein expression was enhanced in cells overexpressing
HMGA1 and even further in cells treated with cAMP, in
which an increase in HMGA1 protein expression was
simultaneously observed, suggesting that induction of
RBP4 by cAMP may occur, at least in part, through activa-
tion of endogenous HMGA1 expression. This hypothesis
was supported by the fact that RBP4 was reduced in cAMP
treated cells in which endogenous levels of HMGA1 were
specifically lowered by transfecting cells with HMGA1
antisense expression plasmid (Figure 2). However, further
experiments are needed to fully explain the role of cAMP
on HMGA1 expression. The functional significance of
HMGA1 in RBP4 gene expression was confirmed in tran-
sient transcription assays in Hepa1 (and differentiated
3T3-L1, data not shown) cells, in which overexpression of
HMGA1 caused an increase in both basal and cAMP-
induced Luc activity from the mouse RBP-Luc reporter
plasmid (Figure 3). This effect was substantiated in HEK-
293 cAMP-responsive cells, a cell line ideally suited for
studying the effects of HMGA1 on transcription since it
does not express appreciable levels of this protein. As
shown in Figure 3, in support of the role that HMGA1
plays in the context of RBP4 gene, the direct effect of cAMP
was less effective in promoting RBP4 transcription in
HEK-293 cells expressing low levels of HMGA1, becoming
considerably higher in cells with forced expression of
HMGA1.
Thus, these data together demonstrate that HMGA1 is of
major importance for transcriptional regulation of the
RBP4 gene, and indicate that a functional link exists
between cAMP, HMGA1, and RBP4.
Hmga1-deficient mice have reduced expression of RBP4 in 
liver and fat tissue and reduced serum RBP4 levels
In the light of the above experimental results, indicating
that HMGA1 plays a positive role in RBP4 gene transcrip-
tion in living cultured cells, it was interesting to analyze
the functional consequences of genetic ablation of
HMGA1 on RBP4 in vivo, in Hmga1-knockout mice. To
RBP4 gene expression is induced by HMGA1Figure 1
RBP4 gene expression is induced by HMGA1. (Top) 
Mouse RBP4-Luc reporter vector (2 μg) was transfected into 
HepG2 and Hepa1 cells plus increasing amounts (0, 0.5, or 1 
μg) of HMGA1 expression plasmid. Data represent the means 
± standard errors for three separate experiments; values are 
expressed as factors by which induced activity increased 
above the level of Luc activity obtained in transfections with 
RBP4-Luc reporter vector plus the empty expression vector, 
which is assigned an arbitrary value of 1. (Middle) HMGA1 
expression plasmid was transfected into HepG2 and 
Hepa1cells. After 6 h of transfection, the cells were treated 
with anti-HMGA1 (100 pmol), siRNA, or a non-targeting con-
trol siRNA, and endogenous RBP4 mRNA expression was 
measured 48 to 96 h later. Western blots of HMGA1 in each 
condition are shown in the autoradiograms. (Bottom) ChIP 
of the RBP4 promoter gene in HepG2 and Hepa1 cells, either 
untreated or pretreated with HMGA1 siRNA. ChIP was done 
using an anti-HMGA1 specific antibody (Ab).Page 3 of 13
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expression of RBP4 mRNA and protein in Hmga1-defi-
cient mice and wild-type controls. As shown in Figure 4,
RBP4 mRNA was severely attenuated in both liver and fat
from Hmga1-null mice, and reduced by 50% in Hmga1
heterozygous mutants, as assessed by real-time quantita-
tive polymerase chain reaction (qRT-PCR). Reduced RBP4
mRNA levels in liver and adipose tissue paralleled the
decrease in RBP4 serum levels as detected by Western blot
analysis of serum samples from age- and body weight-
matched mice with diverse genotypes (Figure 4), thereby
showing the requirement of HMGA1 for full RBP4 expres-
sion in whole animals.
HMGA1 and RBP4 expression increase in liver and fat of 
normal mice after intraperitoneal glucagon injection
Based on our observations in intact cultured cells, indicat-
ing a role for the cAMP signaling pathway in HMGA1 and
RBP4 gene expression, cAMP-inducible transcriptional
activation of the Hmga1 and RBP4 genes was investigated
in vivo, in whole animals, by systemic administration of
the intracellular cAMP-elevating hormone glucagon.
Under these conditions, glucagon-stimulated cAMP
responses in terms of both Hmga1 and RBP4 mRNA
expression were first analyzed in wild-type control mice.
Consistent with our data in Hepa1 cells, Hmga1 and RBP4
mRNA levels significantly increased in liver and fat of nor-
Stimulation of RBP4 mRNA and protein expression by cAMP and HMGA1Figure 2
Stimulation of RBP4 mRNA and protein expression by cAMP and HMGA1. (Upper left) 20 μg of total RNA from 
Hepa1 cells treated with the indicated concentrations of Br-cAMP for 24 h (lanes 1–7) were analysed by Northern blot. 
Hybridization was carried out with an RBP4 cDNA or an 18S RNA probe as a control of the RNA loaded on each lane. 
(Lower left) 20 μg of total RNA from Hepa1 cells treated with 0.5 mM Br-cAMP for the indicated times were loaded on each 
lane (lanes 1–8) and analysed as above. (Right) Hepa1 cells, in the absence or presence of an expression plasmid (1 μg) con-
taining the HMGA1 cDNA in either the sense (s) or antisense (as) orientation, were left untreated or treated with Br-cAMP 
(0.5 mM), total protein extracts were prepared 48 h later and HMGA1 and RBP4 protein expression levels were detected by 
Western blot (WB) with anti-HMGA1 and anti-RBP4 antibodies, respectively. β-actin, control of cellular protein loading. Den-
sitometric analyses of three to five independent blots are shown.Page 4 of 13
(page number not for citation purposes)
BMC Biology 2009, 7:24 http://www.biomedcentral.com/1741-7007/7/24mal mice after intraperitoneal injection of glucagon (Fig-
ure 5). Time course analyses revealed that the induction
and accumulation of Hmga1 mRNA preceded the expres-
sion of RBP4 mRNA in both tissues. In liver, RBP4 mRNA
appeared after that for Hmga1, peaked after 6 h following
glucagon injection, and then remained at a plateau (Fig-
ure 5). In fat, RBP4 mRNA appeared at 1 h after Hmga1
mRNA, peaked after 6 h of glucagon stimulation, and
decreased smoothly thereafter (Figure 5). Increased levels
of Hmga1 and RBP4 mRNAs were paralleled by the
increase of Hmga1 and RBP4 protein expression, as meas-
ured by Western blot analysis of proteins from liver and
fat of glucagon-injected animals (Figure 5). Interestingly,
when similar experiments were carried out in glucagon
injected Hmga1-deficient mice, tissue expression of RBP4
mRNA was severely attenuated in liver and fat from heter-
ozygous (Hmga1+/-) and Hmga1-null (Hmga1-/-) animals
(Figure 6), thereby indicating that HMGA1 is indeed
required for maximal induction of the RBP4 gene in vivo,
in the whole organism, and that the glucagon/adenylate
cyclase system regulates both HMGA1 and RBP4 gene and
protein expression. Consistent with this conclusion, liver
RBP4 mRNA and protein expression levels were lower in
fed wild-type mice, becoming higher during fasting, when
circulating glucagon increases (Figure 6).
As a measure of the glucagon efficacy in glucagon-injected
mice, a liver biopsy was taken before and after glucagon
injection, and cAMP levels in liver were determined for
both control and Hmga1-deficient mice (Figure 6, inset).
No substantial difference was found in basal levels of
cAMP (0.45 and 0.50 in Hmga1-/- and Hmga1+/-, respec-
tively, versus 0.52 μmol/g tissue in controls). After gluca-
gon injection, hepatic levels of cAMP increased to 1.50
μmol/g tissue in control mice, compared with 1.48 and
1.52 in Hmga1-/- and Hmga1+/- mice, respectively. Results
Role of HMGA1 in basal and cAMP-induced RBP4 expressionFigure 3
Role of HMGA1 in basal and cAMP-induced RBP4 expression. Rbp4-Luc reporter vector and HMGA1 expression plas-
mid (sense or antisense) were cotransfected into Hepa1 and HEK-293 cells, either untreated or treated with Br-cAMP. Data 
represent the means ± standard errors for three separate experiments. Transcriptional activity of the RBP4 gene promoter is 
shown as the ratio of luciferase activity to Renilla activity (Luc/Ren) as described in the experimental procedures. Values are 
expressed as the factors by which induced activity increased above the level of Luc activity obtained in transfections with the 
reporter vector alone, which is assigned an arbitrary value of 1. Open bar, mock (no DNA); black bar, pGL3-basic (vector 
without an insert). Western blots of HMGA1 and β-actin in each condition are shown in the autoradiograms.Page 5 of 13
(page number not for citation purposes)
BMC Biology 2009, 7:24 http://www.biomedcentral.com/1741-7007/7/24similar to those shown in the inset of Figure 6 were also
obtained in epididymal and subcutaneous fat pads from
control and mutant animals (data not shown), thus indi-
cating that the glucagon-stimulated cAMP synthesis did
not differ among mice with diverse genotypes.
Hmga1-deficient mice have increased Glut4 expression 
and insulin signaling activity in skeletal muscle and fat
Systemic insulin resistance has been associated with eleva-
tion of serum RBP4, whereas genetic and pharmacological
interventions aimed at decreasing serum RBP4 levels
enhance insulin action and improve insulin sensitivity
[4]. Increased peripheral insulin sensitivity during insu-
lin-tolerance test was previously observed by us in Hmga1-
knockout mice [13]. To verify whether a functional link
indeed existed between HMGA1 and RBP4, and whether
insulin hypersensitivity in Hmga1-deficient mice could be
mediated by the HMGA1-RBP4 system, we carried out
quantitative measurements of Glut4 mRNA transcript
abundance. Examination by qRT-PCR showed a signifi-
cant increase of Glut4 transcripts in both skeletal muscle
and adipose tissues from Hmga1-deficient mice compared
with controls (Figure 7). Accordingly, immunoblotting of
muscle and fat tissue showed a 2- to 3-fold increase of
Glut4 in the insulin hypersensitive Hmga1-knockout mice
compared with controls (Figure 7), clearly indicating that
an inverse correlation between RBP4 and Glut4 indeed
exists in vivo, in this animal model of diabetes, in which
reduced RBP4 may contribute to the maintenance of glu-
cose homeostasis by increasing insulin signaling and
peripheral insulin sensitivity. In agreement with this inter-
pretation, the activation state of the protein kinase Akt, an
important downstream target of PI 3-kinase regulating
insulin serum effects on Glut4 translocation and carbohy-
drate metabolism [17], was increased in mutant animals.
As shown in Figure 7, basal phospho-Akt immunoreactiv-
ity was higher in skeletal muscle and adipose tissues from
Hmga1-deficient mice compared with wild-type controls,
and this increase paralleled closely the increase of Glut4
protein in adipose and muscle plasma membranes from
heterozygous and homozygous Hmga1 mutants. In line
with previous observations on transcriptional repression
of the mouse Glut4 gene by cAMP [18], endocrine upreg-
ulation of Glut4 in Hmga1-deficient mice was substanti-
ated further by in vitro experiments (not shown),
indicating that in isolated adipocytes treated with Br-
cAMP, Glut4 mRNA was decreased in all three genotypes.
A positive correlation of RBP4 levels with markers of lipid
metabolism adversely affecting insulin sensitivity has
been reported recently in both clinical and experimental
studies [19,20]. Hmga1-knockout mice had lower levels of
serum free fatty acids (0.45 ± 0.13 and 0.34 ± 0.07 in
Hmga1+/+ and Hmga1-/-, respectively; P < 0.05), which
might contribute to their improved insulin sensitivity.
Recombinant RBP4 injection reduces Glut4 and insulin 
signaling activity in muscle and fat tissue of Hmga1-
deficient mice, and attenuates insulin hypersensitivity of 
these animals
To demonstrate that increased insulin sensitivity in
mutant mice was directly due to HMGA1 regulation of
RBP4, we determined the effect of recombinant RBP4
administration on Akt phosphorylation and Glut4 pro-
tein expression in skeletal muscle from Hmga1-deficient
mice. As shown in Figure 8, Akt phosphorylation was
reduced in muscle from RBP4-injected mutant animals
compared with saline-injected Hmga1 mutants. The
reduction in Akt phosphorylation in these genotypes cor-
related inversely with RBP4 serum levels in the same ani-
mals (Figure 8) and paralleled the reduction of Glut4 in
skeletal muscle and adipose (not shown) plasma mem-
branes (Figure 8), indicating that, in these conditions,
activation of the Akt-Glut4 pathway is regulated, at least
in part, by circulating RBP4. Plasma insulin levels were
slightly higher in RBP4-injected mice, but no significant
difference was found (1.6 ± 0.2 and 1.2 ± 0.2 in RBP4-
injected Hmga1+/- and Hmga1-/- respectively, versus 1.4 ±
0.1 and 0.9 ± 0.1 ng/ml in saline-injected Hmga1+/- and
Hmga1-/- mice).
Consistent with the condition of insulin hypersensitivity,
we previously reported that the glucose-lowering effect of
exogenous insulin was enhanced in Hmga1-deficient mice
during insulin-tolerance test (ITT) [13]. To support further
the role of RBP4 in insulin hypersensitivity in Hmga1
mutants, we have determined the effect of RBP4 adminis-
RBP4 expression in wild-type and Hmga1-deficient miceFigur  4
RBP4 expression in wild-type and Hmga1-deficient 
mice. RBP4 mRNA in liver and fat from control and Hmga1-
deficient mice, as measured by qRT-PCR (left), and densito-
metric quantification of RBP4 serum levels as detected by 
Western blot (WB) of serum samples (2 μl) from mice with 
diverse genotypes (right). In WB analysis, an anti-transthyre-
tin (TTR) antibody was used to confirm similar amounts of 
protein on each lane. Results are from 4–6 mice in each 
group. *P < 0.01 versus control mice.Page 6 of 13
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otypes during ITT. As shown in Figure 9, injection of
human RBP4 in heterozygous and homozygous Hmga1
mutants caused a less dramatic fall in blood glucose lev-
els, lessening the hypoglycemic response to intraperito-
neal insulin observed in the saline-injected animals. Thus,
taken together, our findings consistently support the role
of HMGA1 as a key element in the transcriptional regula-
tion of genes involved in glucose metabolism and add
new insights into the compensatory mechanisms that may
contribute to counteract insulin resistance in vivo. By
directly regulating RBP4 gene transcription, HMGA1
enhances peripheral insulin sensitivity, ensuring glucose
uptake in skeletal muscle. This, if on one hand might rep-
Hmga1 and RBP4 mRNA and protein expression in vivo, in glucagon-injected wild-type miceFigure 5
Hmga1 and RBP4 mRNA and protein expression in vivo, in glucagon-injected wild-type mice. Total RNA was iso-
lated from liver (upper left) and fat (upper right) of 3-h-fasted mice, before and after intraperitoneal injection of glucagon. Lev-
els of Hmga1 and RBP4 mRNA were measured at the indicated time intervals by qRT-PCR and normalized to RPS9 mRNA 
abundance, as described in Methods. Results are the mean values ± s.e.m. from 4–6 animals per group. Black bars, Hmga1 
mRNA; gray bars, RBP4 mRNA. Representative Western blots from liver (lower left) and fat (lower right) of mice before and 
after glucagon injection are shown. Densitometric analyses of immunoblots are shown in bar graphs as the mean ± s.e.m. of 
data from 3–5 mice per each time point. Black bars, HMGA1; gray bars, RBP4.*P < 0.05 versus control mice (time 0).Page 7 of 13
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ance in animals with a disadvantageous metabolic risk
profile, on the other might indicate that the cAMP/
HMGA1-mediated RBP4 expression during fasting (when
glucagon peaks) may act physiologically to reduce insulin
sensitivity in peripheral tissues, thereby contributing to
the maintenance of euglycemia under this condition. This
was supported by the observation that after an overnight
fasting period (12–16 h) plasma glucose concentration in
wild-type mice was higher than that of Hmga1-deficient
mice (89 ± 5 in Hmga1+/+ mice, versus 72 ± 6 and 62 ± 5
mg/dl in Hmga1+/- and Hmga1-/- mice, respectively; P <
0.05).
Discussion
We have previously shown that loss of HMGA1 protein
expression, induced in mice by disrupting the HMGA1
gene, severely decreased insulin receptor expression
(below 10% of control animals) and phosphorylation in
the major targets of insulin action, largely impaired insu-
lin signaling, and reduced insulin secretion, producing a
type 2-like diabetic phenotype in which defects in both
peripheral insulin sensitivity and pancreatic beta-cell
insulin secretion were coexpressed simultaneously [13].
However, despite the severe decrease in insulin receptor
signaling and insulin receptor production, the glucose-
lowering effect of exogenous insulin was enhanced in
Hmga1-deficient mice during ITT, and the glucose infu-
sion rate necessary to maintain euglycemia was higher in
Comparison of RBP4 mRNA levels in glucagon-injected wild-type and Hmga1-deficient mic , and liver RBP4 expression in wild-type mice during fasting and fedFigure 6
Comparison of RBP4 mRNA levels in glucagon-
injected wild-type and Hmga1-deficient mice, and 
liver RBP4 expression in wild-type mice during fast-
ing and fed. Total RNA was isolated from liver and fat of 3-
h-fasted mice, before (time 0) and after 9 h of intraperitoneal 
injection of glucagon, and RBP4 mRNA was measured by 
qRT-PCR and normalized to RPS9 mRNA abundance. Results 
are the mean values ± s.e.m. from 6–8 animals per group. 
Black bars, Hmga1+/+, n = 8; gray bars, Hmga1+/-, n = 6; white 
bars, Hmga1-/-, n = 6. *P < 0.05 versus each control (time 0). 
Western blots for HMGA1 protein expression are shown in 
liver and fat from all three genotypes (top). The levels of 
RBP4 mRNA and protein (shown at the bottom of the figure) 
were measured in liver of fed and 6-h-fasted wild-type mice 
(6 animals per group), using qRT-PCR and Western blot 
(WB), respectively. *P < 0.05 versus fed mice. Inset, cAMP 
was measured in liver from control and Hmga1-deficient 
mice, in both basal conditions and 3 h after the intraperito-
neal injection of glucagon (1 mg/kg body weight), as 
described in the Methods section. The data are mean ± s.e.m. 
for 4–6 animals per group.
Glut4 and pAkt expression in wild-type and Hmga1-deficient miceFigure 7
Glut4 and pAkt expression in wild-type and Hmga1-
deficient mice. Glut4 mRNA (upper left) and protein con-
tent (lower left) in muscle and fat parallel pAkt protein abun-
dance in skeletal muscle (upper right) and adipose tissue 
(lower right) from control and Hmga1-deficient mice. Repre-
sentative Western blots of Glut4 and pAkt proteins are 
shown, together with the densitometric analyses of six to 
eight independent blots. Black bars, Hmga1+/+, n = 8; gray 
bars, Hmga1+/-, n = 6; white bars, Hmga1-/-, n = 6. *P < 0.05 
versus Hmga1+/+.Page 8 of 13
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[13], supporting the existence of alternative pathways of
insulin signaling promoting glucose uptake and disposal
in certain adverse metabolic conditions such as those
found in the Hmga1-knockout mouse. The existence of
signaling pathways promoting glucose uptake and utiliza-
tion in peripheral tissues through mechanisms that are
independent of insulin has been postulated before, on the
basis of experimental observations supporting the exist-
ence of molecular circuits/pathways that can compensate
for the decrease in insulin-stimulated glucose uptake in
vivo, in both animal models and human patients with type
2 diabetes [21-23]. However, how these compensatory
mechanisms are activated has remained hitherto largely
undefined. As previously shown, consistent with the ubiq-
uitous distribution of HMGA1, insulin receptor expres-
sion was also reduced in pancreatic tissue from Hmga1-
deficient mice [13]. Loss of insulin secretion in response
to glucose has been reported in IRβ knockout mice with
tissue-specific knockout of the insulin receptor in pancre-
atic beta cells [24]. As in the IRβ knockout mice, plasma
insulin after glucose challenge was considerably reduced
in Hmga1-mutant animals, in which the acute first-phase
insulin secretory response was severely blunted [13], indi-
cating a glucose-induced insulin secretory defect. In addi-
tion, substantial abnormalities in pancreatic islet
morphology and size have been described in Hmga1-
knockout mice [13], indicating that decreased insulin
secretion in this genotype may also depend on reduced
beta-cell mass. Thus, defects in both pancreatic beta-cell
insulin secretion and peripheral insulin action coexist
simultaneously in this knockout mouse model of diabe-
tes, in which activation of compensatory mechanisms to
efficiently overcome these metabolic abnormalities may
be of vital importance.
Downregulation of Glut4 in adipose tissue is a typical fea-
ture of insulin-resistant states, such as obesity and type 2
diabetes [25]. It has been found that the decrease in Glut4
expression that occurs in the fatty tissue of obese animals
and humans is accompanied by increased expression and
secretion of the adipocyte-derived RBP4 fraction [4,5],
suggesting that RBP4 production is tightly regulated by
adipose tissue glucose uptake. RBP4 has been recently
implicated in systemic insulin sensitivity in rodents and
humans, in which elevated serum RBP4 levels were asso-
ciated with reduced expression of Glut4 in adipocytes,
and correlated inversely with peripheral insulin sensitiv-
ity. However, based on current data, the role of RBP4 in
insulin sensitivity in humans is still controversial and
might be restricted to rodent models only. Interspecies
differences are known to exist and discrepancies between
humans and mice might emphasize the role of non-
genetic environmental factors and genetic modifiers in
determining the phenotypic variations in RBP4 and insu-
lin sensitivity between humans and animal models. Our
results in the present study clearly indicate that in Hmga1-
knockout mice RBP4 levels are considerably decreased in
serum and in whole liver and adipose tissue extracts,
strictly linking HMGA1 and RBP4 expression. We propose
that HMGA1 deficiency adversely affects RBP4 expression
and this, in animals with a disadvantageous metabolic
risk profile like that observed in the Hmga1-knockout
mouse model, might reflect an adaptive mechanism to
increase glucose uptake and glucose disposal. Consistent
with the results obtained in Hmga1-deficient mice, RBP4
was considerably reduced in cells of both human
(HepG2) and mouse (Hepa1) origin readily expressing
RBP4, following perturbation of endogenous HMGA1
protein expression in cells treated with siRNA against
HMGA1. Conversely, an increase in RBP4 mRNA abun-
dance was observed in both cell lines following forced
expression of HMGA1, consistently supporting a role for
HMGA1 in the transcriptional activation of the RBP4
gene. These findings were substantiated further by ChIP
analysis, showing that HMGA1 indeed binds to the RBP4
locus in intact living cells.
Signal transduction pathways which raise intracellular
cAMP have been reported to have a potential role in the
regulation of RBP4 gene expression [16]. Although the
molecular mechanisms underlying this effect remain
poorly understood, evidence exists supporting the notion
that the regulation of RBP4 gene transcription via the
Effects of recombinant RBP4 administration on Akt phospho-rylation and Glut4 protein expression in Hmga1-deficient miceFigure 8
Effects of recombinant RBP4 administration on Akt 
phosphorylation and Glut4 protein expression in 
Hmga1-deficient mice. Basal (saline) levels of pAkt (left) 
and Glut4 (right) were increased in skeletal muscle of saline-
injected Hmga1-deficient mice compared with controls, and 
were reduced following RBP4-injection (n = 6 per genotype). 
Densitometric quantifications of three independent experi-
ments from 3 animals per genotype are shown, together with 
representative Western blots of pAkt, Glut4, and serum 
RBP4 of saline and RBP4-injected mice. *P < 0.05 versus 
Hmga1+/+.Page 9 of 13
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One important physiological condition in which intracel-
lular cAMP increases is in response to low glucose availa-
bility. In this metabolic setting, a concomitant
predominance of circulating counter-regulatory hor-
mones, in particular pancreatic glucagon acting via the
cAMP pathway, induces glycogenolysis and gluconeogen-
esis in the liver, which produce and release hepatic glu-
cose in the blood. In this regard, the cAMP-element-
binding protein (CREB) has been identified as a critical
transcriptional checkpoint which, in response to cAMP,
promotes hepatic glucose output through the synergistic
activation of distinct transcriptional effector pathways,
which include the PPAR gamma coactivator 1 (PGC1) and
the NR4A orphan nuclear receptors [26].
In this paper, we report that systemic injection of gluca-
gon to wild-type control mice caused an increase in RBP4
mRNA and protein expression, along with an increase of
both intracellular cAMP and HMGA1 levels. Glucagon
effects were attenuated in Hmga1-deficient mice, support-
ing a distinct role for HMGA1 in the regulation of RBP4
gene expression and functionally linking this two genes.
As a consequence of the functional link between HMGA1
and RBP4, a significant increase in Glut4 mRNA and pro-
tein was observed in both skeletal muscle and adipose tis-
sues from Hmga1-deficient mice compared with controls.
An inverse relationship between RBP4 and Glut4 has been
described previously, in the adipose-Glut4-/- mouse, in
which the decrease in Glut4 expression that occurs in the
fatty tissue of this mutant genotype is accompanied by
increased expression and secretion of the fat-derived RBP4
[4]. In our model, instead, RBP4 expression is genetically
impaired due to the lack of HMGA1 and Glut4 is
increased in both muscle and fat, suggesting that abnor-
malities in RBP4 and/or metabolites of the vitamin A
metabolism may directly affect whole-body insulin action
and peripheral insulin sensitivity. In support of this possi-
bility, identification of regulatory single nucleotide poly-
morphisms in the RBP4 gene associated with type 2
diabetes has been recently reported [27,28], while correla-
tions of RBP4 with insulin resistance have been confirmed
Effects of RBP4 on insulin sensitivityFigure 9
Effects of RBP4 on insulin sensitivity. Insulin-tolerance test (ITT) was assessed in Hmga1-deficient mice injected with 
saline alone (left), and in Hmga1 mutants injected chronically with purified RBP4 (right) (n = 6–8 per genotype in each condi-
tion). ITT was performed by measuring blood glucose levels in 12-h-fasted conscious mice injected intraperitoneally with 
human insulin (Human Actrapid, Novo Nordisk), 1 U/kg body weight. Open squares, Hmga1+/+; open circles, Hmga1+/-; open 
diamonds, Hmga1-/-. The degree of statistical significance was less in RBP4-injected Hmga1-deficient mice compared with the 
significance for saline-injected Hmga1 mutants. *P < 0.0001, saline-injected Hmga1-deficient mice versus Hmga1+/+; # P < 0.05, 
RBP4-injected Hmga1-/- mice versus Hmga1+/+.Page 10 of 13
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Although conflicting results have been reported, raising
doubt about the postulated relationship of RBP4 with
insulin sensitivity in humans, our results in Hmga1-defi-
cient mice confirm that an inverse correlation indeed
exists between RBP4 and insulin sensitivity in vivo, in this
animal model of diabetes, lending support to previous
hypotheses that lowering RBP4 levels would be helpful in
ameliorating insulin resistance, at least in mice.
Overall, our findings provide mechanistic insight into the
regulation of glucose uptake and disposal in peripheral
tissues, and support further the role of HMGA1 as a mol-
ecule that is likely to be an important emerging factor in
the transcriptional activity of genes implicated in the
maintenance of glucose homeostasis and metabolic con-
trol, such as the insulin receptor gene [11-13], the leptin
gene [29], and, as shown here, the RBP4 gene. Apart from
the intrinsic biological interest in elucidating the mecha-
nisms leading to improvement in insulin sensitivity, a
clear understanding of the molecular process involved is
of potential importance in the development of new thera-
peutic strategies for patients with metabolic disorders
such as obesity, diabetes, and other insulin resistant
states.
Conclusion
We propose that HMGA1 can serve as a modulator of both
RBP4 gene expression and protein function and represents
an important novel mediator of glucose homeostasis in
vivo.
Methods
Plasmids, transfections, and ChIP
The RBP4-Luc reporter plasmid was obtained by cloning
the NheI/XhoI 1427-bp sequence of the mouse RBP4 pro-
moter (-1417 to +10) into pGL3 (Promega). This frag-
ment was amplified from genomic DNA using the
following modified primers: 5'-TTGCTAGCATGGCTAAG-
GTGCTTGTTGAAA-3', 5'-TTCTCGAGCACACCCACTC-
CATCTCACC-3' and the integrity of this construct was
checked by DNA sequencing. RBP4-Luc reporter plasmid,
together with either the control vector plasmid or expres-
sion plasmid encoding HMGA1 [11], was transiently
transfected into cultured cells using LipofectAMINE 2000
reagent (Invitrogen), and Luc activity was assayed 48 h
later, as previously described [30]. Renilla control vector
served as an internal control of transfection efficiency,
together with measurements of protein expression levels.
For antisense HMGA1 experiments, RBP4-containing vec-
tor was cotransfected into Hepa1 cells with the expression
plasmid pcDNA1 containing the HMGA1 cDNA in the
antisense orientation [12]. Small interfering RNA (siRNA)
targeted to HMGA1 [30] was transfected into cells at 50%
to 60% confluency and cells were analyzed 48 to 96 h
later. ChIP assay was performed in HepG2 and Hepa1
cells, either untreated or pretreated with HMGA1 siRNA as
described previously [31]. Formaldehyde-fixed DNA-pro-
tein complex was immunoprecipitated with anti-HMGA1
antibody. Primers for the RBP4 sequence were used for
PCR amplification of immunoprecipitated DNA (30
cycles), using PCR ready-to-go beads (Amersham Pharma-
cia Biotech). PCR products were electrophoretically
resolved on 1.5% agarose gel and visualized by ethidium
bromide staining.
Animals
Male Hmga1-deficient and wild-type mice aged 6–9
months were studied. The generation of these animals
and many of the physiological characteristics of the mice
have been described in detail [13]. All animal work was
carried out at the Animal Facility at the 'Istituto dei
Tumori di Napoli', and at the Faculty of Pharmacy, Roccel-
letta di Borgia, Catanzaro, using approved animal proto-
cols and in accordance with institutional guidelines.
Serum free fatty acid levels were measured in wild-type
and Hmga1-knockout mice (n = 12–16 per genotype)
using the NEFA C kit (Wako).
Real-time PCR and Western blot
For qRT-PCR, total cellular RNA was extracted from tissues
using the RNAqueous-4PCR kit and subjected to DNase
treatment (Ambion). RNA levels were normalized against
18S ribosomal RNA in each sample, and cDNAs were syn-
thesized from 2 μg of total RNA using the RETROscript
first strand synthesis kit (Ambion). Primers for mouse
HMGA1 (NM_016660.2) (5'-GCAGGAAAAGGATGGG
ACTG-3'; 5'-AGCAGGGCTTCCAGTCCCAG-3'), RBP4
(NM_011255.2) (5'-AGGAGAACTTCGACAAGGCT-3'; 5'-
TTCCCAGTTGCTCAGAAGAC-3'), Glut4 (NM_009204)
(5'-TCATTGTCGGCATGGGTTT-3'; 5'-CGGCAAATAGAA
GGAAGACGTA-3'), and RPS9 (NM_ 029767.2) (5'-CTG
GACGAGGGCAAGATGAAGC-3'; 5'-TGACGTTGGCGGA
TGAGCACA-3') were designed according to sequences
from the GenBank database. A real-time thermocycler
(Eppendorf Mastercycler ep realplex ES) was used to per-
form quantitative PCR. In a 20-μl final volume, 0.5 μl of
the cDNA solution was mixed with SYBR Green RealMas-
terMix (Eppendorf), and 0.3 μM each of sense and anti-
sense primers. The mixture was used as a template for the
amplification by the following protocol: a denaturing step
at 95°C for 2 min, then an amplification and quantifica-
tion program repeated for 45 cycles of 95°C for 15 s, 55°C
for 25 s, and 68°C for 25 s, followed by the melting curve
step. SYBR Green fluorescence was measured, and relative
quantification was made against the RPS9 cDNA used as
an internal standard. All PCR reactions were done in trip-
licate.
Western blot analysis was performed to analyze HMGA1
and RBP4 protein expression in whole-cell liver and fat
extracts from normal and mutant mice, using polyclonalPage 11 of 13
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(AdipoGen, Inc.). For the measurement of serum RBP4,
blood was collected from the retro-orbital sinus, plasma
protein extracts were resolved on 12% SDS-PAGE, blotted
onto nitrocellulose membranes and RBP4 was detected
using rabbit polyclonal antisera at 1:2000 dilution, as sug-
gested by the manufacturer. TTR was detected using a goat
anti-TTR polyclonal antibody (Santa Cruz Biotechnol-
ogy). Rabbit anti-Glut4 polyclonal antibody was used as
previously described [13].
In vivo studies with the peptide hormone glucagon
For systemic administration of exogenous glucagon, mice
were injected in the peritoneal cavity with human gluca-
gon (1 mg/kg body weight) or saline after 3 h of fasting.
At this dose, the peak increase of plasma glucagon in all
genotypes was ~96% ± 10% above pre-injection levels,
reflecting similar previous observations in rodents [32]. At
different times after the injection the mice were killed by
cervical dislocation, the liver and fat were rapidly
removed, frozen into liquid nitrogen and stored at -80°C
until processed. For cAMP determination, frozen samples
were first homogenized in ice-cold trichloroacetic acid
(TCA) (6% wt/vol), and cAMP was determined using the
cAMP enzyme immunoassay kit (Amersham Pharmacia
Biotech), according to the instructions specified by the
manufacturer.
RBP4 purification and injection
Human RBP4 cDNA cloned into a pET3a expression vec-
tor was a kind gift from JW Kelly (The Scripps Research
Institute). Based on previously published methodology
[33], RBP4 protein expression vector was transformed
into the BL21 strain of Escherichia coli (Stratagene),
expanded in suspension culture and induced for 6 h with
1 mM isopropyl-D-thiogalactopyranoside to stimulate
protein expression. Bacteria were pelleted and lysed by
osmotic shock [34]. From this point on, all steps, includ-
ing denaturation, refolding, and RBP4 purification, were
performed essentially as described elsewhere [35]. Protein
fractions were examined by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and immuno-
blotting, and desired fractions were pooled together,
concentrated with an Amicon Centriprep-10 concentrator
(Millipore), and stored at -80°C.
To determine whether elevation of RBP4 affected insulin
hypersensitivity in vivo, in Hmga1-deficient mice, hetero-
zygous and homozygous Hmga1 mutants, were intraperi-
toneally injected twice daily (at 12-h intervals) with 200
μg of purified human RBP4 (13 μg/g body weight per
mouse) for 7 days. This resulted in a daily average serum
level of human RBP4 similar to that of control mice (see
Figure 8), which received physiological saline solution
according to the same schedule above.
Statistical analysis
The ANOVA test was used to evaluate the differences
between the groups of mice. For all analyses, P < 0.05 was
considered significant.
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